Human Immunodeficiency Virus/Human Papillomavirus co-infection and host molecular genetics of cervical carcinoma by Chambuso, Ramadhani Salum
HUMAN IMMUNODEFICIENCY 
VIRUS/HUMAN PAPILLOMAVIRUS 
CO-INFECTION AND HOST 
MOLECULAR GENETICS OF 
CERVICAL CARCINOMA
RAMADHANI SALUM CHAMBUSO 
Thesis Presented for the Degree of  
DOCTOR OF PHILOSOPHY 
Division of Human Genetics, Department of Pathology 
UNIVERSITY OF CAPE TOWN 
August, 2019. 
Primary Supervisor: Professor Raj Ramesar  



















The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
 
Published by the University of Cape Town (UCT) in terms 













The copyright of this thesis grants to the author. No quotation from it or information derived 
from it is to be published without full acknowledgement of the source. The thesis is to be 
used for private study or non-commercial research purposes only.  
 
Published by the University of Cape Town (UCT) in terms of the non-exclusive license 
granted to UCT by the author. 
 
Preface and Declaration 
 
All experimental works described in this thesis were carried out in the Division of Medical 
Virology and the Division of Human Genetics, University of Cape Town, and at the 
Laboratory for Tissue Immunology and the Haematology Laboratory, CD4 unit, National 
Health Laboratory Science (NHLS), Groote Schuur Hospital, Cape Town, South Africa, from 
June 2016 to August 2018, under the supervision of Dr. Eveline Kaambo, Dr. Gloudi 
Agenbag, Dr. Alltallents Murahwa, and the NHLS team. 
 
I, Ramadhani Salum Chambuso, declare that this thesis represents original work by the 
author and has not otherwise been submitted in any form for any degree or diploma at any 
University. Where use has been made of the work of others, it is duly acknowledged in the 
text and reference. Permission of use of figures and images from other peer-reviewed journals 
has been granted by the University of Cape Town, provided they are duly acknowledged in 








Plan of This Thesis 
 
This thesis is divided into six chapters. The first chapter provides a background of cervical 
cancer and the role of human immunodeficiency virus type 1 (HIV-1) and human 
papillomavirus (HPV) co-infection. Furthermore, the role of host genetic factors is 
elaborated. The second chapter (Study I) is a literature review for the host molecular genetic 
variations and HIV-1/HPV co-infection on cervical cancer progression.  
However, chapters 3 to 5 which represent the actual research (Studies II, III and IV) are 
linked together and listed according to the specific objectives of this thesis. The subject 
recruitment involved 200 women histologically diagnosed with cervical disease and 200 
controls. 
Chapter 3 (Study II) represents the investigation of 181 patients for the characterization of 
HPV genotypes within cervical tumour biopsies, and assessment of the relationships with 
cervical disease stage, age, HIV-1 status, absolute CD4 count, and CD4 percentage, and 
further studying the predictive power of these variables for cervical disease stage in a cohort 
of South African women. In Chapter 4 (Study III), the association of Human Leukocyte 
Antigen class II (HLA II) -DRB1 and -DQB1 alleles, with cervical cancer, in HIV-1/HPV 
co-infected women is investigated by using 56 women histologically diagnosed with cervical 
disease and 200 controls, matched for age and ethnicity.  
In Chapter 5 (Study IV), a total of 164 matched-DNA samples from cervical tumour biopsies 
and buccal swabs were investigated for chromosomal loss of heterozygosity (LOH) and 
microsatellite instability (MSI) at the HLA II locus in 74 HIV-1/HPV co-infected women, as 
well as in 90 HIV-1-seronegative women.  
The final chapter is the general discussion, conclusions with the strengths, weaknesses and 







A subgroup of women who are co-infected with human immunodeficiency virus type 1 (HIV-
1) and human papillomavirus (HPV) progress relatively rapidly to cervical disease regardless 
of the number of absolute CD4 count. During infection, viral peptides are recognized by the 
host immune system. It is reasonable to propose that the development of viral-associated 
cancers, like cervical cancer, requires interference with specific immune-response genes. 
This thesis investigates this proposition with consideration of host molecular genetic 
alterations and variations of the human leukocyte antigen class II (HLA II) genes as one of 
the groups of immune-response genes that are involved in directing CD4 T-cell responses 
during infection, in the instance of cervical cancer progression in HIV-1/HPV co-infected 
women.  
Study I, reviewed the available literature on host molecular genetics and HIV-1/HPV co-
infection on cervical cancer progression. This study suggests that the dual pro-oncogenic 
effects of HPV oncoproteins E6/E7 and the HIV-1 oncoprotein Tat, may exacerbate and 
accelerate the rate of cervical disease progression in a subgroup of HIV-1-positive women. 
Additionally, HIV-1-positive cervical cancer has three important carcinogenesis steps: 
firstly, HPV integration into the host genome, secondly, dual pro-oncogenic effects of HPV 
oncoproteins E6/E7, and the HIV-1 Tat oncoprotein in the host genome and, thirdly, the 
accumulation of repeated, unrepaired genetic mutations and genetic alterations within the 
host chromosomal DNA.  Genetic variations or mutations that affect the following host gene 
categories were suggested to be responsible for cervical cancer susceptibility and disease 
progression; (i) genes for the immune-response against oncogenic HPV infection, (ii) 
oncogenes, (iii) tumour-suppressor genes, (iv) apoptosis-related genes, (v) DNA damage-
repair genes, and (vi) cell cycle-regulatory genes.  
However, studies II, III and IV are linked together and listed according to the specific 
objectives of this thesis. Study II, characterized the distribution of HPV genotypes within 
cervical tumour biopsies from a cohort of 181 HPV-unvaccinated South African women and 
studied the relationships with HIV-1 infection, age of patients, absolute CD4 count, CD4 
percentage and the stage of cervical disease, and identified the predictive power of these 
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variables for cervical disease stage. Distribution of HPV genotypes was related to the stage 
of cervical disease in HIV-1-positive women. Older age was a significant predictor for 
invasive cervical cancer (ICC) in both HIV-1-seronegative (p<0.0001, q<0.0001) and HIV-
1-positive women (p=0.0003, q=0.0003). Sixty-eight percent (59/87) of HIV-1-positive 
women with different stages of cervical disease presented with CD4 percentage below or 
equal to 28 and a median absolute CD4 count of 400 cells/µl (IQR 300-500 cells/µl). Of the 
HIV-1-positive women, 75% (30/40) with ICC, possessed ≤28% CD4 cells versus 25% 
(10/40) who possessed >28% CD4 cells (both p<0.001, q<0.001). Furthermore, 70% (28/40) 
of women with ICC possessed absolute CD4 count >350 cells/µl compared to 30% (12/40) 
who possessed absolute CD4 count ≤ 350 cells/µl (both p<0.001, q<0.001).  
Study III, was the first case-control study to investigate the association of HIV-1/HPV co-
infection with specific host HLA II-DRB1 and -DQB1 alleles in cervical cancer. Two 
hundred and fifty-six (256) women of the same ethnicity were recruited, comprising 56 cases 
and 200 age-matched controls. A total of 624 HLA-DRB1 and -DQB1 class II genotypes 
were studied. HLA II-DQB1*03:01 and -DQB1*06:02 alleles were associated with cervical 
cancer in HIV-1/HPV co-infected women (p=0.001 and p<0.0001, respectively) while HLA 
II-DRB1*13:01 and -DQB1*03:19 were rare or absent in women with cervical disease when 
compared to the control population (p=0.012 and 0.011, respectively).  
Study IV, aimed to investigate the host genetic alterations that may be involved in rapid 
tumour progression in HIV-1/HPV co-infected women. The frequency of loss of 
heterozygosity (LOH) and microsatellite instability (MSI) at the HLA II locus on 
chromosome 6p was analysed in cervical tumour biopsy DNA, with regard to HIV-1/HPV 
co-infection in 164 women. Seventy-four women were HIV-1-positive and ninety women 
were HIV-1-seronegative. Tumour DNA from HIV-1/HPV co-infected women demonstrated 
a higher frequency of LOH/MSI at the HLA II locus at 6p21.21 than tumour DNA from HIV-
1-seronegative women (D6S2447, 74.2% versus 42.6%; p=0.001, q=0.003), D6S2881 at 
6p21.31 (78.3% versus 42.9%; p=0.002, q=0.004), D6S1666 at 6p21.32 (79% versus 57.1%; 
p=0.035, q=0.052), and D6S2746, at 6p21.33 (64.3% versus 29.4%; p<0.001, q<0.001), 
respectively. 
 5 
This thesis provides novel insights and adds to the existing knowledge on the relationships 
between HIV-1/HPV co-infection, CD4 immune status, host HLA II allele variations and 
genetic alterations at chromosome 6p in association or likely protection to cervical disease in 
the studied cohort of South African women. Identification of host molecular genetic 
susceptibility to disease with regard to viral infection is important for individualized 






































“This thesis/dissertation has been submitted to the Turnitin module (similarity and 
originality checking software) and I confirm that my supervisor has seen my report and any 
concerns revealed by such have been resolved with my supervisor.”  
“I further confirm that I have been granted permission by the University of Cape Town’s 
Doctoral Degrees Board to include publications in my thesis, and where co-authorships are 
involved, my co-authors have agreed that I may include the publications” 
Name of student: Ramadhani Salum Chambuso 
Student number: CHMRAM001 
Signature:    





Firstly, to my parents, Baba na Mama (Dr. and Mrs. Chambuso), and all my family members. 
My absence was not easy for the whole family, but you supported and encouraged me by all 
means, thank you so much. Baba na mama nyie ni wazazi bora kabisa nashukuru sana kwa 
msaada wenu wa hali na mali katika kuwalea wajukuu zenu kina Leilah, Zakia na Bright. 
 
 
Secondly, to my soul mate, lovely wife, my best friend, my mentor in all of my laboratory 
works, the voice of reasons for my PhD success, and the person who believed in me to sustain 
our everlasting love, the Microbiologist, Dr. Eve Kaambo, PhD, thank you so much. The 
words alone will never be enough to express how thankful I am for the precious support you 
gave me in Cape Town during my studies. You are my ‘iconic woman’, thanks for your 
‘natural’ love. Without forgetting our ‘fish’ babies Michelle, Michael, Daniel, Goldie and the 
‘naughty’ Froggy for their emotional company during tough times. 
 
Wote nyie kwa pamoja, mmenifanya mimi Rama leo niwe ni miongoni mwa watu bora 
kielimu duniani, asanteni sana. 
…………………………………………………………………………………………… 
‘Usione nameremeta, kwetu ni Mzenga, Wazaramo pia tunaweza, asante sana Baba na 
Mama kwa akili hizi za kufikiria na kuwa na ubunifu wa kisayansi’ 
‘Pia napenda sana kumkumbuka na kumshukuru babu yangu mpendwa Ali Dida, kwa 
kunirithisha rangi yake na kichwa chake cha ‘Upara au Ualaza’ kwani ninaamini hiki 
kichwa ndicho kimenipa neema hii, nime-mmisi mke wako biti Pazi Momba’ 
‘Bibi biti Salehe, mumeo Majisu nakusalimu sana, asante kwa upendo wako’ 
‘Tutasoma Maulid takatifu pia na Mdundiko ni lazima uchezwe, sio kwa kumkufuru 







‘God comes first above everything, because he who believes in Him, shall prosper forever, 
asante Mungu’. 
a) Academically 
i) To all patients who agreed to participate in this study, nurses, doctors and many more 
whom I cannot mention all individually, who made this project what it is.  
 
ii) To the project collaborator, Prof. Lynnete Denny and the whole team of MRC 
Gynaecological Cancer Research Centre at the Groote Schuur Hospital, thank you very much 
for all the work you put in for this project. Without your acceptance to assist and participate 
in this project, nothing could have been achieved this far, I thank you. 
 
iii) To my primary supervisor, Prof. R. Ramesar, thank you for the exceptional support and 
the extra time you invested to plan this project. You were the backbone of this project and 
the person to rely-on, during difficulties. Above all, thank you so much for accepting my 
application/request to be my primary supervisor.  
 
iv) To my co-supervisor, Prof. Clive Gray, thank you for all support and your valuable time 
(mostly in Public holidays, Saturdays and Sundays) you invested on the two publications 
which defined this project and you being the senior author. You mentored this project from 
the scratch, even though I was not registered in your Division (Immunology). Above all, 
thank you for accepting my application/request to be my co-supervisor.  
 
v) To my co-supervisor, Prof. Anna-Lise Williamson, thank you for the support and time you 
invested in this project. In reality, you were the key player and the mastermind to navigate 
the whole project, to shape the methodology and the study design from the beginning. Above 
all, thank you for showing trust and shaping my ‘poor laboratory skills’ not only in HPV 
genotyping but also in the whole field of molecular medicine. Nonetheless, thank you for 
accepting my application/request to be my co-supervisor.  
 9 
vi) To the project collaborator, mentor and former primary supervisor, Ass. Prof. Jo-Ann 
Passmore, thank you for all academic support and the knowledge you have provided during 
this journey. You were the first person to host me at the UCT. You were really the best 
mentor, because you supported and showed me the way forward from the beginning, thank 
you so much Jo-Ann. 
 
vii) Many thanks to Dr.Gloudi Agenbag, for the close supervision and, assistance on 
microsatellite analyses, and multiple PCRs at the Human Genetics Laboratory. 
 
viii) Special thanks to the co-worker to my supervisor, and a PhD mentor, Dr. George 
Rebello, for close supervision and mentoring of my manuscripts, project methodology and 
the final chapter of this PhD thesis, thank you George. 
 
ix) To the ‘intelligent girl’ Miss Lerato Majara (Rato), for the laboratory support and 
academic friendship, thanks for the support. What happened, happened for a reason. I wish 
you a lot of success in your career path as I can see you flourishing up there in the sky. It was 
a pleasure knowing you.  
 
x) To Prof. Tim Quinlan, from the Health Economics and HIV/AIDS Research Division 
(HEARD) at the University of KwaZulu-Natal, South Africa for the assistance in discussing 
and reviewing early drafts of this thesis, thank you Tim.  
xi) To Miss Rafiekah Abrahams from the Haematology Laboratory, CD4 unit at the NHLS, 
Groote Schuur Hospital, Cape Town, South Africa for the assistance in CD4-T cell 
enumeration procedure, thank you so much. 
xii) To all members of the Division of Medical Virology and the Division of Human Genetics 
in general, thank you so much for the friendly support and the companionship.  
 






I would like to thank the following; 
 
i) Postgraduate Academic Mobility for African Physician-Scientists (PAMAPS) funded by 
the European Union (EU). 
 
ii) Morogoro Regional Referral Hospital, Tanzania. 
 
iii) The MRC Gynaecological Cancer Research Centre at the Groote Schuur Hospital. 
 
iv) The South African National Research Foundation (NRF). 
 
v) The South African National Health Laboratory Service/s (NHLS). 
 
vi) The MRC Unit for Genomic and Precision Medicine, Division of Human Genetics, 













LIST OF PUBLICATIONS 
 
This thesis is based on the following papers, which are referred to in the text by their study 
Roman numerals. 
Ethical approval: All procedures performed in this PhD study involving human 
participants were in accordance with the ethical standards of the institutional and/or national 
research committees, and with The Declaration of Helsinki (1964) and its later amendments 
or comparable ethical standards. 
The publication strategy statement: All four (4) studies were published and listed below 
from the basic science (literature review) to the actual research according to the PhD study 
specific objectives. 
Study I 
Chambuso R, Gray CM, Kaambo E, Rebello G and Ramesar R (2018). Impact of Host 
Molecular Genetic Variations and HIV-1/HPV Co-infection on Cervical Cancer Progression: 
A Systematic review. Oncomedicine. 2018; 3:82-93. doi: 10.7150/oncm.25573.  
Study II 
Chambuso R, Ramesar R, Kaambo E, A. Murahwa, Mohammed  A, De Sousa M, Denny L, 
Williamson A-L, Gray CM (2020). Age, Absolute CD4 count and CD4 Percentage in 
Relation to the HPV infection and the Stage of Cervical Disease in HIV-1-Positive Women. 
Original research. Medicine, 2020; Vol: No (e19273).dx.doi.org/10.1097/MD-D-19-04693. 
Study III 
Chambuso R, Ramesar R , Kaambo E, Denny L, Passmore J-A, Williamson A-L, Gray CM 
(2019). Human Leukocyte Antigen (HLA) class II -DRB1 and -DQB1 alleles Association 
between HIV-1/HPV Co-infection and Cervical Disease in South African Women. Original 
research. Journal of Cancer, 10(10):2145-2152. doi:10.7150/jca.25600. 
Study IV 
Chambuso R, Kaambo E, Denny L, Gray CM, Williamson A-L, Migdalska-sek M, Agenbag 
G, Rebello G, and Ramesar R (2019). Investigation of Cervical Tumour Biopsies for 
Chromosomal Loss of Heterozygosity (LOH) and Microsatellite Instability (MSI) at the HLA 
II Locus in HIV-1/HPV Co-infected Women. Original research. Frontiers in Oncology; 
doi.org/10.3389/fonc.2019.00951. 
 12 
Reprints of published articles were made with permission from the respective publishers. 
Compliance with Ethical Standards; 
The author contributions statement: 
R.C led A.W, C.G and R.R of the presented idea and developed the theory. L.D and others 
collected the specimens. E.K, G.A and A.M contributed in the laboratory works of the 
research. Together R.R, C.G, A.W, L.D and J.P encouraged R.C to investigate further, to 
carry out specific experiments. R.R, C.G and A.W supervised the final results and findings 
of this work. R.C performed the computations and M.A verified the statistical analysis 
methods. R.C led all authors to discuss the results and the final preparations of the 
manuscripts. 
Conflict of Interest:  Authors declare no conflict of interest. 
Informed consent:  Informed consent was obtained from all individual participants 
included in this PhD study.  
‘Opinions, findings and conclusions or recommendations expressed in all publications and 
in this thesis generated by the listed organizations supported research is that of the authors 









TABLE OF CONTENTS 
 
Preface and Declaration ....................................................................................................... 1 
ABSTRACT .......................................................................................................................... 3 
PLAGIARISM DECLARATION ....................................................................................... 6 
DEDICATION ...................................................................................................................... 7 
ACKNOWLEDGMENTS .................................................................................................... 8 
LIST OF PUBLICATIONS ............................................................................................... 11 
TABLE OF CONTENTS ................................................................................................... 13 
LIST OF FIGURES ............................................................................................................ 15 
LIST OF TABLES .............................................................................................................. 16 
ABBREVIATIONS ............................................................................................................. 18 
CHAPTER 1: Background of Cervical Cancer, the Role of HPV, and HIV-1 Co-
infection and Host Molecular Genetics. ............................................................................ 21 
1.1 Introduction to cancer ................................................................................................. 21 
1.2 Cervical cancer ........................................................................................................... 22 
1.2.1 Epidemiology of cervical cancer .......................................................................... 24 
1.2.2 Risk factors for cervical cancer ........................................................................... 28 
1.2.3 Human papillomavirus (HPV) ............................................................................. 31 
1.2.4 Human Immunodeficiency Virus type 1 (HIV-1) infection, absolute CD4 count 
and CD4 percentage...................................................................................................... 33 
1.2.5 Oncogenes and tumour-suppressor genes............................................................ 36 
1.3 Loss of heterozygosity on chromosome 6p in cervical cancer ................................... 36 
1.3.1 Clinical significance of LOH in cervical cancer .................................................. 39 
1.4 Observational studies: case-control study and cross-sectional study ......................... 40 
1.5 Overall main objective and justifications for this study ............................................. 43 
1.5.1 The main objective ............................................................................................... 43 
1.5.2 Specific objectives ................................................................................................ 43 
i) Specific objective I ..................................................................................................... 43 
ii) Specific objective II................................................................................................... 43 
iii) Specific objective III ................................................................................................ 43 
iv) Specific objective IV ................................................................................................. 43 
 14 
1.5.3 Rationale .............................................................................................................. 44 
1.5.4 Summary of specimen collection .......................................................................... 45 
CHAPTER 2: Impact of Host Molecular Genetic Variations and HIV-1/HPV Co-
infection on Cervical Cancer Progression: A Systematic review ................................... 47 
ABSTRACT ..................................................................................................................... 47 
2.1 Introduction ............................................................................................................... 48 
2.2 Methods ...................................................................................................................... 50 
2.3 Results and Discussion .............................................................................................. 51 
2.4 Conclusions and recommendations ......................................................................... 67 
CHAPTER 3: Investigation of Age, Absolute CD4 count, and CD4 Percentage in 
Relation to HPV infection and the Stage of Cervical Disease in HIV-1-Positive 
Women. ................................................................................................................................ 68 
ABSTRACT ..................................................................................................................... 68 
3.1 Introduction ............................................................................................................... 69 
3.2 Methods ...................................................................................................................... 71 
3.3 Results ........................................................................................................................ 73 
4.4 Discussion .................................................................................................................. 91 
4.5 Conclusions ................................................................................................................ 94 
CHAPTER 4: Human Leukocyte Antigen (HLA) Class II -DRB1 and -DQB1 Alleles 
and the Association with Cervical Cancer in HIV-1/HPV Co-Infected Women in 
South Africa. ....................................................................................................................... 95 
ABSTRACT ..................................................................................................................... 95 
4.1 Introduction ............................................................................................................... 96 
4.2 Methods ...................................................................................................................... 98 
4.3 Results ...................................................................................................................... 101 
4.4 Discussion ................................................................................................................ 109 
4.5 Conclusions .............................................................................................................. 111 
CHAPTER 5: Investigation of Cervical Tumour Biopsies for Chromosomal Loss of 
Heterozygosity (LOH) and Microsatellite Instability (MSI) at the HLA II Locus in 
HIV-1/HPV Co-Infected Women. ................................................................................... 112 
ABSTRACT ................................................................................................................... 112 
5.1 Introduction ............................................................................................................. 113 
5.2 Methods .................................................................................................................... 115 
5.3 Results ...................................................................................................................... 124 
 15 
5.4 Discussion ................................................................................................................ 137 
5.5 Conclusions .............................................................................................................. 144 
CHAPTER 6: General Discussion, Conclusions with the Strengths and Weaknesses of 
This Study, and the Future Perspectives. ....................................................................... 145 
6.1 Summary of the main findings .............................................................................. 145 
6.2 Strengths and Weaknesses of This Study, and the Future Perspectives ................ 148 
REFERENCES ................................................................................................................. 152 
APPENDICES ................................................................................................................... 169 
 
 
LIST OF FIGURES 
 
Figure 1. 1 Illustration of female reproductive organs. ....................................................... 23 
Figure 1. 2 Estimated age-standardised incidence rates (ASR) per 100,000 for cervical 
cancer all ages in the world. ................................................................................................. 25 
Figure 1. 3 Estimated number of cervical cancer cases according to age groups in the year 
2011 in South Africa. ........................................................................................................... 27 
Figure 1. 4 Illustration of the interactions of various risk factors for cervical cancer 
development. ........................................................................................................................ 30 
Figure 1. 5 A schematic diagram showing the human papillomavirus genome. ................. 31 
Figure 1. 6 A diagram showing the structure of an HIV-1 virion particle .......................... 35 
Figure 1. 7 A diagram to illustrate different chromosomal mechanisms for loss of 
heterozygosity. ...................................................................................................................... 38 
Figure 1. 8 A diagram illustrating the methods used for specimen collection. ................... 46 
 
Figure 2. 1 Cervical carcinogenesis in HIV-1/HPV co-infected women ............................ 49 
Figure 2. 2 Host molecular genetic variations and alterations in HIV-1/HPV co-infected 
cervical carcinogenesis. ........................................................................................................ 53 
Figure 2. 3 A schematic diagram showing an overview of the Human Leukocyte Antigen 
(HLA) genes on chromosome 6p.......................................................................................... 56 
 
Figure 3. 1. Illustration of HIV-1 status, HPV genotypes and age groups at different stages 
of cervical disease. ................................................................................................................ 79 
 16 
Figure 3. 2. Relationships between absolute CD4 count (Abs CD4), CD4 percentage 
(%CD4), HPV single or multiple infections, number of women and cervical disease stages 
in HIV-1-positive women. .................................................................................................... 81 
Figure 3. 3. Relationships between age, absolute CD4 count (Abs CD4), CD4 percentage 
(%CD4), CD45 count (CD45) and tumour stages. ............................................................... 88 
Figure 3. 4. Receiver operating characteristic (ROC) curves between age, absolute CD4 
count (Abs CD4), CD4 percentage (%CD4), CD45 count (CD45) in CIN versus ICC. ...... 89 
 
Figure 4. 1 Association of tumour status, specific HLA II alleles and HIV-1/HPV co-
infection. ............................................................................................................................. 106 
 
Figure 5. 1  Electropherograms A, B, C, D, E and F illustrating the allelic status of tumour 
DNA compared to normal DNA in LOH/MSI analyses by using four fluorescently-labelled 
microsatellites markers. ...................................................................................................... 123 
Figure 5. 2 Relationships between LOH/MSI status and HIV-1 status between 
precancerous lesions and ICC tumour biopsies for four DNA markers in A, B, C &D. .... 135 
Figure 5. 3 The relationships in LOH/MSI status between HIV-1-positive and HIV-1-
seronegative women with Hr-HPV infection in four markers in A, B, C&D. ................... 136 
 
 
LIST OF TABLES 
 
Table 2. 1 Summary of host gene polymorphisms, SNPs and chromosomal locations found 
to be associated with either HPV persistence or cervical disease progression worldwide... 58 
 
Table 3. 1: Demographics and the range of variables including clinical predictors measured 
and the stages of cervical disease in the subjects of this study............................................. 74 
Table 3. 2: Cervical disease with different immune predictor variables and age of HIV-1-
positive women ..................................................................................................................... 86 
 
Table 4. 1 Relative risk for cervical cancer development with specific HLA-DRB1and -
DQB1 allele exposure without consideration of HIV-1 co-infection status. ...................... 101 
Table 4. 2 Relative risk for developing cervical cancer in HIV-1/HPV co-infected women 
with specific HLA-DRB1 and -DQB1 allele exposure. ...................................................... 103 
 17 
Table 4. 3 Association of HLA II alleles with cervical cancer susceptibility, likely 
protection and HIV-1/HPV co-infection after confirmation with high-resolution gel typing.
 ............................................................................................................................................ 108 
 
Table 5. 1 Marker names, nucleotide sequences of primers, chromosomal positions and the 
fluorescent dyes used for investigation of LOH and MSI at the respective loci ................ 118 
Table 5. 2 Demographic features and the range of variables including clinical predictors 
measured in the subjects of the study cohort. ..................................................................... 125 
Table 5. 3 Number of paired samples for which each microsatellite marker was 
successfully resolved. ......................................................................................................... 126 
Table 5. 4 Frequency of LOH/MSI according to cervical disease and HIV-1 status ........ 127 
Table 5. 5  The relationship between the odds of having LOH/MSI and HIV-1 status for 
each marker......................................................................................................................... 130 
Table 5. 6  Multivariate analysis in logistic regression for each marker by using LOH/MSI 
as a dependent variable. ...................................................................................................... 132 
 


















ART Antiretroviral therapy 
ASR Age-standardised incidence rate 
Bp Base pairs 
BV Bacterial vaginosis 
CA Capsid protein 
CCR5 C-C chemokine receptor type 5                               
CD4 Cluster of differentiation 4 
CD45 Cluster of differentiation 45 
CD8 Cluster of differentiation 8 
CE Capillary electrophoresis 
CGH Comparative genomic hybridization 
CI Confidence interval 
CIN Cervical intraepithelial neoplasia 
CIS Carcinoma in situ 
CNAs Copy number altered regions 
Cn-LOH Copy-neutral loss of heterozygosity 
CXCR4 C-X-C chemokine receptor type 4             
DNA Deoxyribonucleic acid 
EBV Epstein bar virus 
EDTA Ethylenediaminetetraacetic acid    
FANC Fanconi anemia complementation group 
FCR Flow count rate 
FDR False discovery rate 
FISH Fluorescence in situ hybridization   
G1 phase Gap one phase 
GLOBOCAN Global cancer incidence, mortality and prevalence                                         
Gp Glycoprotein     
GWAS Genome-wide association study 
HAART Highly active antiretroviral therapy                  
HIV-1 Human immunodeficiency virus type 1 
HLA Human leukocyte antigen 
HPV Human papillomavirus 
Hr High-risk 
HREC Human research ethics committee 
 19 
HSIL High-grade squamous intraepithelial lesions 
HSV-2 Herpes simplex virus 2 
IARC International agency for research on cancer 
ICC Invasive cervical cancer 
IBM International business machines corporation                                                           
L1 Major capsid protein 
L2 Minor capsid protein 
LD Linkage disequilibrium     
LEEP Loop electrosurgical excision procedure 
LOH Loss of heterozygosity 
Lr Low-risk 
LSIL Low-grade squamous intraepithelial lesions 
LTI Laboratory for Tissue Immunology 
MHC Major histocompatibility complex 
MSI Microsatellite instability 
MSI-H Microsatellite instability high 
MSI-L Microsatellite instability low 
MSS Microsatellite stable 
Ng Nano gram 
NGS Next generation sequencing 
NHLS National health laboratory service 
OC Oral contraceptives 
OD Optical density 
OR Odds ratio 
ORF Open reading frame 
Pap Papanicolaou 
PBS Phosphate buffered saline 
PCR Polymerase chain reaction 
Phr Probable high risk  
PI Protease inhibitor 
PIC Polymorphism information content 
PLG PanLeucogate 
PT Predictive testing 
RNA Ribonucleic acid                                                 
ROC Receiver operating characteristic 
S phase Synthesis phase 
SANCR South African National Cancer Registry 
SCC Squamous cell carcinoma 
SIL Squamous intraepithelial lesions 
SIVcpz Simian immunodeficiency virus of chimpanzee 
 20 
SIVgor Simian immunodeficiency virus of gorilla 
SNP Single nucleotide polymorphisms 
SPSS Statistical package for social science 
SSO Sequence-specific oligo 
STR Short tandem repeats 
TBE Tris/borate/edta buffer                                                     
TE Tris-edta 
TSG Tumour suppressor gene 
URR Upstream regulatory region 





















CHAPTER 1: Background of Cervical Cancer, the Role of HPV, and HIV-1 Co-
infection and Host Molecular Genetics. 
 
1.1 Introduction to cancer 
 
Cancer is a genetic disease caused by physiologically uncontrolled cell growth and cell 
division [1]. It is a genetic disease not because it can be inherited, but because genetic changes 
must take place over a period of time for cancer to occur [2]. New uncontrolled growth of 
cells that is not under physiologic control is called neoplasia [3]. An abnormal mass of tissue 
is called a neoplasm or a tumour. A tumour that usually does not contain any liquid in it is 
called a solid tumour. A solid tumour can be benign or malignant. A malignant tumour is a 
synonym for cancer [3]. Benign solid tumours start by forming small abnormal cell lesions 
which are commonly called precancerous lesions. In some instances, a precancerous lesion, 
if not treated, may develop into a malignant tumour [4]. A malignant solid tumour penetrates 
the protective basement membrane to destroy and invade adjacent normal organs and may 
spread to distant organs. This spread of cancer cells to distant organs is called metastases [5]. 
In contrast, benign tumours remain contained within the protective layer of the basement 
membrane, and by definition cannot spread or invade adjacent organs. 
 
 
Cancers can be classified according to the type of cells or tissue they originate from. Cancers 
originating in the epithelium and of relevance to the present study, are referred to as 
carcinomas. Carcinoma development involves three major steps: (i) dysplasia, (ii) carcinoma 
in situ (CIS), and (iii) invasive carcinoma. Dysplasia can be classified as low-grade or high-
grade. In low-grade dysplasia, only a few atypical cell changes are seen but do not affect all 
cells. In high-grade dysplasia, multiple atypical changes are seen in the majority of cells, 
accompanied by abnormal cell growth [6]. Carcinoma in situ (CIS) (Latin meaning “in its 
place”) means that cancer cells have not invaded the surrounding tissue or penetrated the 
basement membrane. CIS has a higher risk of transforming into invasive carcinoma than 
dysplasia [7]. Invasive carcinoma if left untreated, spreads beyond the tissue in which it 
originates to adjacent and distant organs [8]. 
 
 22 
Cancer develops in a multi-step process whereby a normal functional cell undergoes one or 
several different genetic changes to evolve into a cancer cell. However, a single genetic 
mutation or alteration is generally not enough to change a normal cell into a cancer cell [9]. 
Usually, a number of independent repeated and physiologically uncorrected genetic changes 
or mutations are required for cells to be transformed into cancer cells [9] . The cancer cells 
are usually self-sufficient in growth factors, insensitive to growth-inhibiting signals, avoid 
body programmed cell death (apoptosis), by-pass the body’s natural defence mechanisms 
and replicate excessively beyond their normal programmed limit [10]. 
 
 
This thesis focuses on a particular carcinoma in women, commonly known as cervical cancer, 
which is caused by a human papillomavirus (HPV) infection [11, 12]. Using a case-control 
study, and cross-sectional studies approach, this research sought to investigate how host 
molecular genetic alterations and variations of the Human Leukocyte Antigen class II genes 
(HLA II) influence cervical disease development with regard to HPV and human 
immunodeficiency virus type 1 (HIV-1) co-infection in a cohort of South African women. 
 
 
1.2 Cervical cancer 
 
In 1984, Professor Harald zur Hausen, a German Virologist, working at the German Cancer 
Research Centre, (Deutsches Krebsforschungszentrum, DKFZ) discovered that HPV is 
causative of cervical cancer [11] for which, he was awarded the Nobel Prize in Physiology 
or Medicine in 2008 [13]. Anatomically, the cervix refers to the lower part of the uterus or 
womb (see Figure 1.1 A). Any cancer that originates in the cervix is called cervical cancer, 
as shown in Figure 1.1 B. 
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Figure 1. 1 Illustration of female reproductive organs. 
(A) the location of cervix, relative to gross anatomy, and the uterus, (B) normal uterus, cervix, 
vagina and the localisation of cervical cancer (in situ). 
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The cervix consists of two types of epithelial cells, namely squamous and columnar epithelial 
cells. Squamous epithelial cells form part of the layers in the cervical epithelium. The 
columnar cells form the glandular epithelium of the cervix. The junction where these two 
layers of cervical epithelial cells meet is called the squamo-columnar junction or the 
transformation zone [14]. This is a junction/zone where columnar epithelium transforms into 
squamous epithelium during embryological cell differentiation. Dysplasia, the first stage of 
carcinoma development, starts at this junction/zone [14]. Cervical cancer can be divided into 
two major types according to its epithelial origin. One arises from cervical squamous cells 
and is called cervical squamous cell carcinoma (SCC). The other stems from the glandular 
epithelial cells and is called cervical adenocarcinoma (ADC) [14]. SCC is the most common 
type and accounts for more than 80% of all cervical cancer cases worldwide. ADC and the 
combination of the two types, called adeno-squamous cell carcinomas, represent 15-20%, 
where other rare types comprise less than 1% [15].  
 
1.2.1 Epidemiology of cervical cancer 
 
Cervical cancer is reported to be the fourth most commonly diagnosed cancer and the fourth 
leading cause of cancer-related deaths among women worldwide [16]. , Globally, in the year 
2018, there were an estimated 570,000 new cases of cervical cancer and about 90% of 
311,000 affected women in low and middle income countries died from the disease [17]. 
Approximately 85% of all newly diagnosed cervical cancer cases and 87% of global cervical 
cancer deaths occur in the less developed countries [18] . Cervical cancer remains the most 
common cause of cancer-related morbidity and mortality in women in Sub-Saharan Africa. 
Internationally, the highest incidence rates of cervical cancer are reported in Sub Saharan 
Africa, India and China, whilst the lowest rates are in Australia/New Zealand and Western 
Asia, Europe and North America [19] (Figure 1.2).  The global burden of cervical cancer is 
projected to increase to nearly 700,000 cases and 400,000 deaths in 2030   [17].
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Figure 1. 2 Estimated age-standardised incidence rates (ASR) per 100,000 for cervical cancer all ages in the world.  
(Figure from the International Agency for Research on Cancer website, GLOBOCAN, available at www.iarc.com, with copyright 
considerations as indicated on the website). 
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In South Africa, cervical cancer is the second most common cause of deaths due to cancer in 
overall mortality, and is the leading cause of cancer deaths among women, accounting for 
17% of cancer deaths among women [20]. In a 16‐year study period (1994–2009), 75,099 
cervical cancer cases were reported, indicating that approximately one in forty South African 
women develops cervical cancer [21]. The average number of new cervical cancer cases per 
annum was reported to be 5,033 in 2011 and 5,735 in 2014 [22]. Despite increasing 
interventions such as cervical cancer screening programs, there has yet to be significant 
change in the overall epidemiology of the cervical cancer burden in South Africa. Cervical 
cancer rates continue to increase among young women, although there is variation of the 
disease burden among different ethnic groups or populations [21].  
 
According to the South African National Cancer Registry (SANCR), there are rare reported 
cases of cervical cancer amongst teenage girls, but there is a marked increase in the incidence 
rate among women 25-29-year-old and which rises rapidly before peaking amongst 45-49-










Figure 1. 3 Estimated number of cervical cancer cases according to age groups in the year 
2011 in South Africa.  
(Image from South African National Cancer Registry, 2011, with slight modification. 








1.2.2 Risk factors for cervical cancer 
 
Anything which increases the chance of developing a certain disease is referred to as a risk 
factor for that disease. However, sometimes, other co-factors have to be present for the 
disease to occur. Briefly, genital HPV types have been subdivided into low-risk (Lr-HPV), 
which are found mainly in genital warts, and high-risk types (Hr-HPV), which are frequently 
associated with invasive cervical cancer [24] . Persistent genital infection with Hr-HPV is 
the major risk factor for cervical cancer [25]. Nonetheless, the majority i.e. 70-90%, of Hr-
HPV infected women, will clear the infection naturally. Only a small fraction of HPV-
infected women develop abnormal cervical lesions and, if these lesions remain untreated, 
progress into invasive cervical cancer [26]. However, the fact that only some Hr-HPV-
infected women develop disease means that while HPV is a necessary risk factor, there must 
be other co-factors within the environment or within some women which contribute to the 
development of cancer [27]. 
 
 
Environmental risk factors have been associated with both HPV infection and cervical 
cancer. For example, the number of sexual partners is presumed to influence the risk of 
acquisition of multiple HPV infections: this is because the HPV infection is transmitted 
through sexual/genital contact [28]. Tobacco smoking is known to increase the risk of 
cervical squamous cell carcinoma. The risk increases with the number of cigarettes smoked 
per day and for the number of years that an individual has been a regular smoker [29].  
 
 
Known internal risk factors include co-infections with other sexually transmitted infections 
or just vaginal infections such HIV-1, genital herpes simplex virus 2 (HSV-2), Epstein-Barr 
virus (EBV), Chlamydia trachomatis, bacterial vaginosis (BV) as well as early age sexual 
debut (before 18 years old) [28, 30]. In addition, there are other known risk factors which are 
combinations of internal and external conditions, such as parity (number of children), low 
socioeconomic status, poor genital hygiene, sex with uncircumcised men, and long term use 
of combined hormonal oral contraceptives (OC) [28]. 
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There is also evidence that genetic inheritance is a significant risk factor for cervical cancer 
[31-33]. Individuals who have biological relatives who had cervical cancer, are twice as 
likely to develop cervical cancer compared to individuals who have no family history of the 
disease [34, 35]. Magnusson et al. [36], have shown that shared genes are more significant 
than shared familial environments in determining the probability of cervical cancer 
development. It mainly reflects the differences in host reactions to HPV exposure, infection 
acquisition, the persistence of the infection and response to viral oncoproteins E6/E7 [27]. 
 
 
In addition, genetic studies have identified associations between cervical cancer development 
and variations in human leukocyte antigen (HLA) class II genes [37-39]. The functions of the 
HLA are viral antigen presentation to the immune system and immune recognition of the viral 
peptides in order to initiate cell-mediated immunity [40]. HLA I (HLA-A, B and C) molecules 
present antigens to CD8 T cells and HLA II (HLA.DR, DQ and DP) present phagocytosed 
extracellular antigens to CD4 T cells. In other words, the immune system can only initiate an 
immune reaction to a virus if the HLA system presents the viral peptides to CD8 T or CD4 T 
cells. Furthermore, it has been suggested that many other immune response genes such as 
TNF, TAP1,TAP279, IL-1080, CCR-281, IFN, KIR, FAS, STING, MICA, TP53, RB1, EX01, 
LAMP3 and MYC in different pathways, influence HPV persistence and cervical cancer 
development [27, 41-43]. Figure 1.4 shows a diagram representing a variety of risk factors 
for the development of cervical cancer. This present study confines itself to consideration of 
the host molecular genetic factors, especially the genetic instability and variations of HLA II 
in determining the rapid transformation of HPV cervical lesions into invasive cervical 














1.2.3 Human papillomavirus (HPV) 
 
HPV is a double-stranded deoxyribose nucleic acid (DNA) virus which belongs to the family 
Papillomaviridae [11]. It has a circular genome which has approximately 55 nanometres in 
diameter, 8,000 base pairs in length. The viral particle is made up of 10% DNA and 90% 
protein. It has two structural proteins and cellular histones which condense the DNA in the 
virion [44]. The actual viral genome and the products it codes for is illustrated in Figure 1.5. 
 




More than 200 HPV genotypes have been reported in humans and other mammals. About 30 
to 40 HPV types can infect the anogenital area and the cervicovaginal mucosa of human 
beings either during sexual intercourse or just skin contact of the genitals [45]. These viruses 
are classified according to the molecular similarity/divergence of their genetic material and 
are assigned a genotype number [46]. Genital HPV types are categorised into three types:  
(i) Low risk (Lr), (ii) probable high risk (PHr), and (iii) High-risk (Hr). Lr HPV genotypes 
include; HPV-6, -11, -40, -42, -54, -55, -61, -62, -64, -69, -71, -72, -81, -83, -89 (HPV-
CP6108) and –IS39 [47]. HPV-6 and -11 mainly cause cutaneous and anogenital warts [48]. 
Lr-HPV is usually associated with benign cervical lesions [49]. PHr-HPV genotypes include; 
HPV-26, -53, -66, -67, -68, -70, -73 and -82. Hr-HPV genotypes include; HIV-16, -18, -31, 
-33, -35, -39, -45, -51, -52, -56, -58 and -59. The International Agency for Research on 
Cancer (IARC) confirmed that Hr-HPV genotypes are carcinogenic in humans [50]. Among 
them, HPV-16 and -18 are responsible for over 70% of all invasive cervical cancer cases 
worldwide [51] . Generally, HPV infects basal keratinocytes of the epidermis through the 
disruption of the skin or mucosal surface and it remains latent in low copy numbers in the 
cell as a circular episome [46].  
 
 
Infections with multiple HPV genotypes or mixed HPV infections can occur and are 
associated with a high risk of developing cervical cancer, with poor survival [52]. HPV 
cannot be cultured in laboratories using cell culture. HPV DNA can be detected mainly by 
the following commonly-used laboratory tests for HPV screening; Cobas® HPV test (Roche 
Molecular Systems, Pleasanton, CA, USA), Linear Array® (Roche Molecular Systems, CA, 
USA) and Hybrid Capture® 2 assay (Qiagen Corporation, Gaithersburg, MD, USA) [53].  
 
 
The HPV genome consists of 3 general regions; (i) an upstream regulatory region (URR) 
containing sequences that control viral transcription and replication, (ii) a second early region 
containing open reading frames (ORFs; e.g. E1, E2, E4, E5, E6 and E7) encoding proteins 
that are involved in multiple functions like trans–activation of transcription, transformation, 
replication, and viral adaption to different cellular environments, and (iii) a third region, 
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called the late region that codes for the L1 and L2 capsid proteins that form the structure of 
the virion and make the viral DNA packaging and maturation possible [54]. HPV requires 
the presence of proliferative epidermal and mucosal epithelial cells in order to successfully 
infect the host. Infection of the supra-basal layer and formation of the structural proteins is 
the next step, where the virus expresses the late genes by initiating replication of the circular 
viral genome. As the virus approaches the upper layers of the mucosa or epidermis, complete 
viral particles are assembled and released. The Hr-HPV oncoproteins, E6 and E7 are 
consistently overexpressed in cervical malignant tissues [54].  
 
 
Although rare, there have been some cervical cancers reported to be HPV negative [55-57]. 
However, progressive loss of the HPV L1 region during the progression to cervical cancer 
has been associated with these findings. The polymerase chain reaction (PCR)-based HPV 
DNA tests detect the L1 region of the virus which could already be lost at the time of invasive 




1.2.4 Human Immunodeficiency Virus type 1 (HIV-1) infection, absolute CD4 count and 
CD4 percentage 
 
The sexual route is the main route for HIV-1 transmission. HIV-1 infection occurs through 
interaction with receptors and co-receptors present in the host cells. The primary entrance of 
HIV-1 into the host system is through CD4 cells. The major co-receptors on the CD4 cells 
include the chemokine receptors, CXCR4 and CCR5 [59].  
 
HIV-1 infection is regarded as pathogenic in the host. The virus replicates and attacks host 
CD4 cells [60]. CD4 cells are types of blood cells that are part of the host immune system, 
they are a type of white blood cells (lymphocytes). CD4 cells are sometimes called T-helper 
cells or T-cells. An absolute CD4 cell count for an adult healthy person ranges from 800 to 
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1050 cells/µl [61]. Upon considering laboratory variations and standard variations, the 
normal CD4 count range within 500 to 1400 cells/µl, depending on the ethnic and 
geographical diversity [61, 62]. In HIV-1-positive women, CD4 count decreases over time 
and at counts below 200 cells/µl, patients become susceptible to opportunistic infections, 
including abnormal cervical lesions and cervical cancer [63]. 
 
In some women, immunosuppression (low absolute CD4 cell count) is associated with 
persistence of Hr-HPV types, growth of cervical neoplastic cells, as well as, the cervical 
disease progression [64]. However, another clinical considerable measure for host immune 
competence is called CD4 percentage of lymphocytes, which shows the relationship of CD4 
cell count in consideration with all white blood cell count and lymphocyte differential in the 
body (including CD45) [65, 66]. In South Africa, the normal range for CD4 percentage of 
lymphocytes for females is suggested to fall between 31.6-58% [62]. Sometimes a single 
CD4 count is unexpectedly high or low, depends on the time of the measurements. In this 
situation, the CD4 percentage of lymphocytes is regarded as a more stable immune marker 
than the CD4 count [67]. In some instances, absolute CD4 count do not always correlate with 
CD4 percentage. The discordance between absolute CD4 count and CD4 percentage suggests 
that other lymphocytes apart from CD4 cells, play a role in host immunity [65, 66]. HIV-1 
may incorporate different host proteins such as HLA I and II proteins into its lipoprotein layer 
during the process of budding [68]. Although they are not the primary targets of HIV-1 
invasion, epithelial cells of the female genital tract are found to be permissive to HIV-1 
infection, in vitro [69].  
 
The HIV-1 genome consists of two identical single-stranded RNA molecules that are 
enclosed within the core of the virus particle [70]. In addition to the structural proteins, the 
HIV-1 genome codes for several regulatory proteins: trans activator protein and RNA 
splicing-regulator are necessary for the initiation of HIV-1 replication, while the other 
regulatory proteins: negative regulating factor, viral infectivity factor, and, virus proteins 
have an impact on viral replication, virus budding, and pathogenesis [70].  
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 The HIV-1 genome is packaged in an unusual conical core particle at the centre of the 
infectious virion [71]. The HIV-1 core is composed of a complex of genomic RNA and the 
nucleocapsid protein surrounded by a shell of the capsid protein (CA) [71] (see Figure 1.6). 
The oncogenic potential of HIV-1 involves Tat proteins, which are early nonstructural 
proteins necessary for viral replication [72]. The oncogenic activity of HIV-1 Tat proteins 
includes degradation of host cellular genes, including tumour-suppressor genes which keep 
cell growth in check (But, which, if muted could promote cell proliferation and 
carcinogenesis [73].  
 
           Figure 1. 6 A diagram showing the structure of an HIV-1 virion particle  
                              (Picture from Rebbert et al., (2011) [60]). 
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1.2.5 Oncogenes and tumour-suppressor genes 
 
Cancers can be hereditary or sporadic. ‘Hereditary’ refers to a cancer predisposition that is 
passed from a parent to a child through inheritance of a key defective gene, i.e. where the 
mutation is in the germ-line. ‘Sporadic’, refers to a cancer that is also the result of a genetic 
change, but which occurs in somatic tissues; this can occur by chance without any implication 
for the inheritance of the mutated gene. About 80% of all cancers are sporadic [74]. In 
sporadic cancers, there are three categories of genes that undergo repeated genetic alterations 
or mutations, namely: oncogenes, tumour suppressor genes and DNA damage-repair genes 
[74]. Oncogenes are genes that have the potential to cause cancer. These genes control cell 
proliferation or apoptosis, or both. Oncogenes can be affected by chromosomal 
rearrangements, point mutations or gene amplification, causing alteration in (onco)gene 
structure or affecting its expression [75]. On the other hand, tumour-suppressor genes (TSG) 
are genes which protect and prevent cells from events leading to cancer development through 
regulation of the cell cycle [75]. Both alleles of a TSG must be mutated to interfere with its 
normal function. Mutations in TSGs increase the risk of cancer development [76]. 
 
1.3 Loss of heterozygosity on chromosome 6p in cervical cancer  
 
Loss of heterozygosity (LOH) is a commonly observed type of genetic alteration in solid 
tumours. The whole functional TSG or part of the chromosome containing a functional TSG 
can be deleted due to chromosomal mutations [77]. However, LOH analysis uses 
polymorphisms that occur near a suspected TSG in a gene of interest, as surrogate markers 
for the gene itself [77]. In clinical settings, LOH assay is an important tool for disease 
diagnosis, prognosis, and treatment. For example, the loss of regions on chromosomes 1p/19q 
are classical molecular markers for oligodendroglioma (brain cancer) assessment [78]. 
Interpretation of the clinical significance of molecular genetic alterations in cancers, requires 
that health professionals and biomedical scientists understand the theoretical fundamentals 
of molecular diagnostic techniques.  
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It has been widely reported that LOH mutations and microsatellite instability (MSI) at 
multiple genomic loci, including the HLA region, are the most common host genetic 
alterations occurring in cervical cancer tissues in all studied populations [79, 80]. This 
possibly indicates that the integrity of the HLA region is compromised during the process of 
carcinogenesis [79, 81, 82]. LOH and MSI are caused by genetic alterations such as the 
physical deletion of a chromosomal region, (including a tumour-suppressor gene), or 
chromosomal non-disjunction during mitotic recombination. It has been hypothesized that 
cervical cancer progression is influenced by the extent of LOH/MSI and HLA variations in 
immune response towards oncogenic HPV clearance. The combined pro-oncogenic effects 
of the HIV-1/HPV co-infection are thought to exacerbate the situation [32, 35, 83, 84]. Host 
genetic variations in the HLA that influence the primary immune response and the severity 
of LOH/MSI at the HLA genomic loci may, therefore, determine which lesions are at the 
highest risk for rapid progression to invasive cervical cancer in HIV-1/HPV co-infected 
women [85, 86]. 
 
LOH can further occur during the following chromosomal genetic events. (Figure 1.7).  
a) Mitotic chromosome non disjunction, which results in whole chromosome loss to form a 
copy-number loss of heterozygosity (cn-LOH) or duplication of only one parental 
chromosome to form a copy-number neutral loss of heterozygosity (cn-neutral LOH) [87]. 
b) DNA double-strand break and repair to form either an interstitial deletion or an unbalanced 
translocation [88]. 
c) Homologous recombination repair to form gene conversion whereby a copy of a segment 
of one parental chromosome is repeated on the other parental chromosome [88].  













1.3.1 Clinical significance of LOH in cervical cancer 
 
LOH can be a useful biomarker in cervical cancer to identify risks of disease progression and 
survival probability, and tumours that may respond to particular therapies [89]. It is an 
important assay to aid in the discovery of novel tumour suppressor genes in cervical cancer 
progression [89]. Another application of the LOH assay occurs when a cancer patient has 
two tumours at different sites, and where there is a question of a second primary tumour, or 
whether one tumour is a metastasis of the other. Differentiating between these scenarios can 
be difficult, especially when the histology is similar. The clinical implications can be 
significant, because a second primary tumour can be treated with the intention to cure, but a 
recurrence or distant metastasis equates to advanced-stage disease, generally with limited 
treatment options. Frequency of LOH using PCR-based microsatellite analyses can be used 
to measure the association and likelihood of cervical cancer progression. 
 
Biomarker assays of early neoplasia still use microsatellite analyses due to the small quantity 
and low quality of DNA extracted from small lesions micro-dissected from formalin-fixed 
paraffin-embedded tissue blocks. LOH can be used as a predictor of cervical cancer 
recurrence. Chromosome loss identified in LOH could change treatment choice in invasive 
cervical cancer, where patients can be individualised and benefit from the addition of 
chemotherapy or radiotherapy. The advantages of using the PCR-based LOH assays include 
the ability to detect small deletions and the ability to enrich for tumour cells through 
microdissection [77]. Minor changes in small populations of cells will not usually be 
identified by most PCR-based assays. Therefore, PCR-based LOH assays are best used to 





The pitfalls that can affect the reliability and sensitivity of LOH analyses, as with any other 
molecular test include:  
i) Contaminated tumour samples. Histologic sections of tumours usually contain a mixture 
of tumour cells, inflammatory cells, stromal cells, and other cellular contaminants. This tissue 
heterogeneity can cause problems in molecular analyses of all types, especially in 
amplification-based procedures. For example, LOH can be masked by heavy contamination 
by normal DNA. Manual microdissection may eliminate the gross contamination in LOH 
analysis [77].  
 
ii) Poor markers. The polymorphic repeat units present near TSGs are only surrogate markers 
for the gene itself. Therefore, the distance between the TSG and the polymorphism will affect 
how tightly the polymorphism is linked to the TSG [77]. 
 
iii) Inadequate DNA. When the DNA concentration is low, one allele may be preferentially 
amplified over the other. When one allele has insufficient amplification for detection, this is 
termed allelic dropout. Allelic dropout can yield false-positive results for LOH.  
 
iv) Lack of a normal comparison sample. Sometimes in tumour pathology, a concordant 
normal sample, such as blood or a buccal swab, from the same patient may not be available 
[77]. 
 
As stated above, LOH is one of the most important clinical assays that can be used to assess 
cancer prognosis, disease diagnosis and to offer individualized treatment options.  
 
 
1.4 Observational studies: case-control study and cross-sectional study 
 
In genetics, association studies evaluate the correlation between genetic variants and a 
disease phenotype in a certain population. In other words, they examine the relationship 
between disease and exposure. Instead of assessing the recombination events, linkage 
disequilibrium (LD) is investigated. LD describes a situation in which some combinations of  
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alleles or genetic markers occur more, or less, frequently in a population than would be 
expected from random formation of haplotypes based on the allele frequencies [90]. If an 
association is observed, a particular allele, genotype, or haplotype will be found more or less 
often, than expected by chance among individuals carrying the trait. Basically, such 
investigations compare the frequencies of variant alleles among affected individuals and 
unaffected individuals.  
 
 
A case-control study is an observational study in which there are only two sample groups 
drawn from the same study population: the case group sample and a control group sample. 
These studies are usually used to suggest factors that may contribute to a disease outcome by 
comparing patients who have that disease (the case group) and closely matched subjects from 
the same population who do not have the disease (the control group) [91]. The comparison 
between cases and controls is by relevant statistical analyses which should show a statistically 
significant difference between the cases and the controls based on statistical power (p-value). 
A population-based case-control study comprises cases and matched controls from the same 
population. The advantage of a population-based case-control study is that, it collects large 
sample sizes with high statistical power to detect small or moderate effects. However, the 
disadvantage of this study design is that the genotypes and haplotypes frequencies may differ 
among different ethnic groups or geographic populations [90]. To overcome this drawback, 




A cross-sectional study is a type of observational study that analyzes and investigates the 
entire population at a specific point in time [91]. At one time point, a population is assessed 
to determine factors for disease causation and whether they were exposed to the relevant 
agent to develop the outcome of interest. A subgroup of the studied population may not have 
been exposed nor have the disease outcome of interest [91]. Cross-sectional studies are 
seldom conducted because of the ethical challenges of not treating subjects for the duration 
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of the study. Data are collected randomly at one point in time and multiple outcomes are 
studied. However, to be scientifically viable, a cross-sectional study should be of adequate 
sample size. To set up a cross-sectional study, a research question has to be formulated. 
Thereafter, a study population and variables of interest relevant to the research question must 
be identified. The researcher will then decide which variables of the study population are 
relevant to the research question.  
 
 
This thesis is based on the above-mentioned observational study designs. Firstly, we used a 
case-control study with candidate gene study approach, which focused on investigating the 
associations between individual genetic variations within a certain population. HLA II of 
interest and cervical cancer disease states were studied according to HIV-1/HPV co-
infection. The HLA II candidate genes were selected based on prior knowledge of their 
biological functions and potential impact on cervical cancer development, or because they 
have been implicated in cervical disease in previous studies [90]. The candidate gene 
approach is better suited for the detection of genetic effects for common and more complex 
diseases like cervical cancer [92]. 
 
 
Secondly, this thesis used two cross-sectional studies to investigate an entire study population 
for HPV genotypes, HIV-1 status, clinical immune cell markers, and frequency of LOH/MSI 
at chromosome 6p associated with age of patients and stage of cervical disease. Associations 
discovered by cross-sectional studies, may raise more questions for further studies, 
particularly because observed effects are typically very small and only confined to a certain 







1.5 Overall main objective and justifications for this study 
 
1.5.1 The main objective   
 
To study the influence of host molecular genetic variations and specifically alterations at the 
HLA II locus, on HIV-1/HPV co-infection and cervical cancer progression in a cohort of 
South African women. 
 
1.5.2 Specific objectives  
 
i) Specific objective I 
To identify genes, host molecular genetic variations and genetic alterations in cervical cancer 
progression that may play a role in disease progression in HIV-1/HPV co-infected women. 
ii) Specific objective II 
To characterize HPV genotypes within cervical tumour biopsies, and assess the relationships 
with cervical disease stage, age, HIV-1 status, absolute CD4 count, and CD4 percentage, and 
to identify the predictive power of these variables for cervical disease stage in the cohort of 
South African women.  
iii) Specific objective III 
To determine whether host HLA-DRB1 and -DQB1 backgrounds were involved in 
progression of cervical cancer disease in HIV-1/HPV co-infected women. 
iv) Specific objective IV 
To investigate whether HIV-1/HPV co-infection provokes additional LOH/MSI at the HLA 





A subgroup of women who are co-infected with HIV-1 and HPV, progress rapidly to cervical 
disease regardless of CD4 count status. During infection, viral peptides are subjected to the 
host immune system. Host genetic factors associated with susceptibility or resistance to 
cervical disease following HPV infection are likely to involve viral immune response genes, 
such as the HLA II. However, the impact of host HLA II genetic variations, HIV-1/HPV co-
infection, and genetic alterations at the HLA II locus on cervical carcinogenesis has not been 
established [93, 94]. Despite a high HIV-1 prevalence in the South Africa [95], there is 
limited data on the impact of host molecular genetic variations, HIV-1/HPV co-infection, 
HIV-1 associated immunosuppression, and cervical disease progression. The relationship 
between LOH/MSI at the HLA II locus on chromosome 6p and the effects of host HLA II 
variations on HIV-1/HPV co-infected cervical carcinogenesis is not known [27]. This 
unknown relationship between HIV-1/HPV co-infection, host molecular genetic variations 
and genetic alterations at the HLA II locus in the development of cervical cancer in a high 
risk population, is a matter of great concern, especially in the light of the current HIV-1 
epidemic in South Africa.  This emphasizes the need to conduct a study on the influence of 
host molecular genetic variations and HIV-1/HPV co-infection on cervical carcinogenesis 
[96, 97].  
 
The impact of this study is expected to enlighten the current knowledge and understanding 
of the interaction between HIV-1/HPV co-infection and rapidly progressing cervical 
carcinogenesis with regard to host molecular genetic variations. The findings will strengthen 
available theories on the primary goal of genetically-targeted therapy, molecular prevention, 
and individualization in cervical cancer prevention and treatment. However, development of 





1.5.4 Summary of specimen collection  
 
The study nurse collected two tubes of whole blood (4ml each) for HIV-1 testing and DNA-
based HLA II typing. Furthermore, the study nurse collected buccal swabs from all consented 
participants. By using colposcopy inspection, Gynaecologists collected punch biopsies of 
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Only a small subgroup of women who are co-infected with HIV-1 and persistent oncogenic 
HPV, progress rapidly to invasive cervical cancer by mechanisms that are currently poorly 
understood. The use of Highly Active Antiretroviral Therapy (HAART), with ensuing 
immune reconstitution of CD4 T-cells, does not appear to prevent rapidly progressing 
cervical carcinogenesis. Therefore, to better understand the cervical cancer pathogenesis in 
HIV-1/HPV co-infected women, this review focuses on identifying host molecular genetic 
variations and genetic alterations in cervical cancer progression that may play a role in 
disease progression. This is an important aspect for individualized genomic profiling and 
targeted molecular prevention to improve the management of the disease in this sub-
population.  
Keywords (Host molecular genetics, cervical cancer, HIV-1/HPV co-infection, genomic 





Every year, more than 530,000 women worldwide are diagnosed with invasive cancer of the 
uterine cervix and approximately 275,000 die from the disease [98, 99]. More than 88% of 
these deaths occur in developing countries especially in sub Saharan Africa [100]. 
 
Oncogenic HPV, is one of the primary causative agents for cervical cancer [101]. However, 
co-infection with HIV-1, may influence cervical disease progression and invasive cancer 
outcomes in some HIV-1-positive women [100, 102-105]. HIV-1-positive women are also 
more likely to have concurrent infections of single or multiple strains of oncogenic HPV, 
compared to HIV-1-seronegative women [101, 103, 106-109]. Furthermore, published data 
clearly shows that, persistent oncogenic HPV and HIV-1 co-infections contribute to rapidly 
progressing cervical carcinogenesis when compared to HIV-1-seronegative women with a 
single, multiple, or no HPV infection [26, 110-112]. Although HIV-1/HPV co-infection is 
common in sub-Saharan Africa, only relatively few infected patients develop cervical disease 
and only about one third of ‘in situ’ cervical carcinomas progress to invasive cancer [106, 
108]. Surprisingly, the risk of developing invasive cervical cancer does not decrease 
following Highly Active Antiretroviral Therapy (HAART), which targets the HIV-1 
infection [106, 113-116]. On the contrary, a proportion of the patients with invasive cervical 
cancer have no detectable HIV-1/HPV viral co-infection [55, 57]. 
 
It has been argued that, despite underlying immunodeficiency and immune reconstitution, 
the existing cervical carcinogenesis in HIV-1/HPV co-infected women is further influenced 
by host molecular genetic factors, which vary between individuals [114, 117, 118] (Figure 
2.1). It has also been suggested that the rate of cervical disease progression and likely 





Figure 2. 1 Cervical carcinogenesis in HIV-1/HPV co-infected women  
(SIL = squamous intraepithelial lesion) 





Specifically, the argument is that, cervical cancer progression is controlled via the 
microsatellite instability (MSI) pathway amongst HIV-1/HPV co-infected women and 
through the loss of heterozygosity (LOH) pathway amongst HPV-only infected women [114, 
117, 123, 124]. While many studies have documented the association between HIV-1 
infection and rapidly invasive cervical cancer development, none have shown a direct link 
between HIV-1/HPV co-infection and the degree of disease invasiveness and rate of 
progression [125-127]. 
 
These considerations have determined the focus of this review, which is to assess the current 
knowledge of the influence of host molecular genetic variations, genetic alterations, and 
HIV-1/HPV co-infection on rapidly progressing cervical carcinogenesis. We have reviewed 
published cohort studies and further investigations. We have also examined the evidence for 
possible involvement of host molecular genetic alterations and immunogenetic variations in 
HIV-1/HPV co-infected cervical carcinogenesis. This review stems from research conducted 
into existing knowledge on individualized genomic profiling and targeted molecular 




This study has conducted the methodology according to similar published studies [86, 129]. 
A comprehensive, systematic literature search of peer-reviewed, published articles from the 
NCBI, PubMed, EBSCO, Medline, Elsevier Science, Springer Link and the Google Scholar 
bibliographic databases was carried out. The study included all original research studies, 
short communications, critical reviews and meta-analyses, reports on genes susceptible for 
cervical cancer and immune response, and factors changing risk or offering likely protection 
of cervical cancer development, published prior to May 31st 2018. Information on specific 
alleles and/or genes were noted and critically reviewed. The key words/phrases used for the 
search were ‘host molecular genetics’, ‘cervical cancer susceptibility’, ‘HIV-1/HPV co-
infection’, ‘HIV-1 and cervical cancer’, ‘cancer genomic profiling and molecular targeted 
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prevention’, ‘cervical cancer, mutations and viruses’ and ‘cervical cancer genetics’. The 
present study excluded all studies on epigenetics of cervical cancer, as these were not deemed 
to be relevant to the study topic and focus. There were no specific analytical methods used 
for examination of articles due to the nature of the study.  
 
2.3 Results and Discussion 
 
In this section the study will discuss; 
1. Cervical cancer pathogenesis, HAART and HIV-1/HPV co-infection. 
2. Host HLA polymorphisms, genetic mutations and HIV-1/HPV co-infection in 
cervical cancer progression. 
3. Molecular genetic variations, genes, chromosomes, SNPs and HPV persistence 
in cervical disease progression and susceptibility. 
4. What is not known in host molecular genetics of cervical carcinoma? 
 
2.3.1 Cervical cancer pathogenesis, HAART and HIV-1/HPV co-infection 
The pathogenesis of cervical cancer involves three important steps; high-risk HPV viral 
genome integration into host genome, the oncogenic effects of HPV oncoproteins E6, E7, 
and the accumulation of recurrent, unrepaired genetic alterations in host chromosomal DNA 
[117, 130-132]. Furthermore, there is an interaction between HPV and HIV-1 co-infections, 
resulting in an increased risk of HPV-associated morbidity and cervical cancer mortality 
among HIV-1-positive women [127, 133]. In a few cases, HIV-1/HPV-associated cervical 
cancerous cells, non-genetically regress spontaneously to pre-cancerous cells (but not going 
back to normal cells). Persistent accumulation of uncorrected mutations and additional pro-
oncogenic effects of HIV-1 Tat and HPV E6/E7 oncoproteins, lead to the progression of 
cancerous cells to invasive malignant cancer cells, regardless of the use of HAART [108, 
111, 127, 134, 135] (Figure 2.2).  
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       Figure 2. 2 Host molecular genetic variations and alterations in HIV-1/HPV co-
infected cervical carcinogenesis. 
(Figure from Chambuso et al., (2018) [27] with reprint permission from the Journal 
Oncomedicine). 
 
The immunosuppressive effects of HIV-1 infection are associated with the rapid progression 
of HPV-induced cervical pre-malignant lesions. This may influence the rapid onset of 
cervical disease and further effects on clinical outcome. However, the direct mechanism is 
not clear [93, 136, 137]. Additionally, the effects of duration of HAART use in cervical 
carcinogenesis prevention are still unknown [138, 139] .  
 
A study by De Jong et al. [140], they suggested that the absence of functional HPV16-specific 
CD4 T-cell immune responses found in women with cervical cancer may explain further 
development of the cervical disease despite immune reconstitution following HAART 
initiation or in patients with competent CD4 cell count. Additionally, it has been already 
reported that not all women who progress rapidly to invasive cervical cancer are HIV-1-
positive. This suggests that there are many other possible host factors apart from 
immunosuppression or HIV-1/HPV co-infection that may play a role in rapidly progressing 
cervical carcinogenesis [117, 133, 141, 142]. 
 
HIV-1 proteins can directly cause cancer growth by interfering with cellular functions [105, 
133, 139, 143]. For example, HIV-1 Tat proteins directly interact with the host tumour-
suppressor genes, p53/pRb/p130/p107, and induce increased cell proliferation, which 
promote the effect of HPV oncoproteins E6/E7 in the rapidly progressing cervical 
carcinogenesis [126, 133, 139, 143, 144]. The increased rate of HPV-associated cervical 
disease in HIV-1-positive women is aggravated by HIV-1/HPV molecular interactions 
because HIV-1 Tat proteins can modulate HPV E2 expression, which in turn, influences HPV 
viral replication [145, 146]. However, Hirbod et al. [147], Nkwanyana et al. [148] and Bebell 
et al. [149] have suggested that cervical mucosal inflammation in HIV-1 infected women 
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may be associated with low CD4 cell counts during acute infection. Although this suggestion 
agrees with cancer microenvironment theories that chronic and persistent inflammation 
contributes to cancer development and can predispose to rapidly progressing cervical 
carcinogenesis, the effect has been observed only in a subgroup of HIV-1/HPV co-infected 
women [150-152]. It has been shown that, inflammatory mediators on the surface of the 
uterine cervical epithelial cells, can promote adhesion of HIV-1 infected leukocytes. This in 
turn facilitates HIV-1 Tat proteins uptake by cervical epithelial cells before their 
transformation into cancerous cells [144].  
 
The oncogenic potential of high-risk HPV may contribute to the accumulation of mutations 
in proto-oncogenes and tumour suppressor genes between the G1-phase and S-phases of the 
cell cycle in the host [117, 153]. This process is mostly mediated by the oncoproteins E6/E7, 
which hijack host genomic DNA, then bind and inactivate the tumour-suppressor genes, p53 
and the retinoblastoma (pRb), respectively, to further inhibit apoptosis. This process is 
achieved through the Ubiquitin-mediated degradation pathway [110, 154-156]. 
 
It is clear therefore that, apart from immunosuppression, additional genetic and genomic 
alterations are necessary for pre-cancerous cells to sufficiently progress into malignant and 




2.3.2 Host HLA polymorphisms, genetic mutations and HIV-1/HPV co-infection in 
cervical cancer disease progression 
 
In some populations, carcinogenesis of squamous cell carcinoma is more susceptible to genetic 
variations and alterations than adenocarcinoma [158, 159]. Since the immune system normally 
mobilizes to clear viral infections, the development of virus-associated cancers results from a 
failure of anti-viral immunity. Furthermore, in cervical carcinogenesis, host immune-
competence gradually diminishes as cervical disease progresses to invasive cervical cancer 
[154].  
 
The genes coding for the HLA system, which reside on the short arm of human chromosome 6, 
(except for the gene for β2-microglobulin) (see Figure 2.3) play a central role in immune 
recognition and the subsequent clearance of virally infected cells [39, 160-164]. Therefore, any 
variations or structural genomic changes within the HLA region, which influence immune 
evasion by viruses and cancer cells, may determine the lesions likely to progress to invasive 
cancer [39, 134, 139, 162, 165]. In a study of HLA in cervical cancer patients compared to 
healthy controls, expression of HLA I, were downregulated, suggesting that host genetic 
variations of HLA I also have a significant bearing on specifically HPV-16 related cervical 







Figure 2. 3 A schematic diagram showing an overview of the Human Leukocyte Antigen 
(HLA) genes on chromosome 6p. 
 
HPV-16 E5 oncoprotein and downregulation of the surface HLA I expression has already been 
reported [167]. However, genetic predisposition and variability in the HLA genes have shown 
considerable contradictory findings in different study populations [85, 86, 168]. Variations in 
HLA II and cervical cancer susceptibility have been investigated in different geographical 
populations with inconsistent findings, highlighting the complexity of the 
viral/host/environmental ecosystem [39, 159, 168-172]. For example, predispositions of the 
HLA system and a positive cervical cancer association with the TNF for apoptosis were 
previously reported [173-175]. Although in the mixed ethnicity South African populations, 
TNF G-308 did not show any association with cervical cancer susceptibility [129, 176].  
 
It has been widely reported that LOH mutations and MSI at multiple genomic loci, including 
the HLA region, are the most common host genetic alterations seen in cervical cancer tissues 
[79, 80]. This possibly indicates that the integrity of the HLA region is compromised during 
the process of carcinogenesis [79, 81, 82]. LOH and MSI are caused by genetic alterations such 
as the physical deletion of a chromosomal region, a TSG, or chromosomal non-disjunction 
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during mitotic recombination. It has been reported that the mechanisms of LOH/MSI may be 
remarkably chromosome-specific [32, 77, 79, 162], with some chromosomes being completely 
lost while more than half of the losses are associated with the loss of only a part of the 
chromosome [78, 79]. Essentially, the mechanism underlying HIV-1/HPV co-infection and 
cervical cancer development with regard to LOH/MSI or immunogenetic variations is still 
poorly understood [161]. It has been hypothesized that, cervical cancer progression is 
influenced by the extent of LOH/MSI and HLA variations in immune response towards 
oncogenic HPV clearance and the combined pro-oncogenic effects of the HIV-1/HPV co-
infection [32, 35, 83, 84].  
 
Host genetic variations in the HLA that influence the primary immune response and the severity 
of LOH/MSI at the HLA genomic loci may, therefore, determine which lesions are at the 




2.3.3 Molecular genetic variations, genes, chromosomes, SNPs and HPV persistence in 
cervical disease progression and susceptibility. 
  
Currently, there are no consistent data on the association between any host gene polymorphism 
and disease outcome for cervical cancer [177]. In studies of different chromosomes, the 
changes involving loss of 2q, 3p, 4p, 4q, 5q, 6q, 11q, 13q, 17q and 18q regions and gain of 1q, 
3q, 5p and 8q at various stages of cervical cancer have shown a possible association with either 
oncogenic HPV persistence or cervical cancer disease progression [153, 178]. (Table 2.1). 
Presence of chromosomal aneuploidy, which increases genomic instability in rapidly 
progressing carcinogenesis, was reported in both cervical pre-cancer and cervical invasive 
cancer [179-181]. Furthermore, the presence of an isochromosome 5p associated with cervical 














Table 2. 1 Summary of host gene polymorphisms, SNPs and chromosomal locations found to 
be associated with either HPV persistence or cervical disease progression worldwide. 




HOST GENES AND 
SNPs CHROMOSOME 
COHORT SIZE AND 
NATURE OF THE STUDY 
POPULATION 
STUDIED 




A) Genes involved in HPV 
persistence     
 
CTLA-4,−318 C/T 2q33.2 
 
 
Case-control, 144 cases vs 378 
controls Taiwan [186]           - 
STING 5q31.2 Cross-sectional, 148 patients Thailand  
 
 
E2 downregulates STING 
[187]   
HLA-DQB1 6p21.32 
 
Case-control, 1306 cases vs 
288 controls  Sweden [169] 
 
E5, E7 downregulate 
expression of MHC 
molecules [188] 










469cases, 390 women with 








          - 
     
     
 MICA 6p21.33 GWAS, 1075 Cases and 4014 
Controls 
Sweden [32] E5, E7 downregulate 
expression of MHC 
molecules [188] 
 




469cases, 390 women with 
persistent Hr-HPV and 452 
controls 
Costa Rica 
[189]           - 
     
 
 
IFNA1 9p21.3 Cross-sectional, 148 patients  Thailand 





IL2RA, rs2476491 10p15.1 
Double case-control, 141 
cases, 38 HSIL and 176 




E6, E7 interferes with 
cytokines pathways [188, 
191] 
     
PRDX3, rs7082598 10q26.11 
 
 
Cross-sectional, 68 patients China  
  
 
E6, E7 downregulate 
PRDX3 [192] 
     
 




469cases, 390 women with 
persistent Hr-HPV and 452 
control 
Costa Rica 
[193]           - 
     
 




469cases, 390 women with 
Costa Rica 
[189]           - 
 60 
persistent Hr-HPV and 452 
control  
 




469cases, 390 women with 
persistent Hr-HPV and 452 
control 
Costa Rica 
[189]           - 
     
TP53(p53), rs1042522  17p13.1 
 
 





and IL18, rs1834481 17p13.2 
 
Case-control, 246 cases vs 310 
controls, 12 SNPs in seven 




TYMS, rs2342700 18p11.32 
 
 
Case-control, 65 cases vs 202 
controls Nigeria [196]           - 
     
 
 
RPS19, rs2305809       19q13.2 
Case-control, 65 cases vs 202 
controls Nigeria [196]           - 
     




469cases, 390 women with 














B) Genes involved in 
cervical disease 
progression     
 
EXO1, rs4149963 1q43 
Double case-control, 
469cases, 390 women with 
persistent Hr-HPV and 452 
controls 
Costa Rica 
[197]            - 
TIPARP, rs2665390 3q25.3 






Thailand [199]             - 







E6, E7 increase APOBEC-
mediated mutagenesis [201]. 




Double case-control, 47 cases, 


















E1, E2 ORFs disruption 
interferes RFC4 [204] 




Double case-control, 416 
cases, 356 women with 




 E6 interacts with POLN 
[205] 




MIR146A, rs2910164  5q33.3 
 
 
Case-control, 447 cases vs 443 






















E6 down-regulates TNF 
[209] 




Cross-sectional, 167 cc 





Descriptive, Case series, 1 cc 
patient USA 
E7 fusion causes MYC 
overexpression [41] 
 CDKN2A (p16) 9p21.3  Cross-sectional, 139 cases Japan [211] 
 
 
E7 inactivates Rb1 (p16 





TAP  11q12.3 Descriptive, in vitro China [42] 
 
E7 down-regulates TAP 
[209] 
     
 




Double case-control, 416 
cases, 356 women with 






E6 inhibit interferon related  
responses [43, 209]. 












E2 interacts MDM2 
ubiquitin ligase [212] 
     









E7 binds and degrades pRb 
[213, 214]. 
 
CYP1A1 m2,  rs1048943 




Case-control, 100 cases vs 100 
controls India [215]          - 
 
TELO2, rs4786772 




Double case-control, 416 
cases, 356 women with 
persistent Hr-HPV and 425 
controls 
Costa Rica 
[193]           - 





469cases, 390 women with 







    
 
CYBA, rs7195830 16q24.3 
Double case-control, 
469cases, 390 women with 
persistent Hr-HPV and 452 
controls 
Costa Rica 








Double case-control, 416 
cases, 356 women with 






E7 binds zinc ions to 
prevent EVER1/2 and E5 








Descriptive, Case series, 3 cc 
patients 
USA and Brazil 
[217] 
E6 induce expression of 
FGF-BP [217] 
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It has been observed that, Hr-HPV-DNA potentially integrates into more than 117 unique sites 
into the host genome to influence cervical carcinogenesis [218, 219]. Several other genomic 
regions with changes in the number of DNA copies (copy number-altered regions or CNAs), 
common in solid tumours, have been confirmed by comparative genomic hybridization (CGH), 
Florescent ‘In situ’ Hybridization (FISH) and SNPs, reflecting the important role of HPV 
infection and specific genomic alterations in cervical carcinogenesis [220].  
 
Individuals with a Tp53 polymorphism in codon 72 (Arginine homozygosity) have been 
reported to be at a seven times higher risk for HPV-associated cervical cancer development 
than the heterozygous genotype [129, 194]. However, a pooled data analysis of 49 studies 
worldwide published in 2009, found no association between cervical cancer and the TP53 
codon 72 polymorphism [221]. The most frequently-mutated tumour-suppressor gene in 
cervical cancer is believed to be Cystatin E/M, however, these results are not consistent in 
different study populations [222, 223]. 
 
Previous studies in cervical cancer molecular genetics using SNPs have shown that the 
accumulation of cellular genomic damage such as point mutations, gene amplifications, and 
LOH/MSI in both pre-cancerous and cancerous lesions occurs at rs13117307 at 4q12, 
rs8067378 at 17q12, rs4282438 and rs9277952 at 6p21.32 [176, 219]. There were, however, 
no SNPs associated with cervical cancer risk in p21 rs1801270, BRIP1 rs2048718, and 
rs11079454 polymorphisms [224]. Furthermore, the recurrent cellular genetic alterations in 
cervical cancer were observed only in primary mutational signatures, 1B and 2(APOBEC) 
[225, 226]. Women who are carriers of genes or alleles that may affect the expression of 
immune molecules capable of HPV infection recognition are at increased risk for developing 
cervical cancer. However, variations in CD83, a marker of dendritic cell maturation that may 
assist the T cell response to HPV infection, have shown little or no influence on cervical cancer 
[227, 228]. Contrarily, Yu et al. [229] in 2009, confirmed an association between CD83 
polymorphisms and cervical cancer susceptibility and suggested that polymorphisms in this 
gene and cervical disease association may depend on tumour histology.  
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Mutations in the cyclin dependent kinase inhibitor, WAF1 have shown a positive association 
with cervical cancer susceptibility, although some studies, based on different study populations 
report contradictory findings [129, 230, 231]. Somatic genomic mutations, notably copy 
number variations, in the genes PIK3CA, STK11, PTEN, TP53, and KRAS 4-7, have been 
associated with cervical cancer development [128, 153]. Mutations, and/or polymorphisms in 
transporters associated with antigen processing genes, TAP-1 and TAP-2 were not associated 
with the development of cervical cancer [232, 233]. Although, Zoodzma et al. [159] reported 
an increased risk of cervical cancer in individuals with allele 184 at the MICA locus (with a 
recessive effect), subsequent investigations have not been able to replicate this finding [234].  
 
Certain heritable syndromes involving defects in the DNA damage-repair system, which 
present susceptibility to cervical cancer have been studied. For example, Fanconi anemia 
syndrome (caused by mutations in the genes FANCA, FANCC, FANCL), is an inherited genetic 
disorder characterized by defects in the DNA damage-repair system. In addition, Mathew, 
[235] suggested an association between this syndrome and cervical cancer. However, in a 
subsequent study in a Swedish population, no association between Fanconi anemia and 
susceptibility to cervical cancer was shown [236]. Enigmatically, however, in a study using 
FANCA deficient mice, Park et al. [237] demonstrated susceptibility of HPV 16 E7-driven 
cervical cancer.  
 
The ERAP1-575 on chromosome 5, and the TAP2-379, and TAP2-651 loci on chromosome 
6, have been tested in Asian populations, and shown to be consistently associated with 
cervical cancer risk [238, 239]. The rs799917 TT genotype in the BRCA1 has been associated 
with a significantly decreased risk of cervical cancer [176, 240]. Some variants in the 
chemokine receptor-2A (CCR2A), a transcribed isoform of CD192, situated on chromosome 
3p21, have demonstrated a protective effect against the invasive cervical cancer development 
from squamous intraepithelial lesions (SIL) in Swedish, Portuguese, and South African 
indigenous and Mixed-Ancestry populations. It has also been described as a risk allele for high-
grade squamous intraepithelial lesions and cervical cancer development in healthy individuals. 
In other studies, however, the G46295A variant in CD192 was reported not to confer genetic 
susceptibility towards cervical cancer development [129, 241-243]. 
 65 
The activation of Caspase 8 (CASP8) represents an important initiating event in the death 
receptor-induced apoptosis gene. However, the deleted allele of the CASP8 polymorphism has 
been associated with decreased risk for cervical cancer in a Chinese population [244]. Studies 
in African populations have not found any association between CASP8 polymorphisms and 
cervical cancer susceptibility [155].  
 
Although, we have discussed numerous interactions of several genes, chromosomes, SNPs and 
the HPV oncoproteins E6/E7, the exact mechanisms of interactions with the HIV-1 co-
infection, and the mechanisms by which the combined pro-oncogenic effects of HIV-1 Tat 
proteins and HPV oncoproteins E6/E7, further provoke additional genetic alterations in some 
women to influence the rate of cervical cancer progression is not yet known [144, 245].  
 
2.3.4 What is not known in host molecular genetics of cervical carcinoma? 
There is a lack of available research addressing some specific questions that need to be asked:  
a) Why do variations at the MHC II locus increase the risk of cervical cancer? 
Although this has not been studied before in an HIV-1/HPV co-infected population, 
it does appear that the main host genetic susceptibility factors for cervical cancer 
may be related to the immune recognition of HPV-infected or HPV transformed 
cervical epithelial cells [170].  
 
b) Do variations in the HLA II-DRB1 and -DQB1 influence HIV-1-positive cervical 
carcinogenesis [246]?  
 
c) Are host molecular genetic polymorphisms at certain genomic loci more likely to 
influence cervical carcinogenesis in HIV-1/HPV co-infected women [170]? The 
immunogenetics of cervical carcinomas from HIV-1-positive women have not yet 
been studied [247, 248].  
 




e) What are the effects of HAART on the incidence and severity of cervical cancer in 
HIV-1/HPV co-infected women with regard to molecular genetic variations? 
 
f) How do the anti-apoptotic effects of Protease Inhibitors (PI), influence cervical 
carcinogenesis [135]? 
 
g)  Can the significant genomic loci, candidate tumour suppressor genes and the 
biological pathways of the genetic framework of susceptibility or heritability to 
cervical cancer, which have been indicated by the reported genome-wide 
association studies, be elucidated [171, 194, 234]? 
 
h) Can further research confirm whether susceptibility loci in one population are 
specifically replicated in another e.g. HLA, 4q12, 17q12 [168, 224, 249, 250]? 
 
i)  Why is the apparent effect of the P72R polymorphism in the TP53 not consistent 
in different ethnicities [224]? This is despite the evidence that cervical cancer 
susceptibility loci in each ethnic group vary considerably. 
 
j) Does HIV-1/HPV co-infection provoke additional host genetic alterations on 
chromosome 6p specifically at the HLA II loci, DRBI and DQB1, to influence the 
rate of cervical disease development in HIV-1/HPV co-infected women [246]? 
However, this thesis has answered this question in chapter five (5) after molecular 
investigation in a cohort of South African women. 
 
Overall, the evidence suggests that HPV persistent infection with oncogenic genotypes is a 
necessary, but not sufficient, risk factor for cervical carcinogenesis. This study hypothesizes 
that, HIV-1 co-infection exacerbates and increases the rate of progression to invasive cervical 
cancer by promoting additional genetic alterations and mutations on chromosome 6p by the 




2.4 Conclusions and recommendations 
 
This is the first study to assess the HIV-1/HPV co-infection and correlation with host molecular 
genetics in the development of cervical cancer. Although there are limited published data on 
the interaction of the HIV-1 Tat proteins and HPV oncoproteins, E6/E7, and host molecular 
genetic susceptibility to cervical cancer progression, this review compiles the reports on the 
major host molecular genetic risk factors that have been shown to be associated with both 
rapidly progressing cervical cancer progression and susceptibility.  
 
This review considers the gaps in knowledge for cervical cancer progression in general, and in 
HIV-1/HPV co-infected women, particularly. This study has provided an updated literature 
review, which includes a large number of genes and possible mutations for host molecular 
genetic susceptibility to cervical cancer development. The influence of HIV-1/HPV co-
infection, HIV-1 Tat protein, HPV oncoproteins E6/E7, and host tumour suppressor-genes in 
the disease time course has been discussed and compared in various published studies. Proper 
focus on high-risk populations for cervical cancer disease (e.g. HIV-1 infected women) should 
decrease the number of advanced cases of invasive cervical cancer by identification of early 
molecular genetic changes. This can be achieved by assessing molecular genetic risk factors 
using predictive testing (PT) for cervical disease development in HIV-1/HPV co-infected 
women [251, 252]. In addition, the implementation of new genetic profiling and cervical 
cancer-screening programs for all women infected with HIV-1 is envisaged [252]. 
 
At this stage, it is not easy to point to one or a few genes that may affect susceptibility, severity 
or increase rate of progression of cervical cancer in the presence of HIV-1 and HPV co-
infection as many genes are involved in different molecular pathways. Generally, the genetic 
variations or mutations that affect host genes for the immune response against oncogenic HPV 
clearance, oncogenes, tumour-suppressor genes, apoptosis-related genes, DNA damage-repair 
genes and cell cycle-regulatory genes are responsible for cervical cancer susceptibility and 
rapidly progressing disease. There is also inter-population or multi-population differences and 
a range of confounding host and viral factors, including environmental effects such as host 
behaviour and demographics. This may be why different genes have been found to be 
associated, or not associated, with cervical cancer development in different study populations.  
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CHAPTER 3: Investigation of Age, Absolute CD4 count, and CD4 Percentage in 
Relation to HPV infection and the Stage of Cervical Disease in HIV-1-Positive Women. 
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A subgroup of women who are co-infected with HIV-1and HPV, progress rapidly to cervical 
disease. HPV genotypes within cervical tumour biopsies were characterized and assessed for 
relationship with cervical disease stage, age, HIV-1 status, absolute CD4 count, and CD4 
percentage, and the predictive power of these variables for cervical disease stage was identified 
in a cohort of South African women.  
Methods  
One hundred and eighty one (181) women who were histologically diagnosed with cervical 
disease were recruited, of whom 87 were HIV-1-positive and 94 were HIV-1-seronegative. 
Colposcopy-directed tumour biopsies were confirmed by histology and used for genomic DNA 
extraction. The Roche Linear Array® HPV genotyping test was used for HPV genotyping. 
Peripheral whole blood was used for HIV-1 rapid testing. Fully automated FC500 
MPL/CellMek® with PanLeucogate (PLG) was used to determine absolute CD4 count, CD4 
percentage and CD45 count. A chi-squared test, logistic regression model, parametric 
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Pearson’s correlation, and ROC curves were used for statistical analyses. The Benjamini-
Horchberg test was used to control for false discovery rate (FDR, q-value). All tests were 
significant when both p and q were <0.05. 
Results 
Age was a significant predictor for invasive cervical cancer (ICC) in both HIV-1-seronegative 
(p<0.0001, q<0.0001) and HIV-1-positive women (p=0.0003, q=0.0003). Sixty eight percent 
(59/87) of HIV-1-positive women with different stages of cervical disease presented with a 
CD4 percentage equal to or less than 28%, and a median absolute CD4 count of 400 cells/µl 
(IQR 300-500 cells/µl). Of the HIV-1-positive women, 75% (30/40) with ICC, possessed ≤28% 
CD4 cells versus 25% (10/40) who possessed >28% CD4 cells (both p<0.001, q<0.001). 
Furthermore, 70% (28/40) of women with ICC possessed CD4 count >350 compared to 30% 
(12/40) who possessed CD4 count ≤ 350 (both p<0.001, q<0.001).  
Conclusions 
Age is an independent predictor for ICC. In turn, development of ICC in HIV-1-positive 
women is independent of the host CD4 count and associates with low CD4 percentage 
regardless of absolute CD4 count that falls within the normal range. Thus, using CD4 
percentage may add a better prognostic indicator of cervical disease than absolute CD4 count 




Cervical cancer is the most common cause of cancer-related morbidity and mortality [99, 253], 
and the most common AIDS-related cancer in women in sub-Saharan Africa [254, 255]. 
Women who are infected with HIV-1, are more likely to have higher prevalence of genital 
oncogenic high-risk HPV infection than women who are not infected with HIV-1 [26, 100]. 
Persistent infection of HPV can lead to the development of cervical precancerous lesions [127]. 
These precancerous lesions can progress to ICC if not treated or without an effective immune 
response to clear the persistent oncogenic Hr-HPV infection [256]. 
 
HPV-infection screening is conducted to identify HPV genotypes causing the lesion and proof 
of viral replication in the cervical lesion [257, 258]. Partial genotyping is recommended when 
 70 
HPV screening is used [259]. In HIV-1-positive women with cervical disease, multiple 
infections with different HPV genotypes are common [26]. Additionally, genotype-specific 
HPV burden from the primary cervical lesion may determine the progression of pre-invasive 
to invasive cancer [26, 260, 261]. However, there is limited data on HPV genotypes associated 
with cervical abnormalities in HIV-1-positive women drawn from the tumour itself in 
correlation with immune cell markers, such as absolute CD4 count and CD4 percentage [257, 
262-264].  
 
Within the tumour, extrachromosomal HPV viral genomes often become integrated into the 
host genome. This integration event is thought to drive oncogenesis by dysregulating 
expression of the viral oncogenes E6 and E7, leading to inactivation of critical cell-cycle 
checkpoints and increased genomic instability in the host [130, 265]. However, many previous 
studies used only cytology results synonymously with cervical premalignant changes and none 
of them correlated with absolute CD4 count and CD4 percentage, concurrently [266-268]. 
Because cytology is only a screening test, it is important that the oncogenic HPV genotypes be 
confirmed inside the tumour itself [263]. Lack of characterization of age, CD4 count and CD4 
percentage concurrently in women with cervical disease, makes the association of diagnostic 
clinical immune parameters in women with cervical disease unclear, particularly in HIV-1 
infected women in South Africa, where HIV-1 prevalence and infection rates in women are 
amongst the highest in the world [95].  
 
The aim of this study was to characterize HPV genotypes within cervical tumour biopsies and 
to assess the relationships of cervical disease stage with age, HIV-1 infection status, absolute 
CD4 count, CD4 percentage and to identify the predictive power of these variables for cervical 








Research ethics  
Ethical approval was granted from the Human Research Ethics Committee (HREC) of the 
University of Cape Town (HREC903/2015). All methods were performed in accordance with 
the relevant guidelines and regulations of the Departments of Gynaecology of all respective 
hospitals and the Provincial Department of Health of the Western Cape Province and the South 
African National Health Laboratory Service (NHLS). Subjects were recruited with informed 
consent: Written and signed consent forms in the language of the subject’s choice were 
obtained in the presence of a witness. This was after detailed discussion with patients regarding 
the aims and nature of the study. A trained Registered Professional Nurse who was fluent in 
the relevant languages explained the details of the study and answered questions from the 
patients before their consent was requested. 
 
Study design, subjects, HIV-1 testing and CD4 T lymphocytes enumeration  
As part of a large ongoing hospital-based project, this cross-sectional study recruited 181 
women with histologically confirmed cervical cancer biopsies from the Groote Schuur 
Hospital, Somerset Hospital and Victoria Wynberg Hospital in Cape Town, in the Western 
Cape Province of South Africa. All participants were above 18 years of age and the recruitment 
process was conducted from June 2016 to March 2017. All women were referred from 
peripheral health centers to these three hospitals after cervical screening with abnormal Pap 
smear or suspicions of cervical malignancy after gynaecological examination. Patients were 
recruited from the outpatient gynaecological cancer assessment clinics, colposcopy clinics and 
the gynaecological emergency rooms. Inclusion criteria were newly diagnosed patients with 
cervical disease and ability to consent. Using colposcopy inspection, Gynaecologists collected 
punch biopsies of abnormal cervical lesions. The biopsied tissues were stored in transport 
medium and sent to the Anatomical Pathology laboratory for histopathological analyses. The 
staging summary of cervical disease presented in this study was done as recommended by the 
revised FIGO staging guidelines [269].  
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According to the South African HIV-1 testing algorithm, peripheral whole blood (4ml) was 
collected in EDTA tubes (BD Vacutainer®, Johannesburg, South Africa). Approximately 20µl 
of the collected peripheral whole blood was used for rapid HIV-1 antibody testing (Determine, 
Alere, Inc., Johannesburg, South Africa) [270]. All HIV-1-positive women were on 
antiretroviral therapy (ART), and absolute CD4 count, CD4 percentage and CD45 white cell 
count were performed automatically using fully automated FC500 MPL/CellMek ™ system 
with a PanLeucogate (PLG) (modified gating strategy) platform as described elsewhere by 
Coetzee et al [271]. Generally, a CD4 percentage of 14-28% corresponds to an absolute CD4 
count between 200 and 500 cells/microliters [272]. The cut-off for CD4 percent depends on 
the region and inter-assay or inter-laboratory variability [65, 66, 273]. For example Guiguet et 
al [274], used a cut-off of below or equal to 20% and above 20% in their study population in 
France. However, in South Africa, the laboratory CD4% reports show in a cut-off as below or 
equal to 28% and above 28%. 
 
HPV DNA detection and typing  
Genomic DNA was extracted from histologically confirmed cervical tumour specimens by 
using reagents in the Qiagen® QIAamp DNA Mini purification kit (Qiagen, Johannesburg, 
South Africa) according to the manufacturer’s protocol. The extracted DNA was quantified 
using a Nanodrop® Spectrophotometer (Thermo Fisher Scientific, Johannesburg, South 
Africa). Due to the high concentration of genomic DNA from the tissue biopsies, the DNA was 
diluted using nuclease free water (Thermo Fisher Scientific, Johannesburg, South Africa) to a 
recommended final concentration of 0.2ng/µl. The PCR-based Roche Linear Array® HPV 
genotyping test (Roche Molecular Systems, Pleasanton, CA, USA) which identifies and 
distinguishes about 37 different HPV genotypes [HPV-6, -11, -16, -18, -26, -31, -33, -35, -39, 
-40, -42, -45, -51, -52, -53, -54, -55, -56, -58, -59, -61, -62, -64, -66, -67, -68, -69, -70, -71, -
72, -73, -81, -82, -83, -84, -89 (HPV-CP6108) and –IS39] was used for typing HPV according 






All statistical analyses were performed as recommended in previous studies [275, 276]. A Chi-
squared test was used with descriptive statistics to summarize the simple statistics in different 
stages of cervical disease according to different clinical predictor variables such as age, HPV 
and HIV-1 infections, age at sexual debut, parity and tobacco use. For HIV-1-positive women, 
in order to study immune predictor variables and age of patients, concurrently, a multinomial 
logistic regression model was used with cervical disease as a dependent categorical variable 
and CIN 1 as a reference category to show the relationship of the stage of cervical disease with 
age, absolute CD4 count, CD4 percentage and CD45 count for each stage of cervical disease. 
The correlation between absolute CD4 count and CD4 percentage was performed using 
parametric Pearson’s correlation analyses. Receiver operating characteristic (ROC) curves 
were used to assess sensitivity and specificity by calculating the area under the curves (AUC) 
to predict disease outcome by GraphPad Prism® 8 software (www.graphpadPrism.com). 
Normal distribution two-proportion z-test was used to test for statistically significant 
differences between two proportions within the same categorical group. All p-values were 
corrected for False Discovery Rate (FDR) by the Benjamini-Hochberg’s method and the 
adjusted p-values (q-values) were reported. All odds ratios (ORs), 95% confidence intervals 
(95% CIs) and the p-values calculated for multiple comparisons were 2-tailed, and considered 




Characteristics of the study cohort 
The study cohort comprised of 181 women histologically diagnosed with cervical disease, of 
whom 87 were HIV-1-positive and 94 were HIV-1-seronegative (Table 3.1). The clinical 
predictor variables associated with cervical disease in this study population were: age in years 
(p<0.001, q=<0.001), HPV infection (p=0.012, q=0.018), HIV-1 infection (p<0.001, 
q=<0.001), parity (number of children) (p<0.001, q<0.001) and tobacco use (p=0.031, 
q=0.0372) (Table 3.1), consistent with previously published reports on factors associated with 
cervical disease [277, 278]. Of this study cohort: about 18.8% were documented with age of 
sexual debut below 16 years, while 85.5% were positive for HPV infection by DNA test, and 
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67.8% who were diagnosed with ICC were HIV-1-positive. There were significant associations 
between age above 40 (p=0.021, q=0.063), HIV-1 positive status (both p and q <0.001), and 





Table 3. 1: Demographics and the range of variables including clinical predictors measured 




    Predictor    
      variable % (n/N) 
CIN 1,n= 29     
         (%) 
     CIN 2,n= 48   
            (%) 
 CIN 3, n= 45   
         (%) 
Invasive, n=59    
            (%) 
                                                 FDR 
 95%-CI                 p-value   q-value 
       
Median age, 
y (range)             37 (28-64)            35 (20-51)     41 (26-53)       47 (26-91)                                 
Age in years                                       
<30 7.7 (14/181) 1(3.4)               9 (18.8) 2 (4.4) 2 (3.4) Ref.  
30-40 48.6 (88/181) 22(75.9) 27(56.3) 20(44.4) 19(32.2) 1.65(0.3-16.4)      0.729        0.94 
> 40 43.6 (79/181) 6 (20.7) 12 (25) 23 (51.1) 38 (64.4)   5.6(1.1-53.5)      0.021        0.063 
       
Age at sexual 
debut (in years)       
< 16 18.8 (34/181) 9 (31) 10 (20.8) 7 (15.6) 8 (13.6) Ref. 
16 to 18 45.3 (82/181) 13 (44.8) 17 (35.4) 21 (46.7) 31 (52.5) 1.2(0.4-3.2)           0.812       0.812 
> 18 35.9 (65/181) 7 (24.1) 21 (43.8) 17 (37.8) 20 (33.9) 0.9(0.3-2.4)           0.803       0.9 
       
HPV infection *              
Untypable 
(Negative) 14.5 (25/173) 7 (26.9) 8 (17.4) 5 (11.4) 5 (8.8) Ref. 
Positive  85.5 (148/173) 19 (73.1) 38 (82.6) 39 (88.6) 52 (91.2) 2.1(0.7-7.7)           0.17         0.31 
     98888I         7 
Single HPV**  42.6 (63/148) 6(33.3) 17(44.7) 23(57.5) 17(32.7) Ref. 




* 8 samples with invalid HPV results were disregarded in the HPV infection analysis; 3 samples from CIN 1, 2 samples from CIN 2, one sample 
from CIN 3 and two samples from ICC. 
** 25 samples with untypable HPV (HPV negative) were disregarded in the analysis; 8 samples from CIN 1, 8 samples from CIN 2, 4 samples 
from CIN 3 and 5 samples from ICC. 
(Univariate analysis by linear regression model, cervical disease as a dependent variable, all p-values were adjusted for false discovery rate by the 
Benjamini-Hochberg test) 
Whereas: n=actual number of patients, N=total sample size, CIN = Cervical intraepithelial neoplasm, 1 = Mild, 2= Moderate, 3 = Severe. 
- (Chi-squared test, continuity of correlation (Yates) was not used due to the nature of the analysis).
       
HIV-1 status              
Negative 51.9 (94/181) 20 (69) 34 (70.8) 21 (46.7) 19 (32.2) Ref. 
Positive 48.5 (87/181)   9 (31) 14 (29.2) 24 (53.3) 40 (67.8) 3.4(1.7-6.5)          <0.001    <0.001 
       
Parity           
0 to 4 55.8 (101/181) 20 (69) 35 (72.9) 24 (53.3) 22(37.3) Ref. 
> 4 44.2 (80/181)   9 (31) 13 (27.1) 21 (46.7)  37 (62.7) 3.1(1.6-5.9)          <0.001     <0.001 
       
Tobacco use                
No 72.4 (131/181) 26 (89.7) 36 (75) 29 (64.4) 40 (67.8) Ref. 




Relationship between specific HPV genotypes, HIV-1 status, and tumour stages within 
different age groups. 
Age, HPV genotypes, and HIV-1 status at different stages of cervical disease were investigated 
in the study cohort. As anticipated, HPV-16 genotype was evident most frequently, either as a 
single infection or in mixed infections with other HPV genotypes. Furthermore, HPV-16 
genotypes were present at a significantly higher frequency in the ICC of HIV-1-positive 
patients (72.5%, 29/40) than in the ICC biopsies from HIV-1-seronegative women (21.1%, 
4/19). There was a moderate correlation between CD4 count and CD4 percentage, irrespective 
of single or multiple HPV infections (r=0.68, p<0.001). Collectively, these results show the 
presence of mixed HPV infections in both HIV-1-positive and HIV-1-seronegative women 
(Figure 1A, 1B, 1C and 1D). 
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                                                   -Some women may be counted more than once due to multiple HPV infections
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Figure 3. 1. Illustration of HIV-1 status, HPV genotypes and age groups at different stages of 
cervical disease.  
(A) Unsupervised hierarchical clustering showing HPV genotype distribution according to 
HIV-1 status (green = HIV-1-seronegative: red = HIV-1-positive), tumour stage (CIN 1-3 and 
invasive, and age in years <30; 30-40; >40). The X-axis represents individual biopsy samples 
and the Y-axis shows HPV genotypes. The presence of a specific HPV genotype is shown as 
solid black bars (1) and no colour (0) represents the absence of HPV genotype. The colour bars 
above the map indicate the HIV-1 status, tumour stage and age groups in years. (B &C) 
Histograms showing the numbers of women with specific HPV genotypes with precancerous 
lesions and with ICC, respectively. (D) Pearson correlation between absolute CD4 count and 
CD4 percentage in women with single HPV genotype (solid circles) and multiple HPV 
genotypes (open triangles). 
Where;  
CIN is cervical intraepithelial neoplasm, 1= mild, 2= moderate, 3= severe. Colour blocks do 
not represent the actual number of patients.  
 
Hr-HPV = High risk HPV: HPV-16,-18,-31,-33,-35,-39,-45,-51,-52,-56,-59. 
PHr-HPV = Probable high risk HPV: HPV-26,-53,-66,-67,-68,-70,-73 and -82. 
Lr-HPV = Low risk HPV: HPV-6,-11,-40,-42,-54,-55,-61,-62,-64,-69,-71,-72,-81,-83 (HPV-




Comparison between CD4 status, HPV infection and cervical disease in HIV-1-positive 
patients. 
Consequently, the relationship between absolute CD4 count with CD4 percentage, HPV 
infection and cervical disease was examined in the HIV-1-positive women group in this study. 
Previous studies have shown that in some women, the stage of clinical immunosuppression 
during HIV-1 infection does not associate with stage of cervical disease (or ICC) [279]. 
Equally, high CD4 count and antiretroviral therapy do not appear to prevent HPV infection and 
cervical disease development [26, 279]. In this study, approximately 68% (59/87) of HIV-1-
positive women with different stages of cervical disease presented with a CD4 percentage 
below or equal to 28% and a median absolute CD4 count of 400 cells/µl (Inter quartile range, 
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IQR, 300-500 cells/µl (Figure 3.2A). When the association between absolute CD4 count 
versus CD4 percentage was examined, there were significant moderate to strong correlations 
in all CIN (overall r=0.68, p<0.001; for CIN r=0.83, p<0.001, and a weak correlation in ICC 
(r=0.32, p=0.043), Supplementary figure 3.1, -A, -B, and -C). Cervical disease was more 
prevalent in women with low CD4 percentage regardless of the absolute CD4 count (Figure 
3.2, -B, and -C). Moreover, larger proportion of women with ICC (70%, 28/40) possessed CD4 
count higher than 350, compared to 30% (12/40) who possessed CD4 count ≤ 350 (p<0.001, 
q<0.001, Figure 3.2D). Furthermore, 75% (30/40) of women with ICC, possessed a CD4 
percentage ≤28 versus 25% (10/40) who possessed CD4 percentage > 28% (p<0.001, q<0.001, 
Figure 3.2E). Notably, high absolute CD4 count ≥350 cells/µl was not protective against CIN 
3 and ICC despite significant differences in CD4 count (All p<0.001, q<0.001, Figure 3.2D). 
Additionally, there was no significant difference between single and multiple HPV infections 
by immune cell status in both CIN and ICC (Supplementary figure 3.2, -A, -B, and -C). 
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Figure 3. 2. Relationships between absolute CD4 count (Abs CD4), CD4 percentage (%CD4), HPV 
single or multiple infections, number of women and cervical disease stages in HIV-1-positive women.  
(A) Box and whisker plots showing the relationship between % CD4 and Abs CD4 with the number of 
patients and median CD4 count. (B) Scatter plots showing comparisons of levels of Abs CD4 between 
CIN and ICC (C) Scatter plots showing comparisons of % CD4 between CIN and ICC (D) Histograms 
showing the number of women and comparisons of tumour stages and Abs CD4 within cervical disease 
groups (F) Histograms showing the number of women and comparisons between tumour stage and % 
CD4 within cervical disease groups. 
Where; R2 = is the proportion of the variance (coefficient of determination), p = statistical power   and 
q= Benjamini-Horchberg false discovery rate. 
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Supplementary Figure 3. 1. Scatter plots showing the relationships between absolute CD4 
count (Abs CD4), CD4 percentage (%CD4) and CD45 count (CD45) in CIN and ICC. 
 (A) Overall correlations between abs CD4 versus % CD4 versus CD45 count in all disease 
stages. (B) Correlations between abs CD4, % CD4 and CD45 only in ICC. (C) Correlations 
between abs CD4, % CD4 and CD45 only in CIN. 
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 Supplementary Figure 3. 2. Scatter plots showing the relationships between single and 
multiple HPV infections by absolute CD4 count (Abs CD4), CD4 percentage (%CD4) and 
CD45 count (CD45) in CIN and ICC.  
(A) Relationships between single and multiple HPV infections by Abs CD4 in CIN and ICC 
(B) Relationships between single and multiple HPV infections by % CD4 in CIN and (C) 
Relationships between single and multiple HPV infections by CD45 in CIN and ICC. 
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Comparison between age of patients, CD4 status and cervical disease in HIV-1-positive 
patients. 
Aging and cancer are highly interconnected, ageing being a significant risk factor for cancer 
development [280]. However, in cervical cancer, it has already been reported that HIV-1-
positive women develop invasive cervical cancer earlier, and at a younger age compared to 
HIV-1-seronegative women [99, 100, 281]. Since there is limited data on the impact of age and 
clinical immunological markers according to single or multiple HPV infections in cervical 
cancer development amongst HIV-1-positive women in Africa, this study sought to investigate 
the relationship between stage of cervical disease, single or multiple HPV infections, age, 
absolute CD4 count and CD4 percentage in HIV-1-positive women by using parametric 
Pearson’s correlation test. Although there was no statistically significant correlation between 
age of patients and levels of CD4 count, as well as the age of patients and CD4 percentage, an 
even distribution of HPV single or multiple (genotype) infections was observed, regardless of 
age, absolute CD4 count or CD4 percentage. (Supplementary figure 3.3, -A, and -B). 
Supplementary Figure 3. 3. Relationship between age of patients and levels of immune cell 
markers.  
(A) Correlation between age and absolute CD4 count (Abs CD4). (B) Correlation between 
age and CD4 percentage (%CD4). 
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To investigate the effects of multiple immune predictor variables and age of patients at different 
stages of cervical disease, a statistical model of risk was created by using multinomial logistic 
regression that adds age, absolute CD4 count, CD4 percentage and CD45 white cell count as 
covariates to correct for multiple comparisons. Women older than 30 years had nearly 4 times 
the odds of developing ICC, however, the q value was not significant (p = 0.043, q= 0.172) 
(Table 3.2). The results show that both CD4 count > 350 cells/µl and CD4 percentage > 28% 









                                                  Table 3. 2: Cervical disease with different immune predictor variables and age of HIV-1-positive women 
 
CIN = Cervical intraepithelial neoplasm, 1 = Mild, 2= Moderate, 3 = Severe (Multinomial logistic regression model with cervical disease as a 
dependent variable, CIN 1 as reference category and all p-values were adjusted for false discovery rate (FDR) within a column of each cervical 
disease stage by the Benjamini-Hochberg test
                                                                                                                                                      Cervical disease stage 
  
         CIN 2 (n= 14)    CIN 3 (n=23)                     ICC (n=40)  
Predictor  
variable                     %(n/N)             
  Adjusted 
OR(95% CI) p-value       
 
                                      Adjusted         
FDR q-value              OR(95% CI)           p-value       FDR q-value 
Adjusted 
OR(95% CI) p-value      FDR q-value  
       
Age (years)                       
≤30                           9.2(8/87)    Ref.      
>30                       90.8(79/87)   0.6(0.2-2.2) 0.42        0.84                    1.4(0.4-5.1)              0.626             0.936 3.7(1.5-13.1)    0.043            0.172  
       
CD4 count                 
≤ 350                       31(27/87)    Ref.      
> 350                       69(60/87)    0.9(0.1-6.1) 0.911        1.215                   3.6(0.5-24.6)            0.192            0.576     2.7(0.5-15.7)     0.255           0.255  
       
CD4 percentage       
≤ 28                          68(59/87)     Ref.      
> 28                          32(28/87)    0.2(0.03-2.1) 0.194        0.776                   0.9(0.2-5.3)              0.908            0.908      0.3(0.04-1.5)     0.131           0.175  
       
CD45      
≤ 4 x 10 9                 5.7(5/87)     Ref.      
> 4 x 10 9               94.3(82/87)     1.1 (0.1-12) 0.92        0.92                            N/A                       N/A              N/A       17(1-307)     0.051           0.102  
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This study next set out to determine whether there was any relationship between cervical 
tumour stage, age, CD4 cell levels, and HIV-1 status. The results show that there was no 
significant age difference between HIV-1-positive and HIV-1-seronegative women 
(p=0.4792, Figure 3.3A). However, there were weak to moderate significant correlations 
between age and stage of cervical disease in both HIV-1-positive and HIV-1-seronegative 
women (r=0.39, p=0.0002 and r=0.44, p<0.0001, respectively, Figure 3.3, -B, and -C). 
However, there was no correlation between tumour stage and absolute CD4 count, CD4 









Figure 3. 3. Relationships between age, absolute CD4 count (Abs CD4), CD4 percentage 
(%CD4), CD45 count (CD45) and tumour stages.  
(A) Box and whisker plots showing difference in age between HIV-1-positive and HIV-1-
seronegative women with cervical disease. (B) Correlation between age and tumour stage in 
HIV-1-positive patients. (C)  Correlation between age and tumour stage in HIV-1-
seronegative patients. (D, E &F)  Correlations between Abs CD4, %CD4, CD45 and tumour 







Lastly, this study wished to determine whether age or the immune status of patients was 
predictive of cervical disease stage. ROC curves reflected that age was highly predictive of 
whether a woman was likely to be diagnosed with any of the CIN stages, including ICC, and 
not CD4 absolute count, CD4 percentage, nor CD45 count. Thus, only age was an 
independent predictor of cervical disease for both HIV-1-positive and HIV-1-seronegative 
patients [p=0.0003 and <0.0001, respectively, Figure 3.4 and supplementary figure 3.4 (-
A, -B, -C, -D, and -E)].  
Figure 3. 4. Receiver operating characteristic (ROC) curves between age, absolute CD4 
count (Abs CD4), CD4 percentage (%CD4), CD45 count (CD45) in CIN versus ICC.  
(A) ROC curve of age between CIN versus ICC in HIV-1-seronegative women. (B) ROC of 
age between CIN versus ICC in HIV-1-positive women. (C) ROC curve of Abs CD4 between 
CIN versus ICC in HIV-1-positive women. (D) ROC curve of % CD4 between CIN versus ICC in 
HIV-1-positive women. (E) ROC curve of CD45 between CIN versus ICC in HIV-1-positive women. 
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Supplementary figure 3. 4. Receiver operating characteristic (ROC) curves between age, 
absolute CD4 count (Abs CD4), CD4 percentage (%CD4), CD45 count (CD45) in CIN 1 &2 
versus CIN 3.  
(A) ROC curve of age between CIN 1 &2 versus CIN 3 in HIV-1-seronegative women. (B) 
ROC of age between CIN 1 &2 versus CIN 3 in HIV-1-positive women. (C) ROC curve of 
Abs CD4 between CIN 1 &2 versus CIN 3 in HIV-1-positive women. (D) ROC curve of % 
CD4 between CIN 1 &2 versus CIN 3 in HIV-1-positive women. (E) ROC curve of CD45 






In this study, the distribution of HPV genotypes from 181 histologically-confirmed cervical 
tumour biopsies from HPV-unvaccinated women was investigated. An attempt was made to 
relate the stage of cervical disease with age, HIV-1-infection status and immune status (as 
measured by absolute CD4 count and CD4 percentage). A partial disconnect was observed 
between absolute CD4 count and CD4 percentage in HIV-1-positive women with cervical 
disease, where more women with invasive cervical cancer showed low CD4 percentage 
irrespective of the absolute CD4 count that falls close to normal range. This finding reveals 
some intriguing distinctions in low CD4 percentage in HIV-1-positive women diagnosed 
with invasive cervical cancer that requires further investigation. This is an important 
information because cervical disease progression differs significantly amongst HIV-1-
positive women. It further suggests that other clinical immune cell markers apart from CD4 
cells may be involved in the progression of cervical disease. Also the study results show that 
the distribution of HPV genotypes is related to stage of cervical disease in HIV-1-positive 
women.  
 
This study is the first to report a partial disconnect between absolute CD4 count and CD4 
percentage with cervical disease. There is also a novel association between low CD4 
percentage and age (above 30 years) for HIV-1-positive women with invasive cervical 
cancer, where age was also significantly predictive for cervical cancer disease. In fact, only 
age was a significant independent predictor for stage of cervical disease in both HIV-1-
seronegative and HIV-1-positive women. These results suggest that, both age and CD4 
percentage are related to the development of cervical disease, but only age is a strong 
predictor for ICC disease outcome. Previously, Denny et al. [282], van Aardt et al., [283] 
and Naucler et al., [284] studied the distribution of HPV genotypes between HIV-1-positive 
and HIV-1-seronegative women, by using cervical tissue biopsies. However, they 
investigated only women with invasive cervical cancer and they did not consider the effects 
of age, CD4 count and CD4 percentage concurrently, while the present study does.  
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In the present study population, the significant positive linear correlation between absolute 
CD4 count and the CD4 percentage was not perfect (r=0.69, r2=0.48) and this was interpreted 
as only a partial disconnect between absolute CD4 count and CD4 percentage. In clinical 
HIV-1 studies, discordance between absolute CD4 count and the CD4 percentage have been 
reported in HIV-1-infected patients depending on the study population and the disease of 
interest [65, 285-287]. However, Anyimadu et al. [288] reported a discordance of 71.4% 
(20/28) in one of the sub-groups of HIV-1 infected patients. In this study, a discordance of 
about 68% (59/87) in HIV-1-positive women diagnosed pathologically with cervical disease 
was observed. The discordance between absolute CD4 count and CD4 percentage suggests 
that other lymphocytes apart from CD4 cells may be involved in the development of cervical 
disease. This is because CD4 percentage shows the relationship of CD4 cells in consideration 
with white blood cell count and lymphocyte differential in the body [65, 66]. Apart from 
CD4 cells, other immune cells could play a role in the development of cervical disease 
include, cytotoxic T cells (CD8+ T cells), B lymphocytes, natural killer cells, and other 
natural killer T cells [289]. 
 
An even distribution of single and multiple HPV infections, and cervical disease stage, 
regardless of  CD4 count which falls within the normal range, was an observation similar to 
two previous reports [26, 290]. However, Denny et al. [291] found that having a CD4 count 
of more than 500/mm3 was protective against the development of cervical disease for 36 
months, once the analysis was adjusted for age, sexual activity and HIV-1 viral load. This 
discrepancy between the present study and that of Denny et al. [291], may be due to the fact 
that this study did not consider patient follow up and HIV-1 viral load. However, de Jong et 
al. [140], suggested that, there is an absence of functional HPV-16 specific CD4 T-cell 
immune response in some women. This may justify and explain the findings of ICC despite 
competent CD4 count observed in some women. Since there is no level of absolute CD4 
count that puts HIV-1-positive women at lower risk for persistent infection with oncogenic 
HPV and cervical disease development, we suggest that HIV-1-positive women may be ideal 
for individualized HPV vaccination of adult HIV-1-positive women, as proposed by Dlamini 
et al. [292]. 
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In HIV-1-positive women, HPV-16 genotype presented more in ICC biopsies than in non-
invasive cancer biopsies (Figure 3.1B &C). However, we did not have enough sample size 
to assess the statistical significant difference. Future studies should focus on large sample 
size for this type of association analysis. Similar findings of high frequency of HPV-16 
genotype infection as a single infection or in mixed infections with other HPV genotypes in 
HIV-1-positive women with cervical disease have been reported previously in different parts 
of the world, namely Brazil [262], Burkina Faso and South Africa in one study with samples 
from the two countries [293], Cameroon [294], South Africa [115, 257, 282] and the USA 
[295, 296]. Three studies; one from Mozambique [284], one from two countries, Kenya and 
South Africa [297], and one from South Africa [56], did not find the association of HIV-1 
infection and HPV-16 genotype infection. However, two studies; the one from Kenya and 
South Africa, and the one from South Africa, used cervical swabs or brushes to collect 
cells/tissues around the cervix for HPV testing. Inconsistency in HPV-16 association in HIV-
1-positive women using tumour biopsies and cervical swabs between the present study and 
other studies, could be due to sample size difference, different study populations and 
possibility of cross contamination with other genital HPV genotypes during biopsy 
processing or swab collection.  
 
The strengths of the present study include: the use of histologically-confirmed cervical 
biopsies from precancerous lesions and invasive cancer, showing HPV distribution from 
cervical tumours from both unvaccinated HIV-1-positive and HIV-1-seronegative women, 
timely enumeration of CD4 cells in HIV-1-positive women. The limitations may include: 
being a cross-sectional study, hospital-based studies are likely to have some selection bias, 
limited sample size, possibilities of genital HPV contamination during biopsy collection and 
processing; a lack of focus on detailed information on immune status with regard to HIV-1 
and HPV viral loads, duration of ART, no follow up of absolute CD4 count, and the time of 
acquisition of HIV-1 or HPV infection need to be taken into account. Also there was no 





The present study suggests the presence of a partial disconnect between absolute CD4 count 
and CD4 percentage in a subgroup of HIV-1-positive women histologically diagnosed with 
cervical disease. HPV infection and cervical disease stage are irrelevant to the host CD4 
immune status, but the cervical disease was more prevalent in women with low CD4 
percentage regardless of the number of absolute CD4 count that falls within the normal range. 
However, only age is a strong independent predictor for ICC in both HIV-1-positive and 
HIV-1-seronegative women. Additional results of CD4 percentage should be used 
concurrently with absolute CD4 count to monitor cervical disease in HIV-1-positive women. 
Comprehensive investigation of low CD4 percentage with regard to HIV-1 and HPV viral 
loads in women with cervical disease is warranted in order to determine if this relationship 
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A subgroup of women who are co-infected with HIV-1 and HPV, progress rapidly to invasive 
cervical cancer, regardless of antiretroviral therapy (ART) or immune status. We posit that 
HIV-1/HPV co-infection along with specific host HLA II -DRB1 and -DQB1 alleles are 
involved in the development of cervical cancer. 
Methodology 
A hospital-based genetic susceptibility case-control study was conducted in Cape Town, 
South Africa. A total of 256 women of the same ethnicity were recruited, from which a total 
of 624 HLA-DRB1 and -DQB1 class II genotypes were determined. HLA II candidate genes 
were characterized using PCR-based, Luminex intermediate-resolution genotyping and 
confirmed significant associated genotypes at four-digit resolution by high-resolution gel 
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typing. Overall, 160 alleles were analyses from subjects with cancer, 64 alleles from subjects 
with precancerous lesions, and 400 alleles were analyzed from healthy control women. 
Whole blood was used for HIV-1 antibody testing and HLA II typing. Cervical tumour tissue 
biopsies were used for HPV genotyping. Tests were statistically significant if p<0.05. 
Results 
Women who were co-infected with HIV-1/HPV had advanced cervical disease compared to 
women who were HIV-1-seronegative. HLA II -DQB1*03:01 and -DQB1*06:02 alleles were 
associated with cervical cancer in HIV-1/HPV co-infected women (p=0.001 and p<0.0001, 
respectively) while HLA II-DRB1*13:01 and -DQB1*03:19 were rare or absent in women 
with cervical disease when compared to the control population (p=0.012 and 0.011, 
respectively).  
Conclusions 
Associations between HLA II genotypes with cervical cancer, or likely protection from 
cervical cancer disease in HIV-1/HPV co-infected South African women were described. 
Identifying mechanisms that give rise to this likely protective HLA association will provide 
insight into the development of immune-based prevention measures. 





Each year, cervical cancer accounts for 528,000 new cases and 266,000 deaths worldwide 
[99]. Despite the recent implementation of HPV vaccine programs, cervical cancer still 
remains the most common cause of cancer-related mortality in women in Sub-Saharan Africa 
[18]. Approximately 99% percent of all cervical cancer cases are associated with persistent 
infection with oncogenic HPV, which is a causative organism for this disease [26]. 
Furthermore, women with HIV-1 infection are more likely to have a concurrent persistence 
of HPV infection than women who are not HIV-1-positive [26]. However, only a small 
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subgroup of HIV-1/HPV co-infected women will develop invasive cervical cancer [100]. 
This is regardless of HIV-1 suppression with antiretroviral therapy (ART) or with high CD4 
cell count [282]. 
 
 
Although associations between HPV infection and Human Leukocyte Antigen (HLA) 
genotypes have previously been described [38], the relationship between HIV-1/HPV co-
infection, HLA II and cervical cancer development has not been reported [27]. It is also 
unclear what the immune mechanism would be [104]. It is well established that T-cell 
recognition of virally-infected cells works through class I restricted-epitope recognition and 
that down-regulation of the viral peptide-HLA complex on the infected cell may lead to 
protection from cytotoxic T cells [166]. This would impair the ability of the individual to 
clear virus and thus allow HPV infection to persist [298]. Moreover, apart from the frequent 
overexpression of HPV E6 and E7 viral oncoproteins in cervical cancer, HPV-16 E5 protein 
has been shown to interfere with both HLA I and II antigen presentation [299]. This suggests 
that the HPV may inhibit CD4+ helper T-cells recognition through down-regulation of HLA 
II molecules and thereby evade host immunity. This effect might be exacerbated by the added 
effect of HIV-1 co-infection [300]. HIV-1 Tat proteins can directly interact with the 
pRb/p130/p107/p53 tumour-suppressor genes and induce increased cell proliferation which 
may promote the effect of HPV oncoproteins E6 and E7 in accelerated cervical 
carcinogenesis [143, 145]. 
 
 
The etiology of cervical cancer has been related to certain high-risk HLA II genes [39]. 
Polymorphisms in HLA-DRB1 and -DQB1 genes are hypothesized to play a role in 
carcinogenesis of cervical cancer [38]. Despite considerable scientific interest, findings of 
different published studies have been inconsistent [86, 169, 298]. Several studies have 
reported the protective effects of HLA-DRB1*13:01-DQB1*06:03 haplotypes on cervical 
cancer development and a positive association between HLA -DQB1*03:02 genes and 
cervical disease progression. However, this is not consistent in different population groups 
[111, 122, 171].  
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This study seeks to determine whether host HLA-DRB1 and -DQB1 backgrounds in HIV-
1/HPV co-infected South African women, are involved in cervical cancer disease 
development. These results add new knowledge to the existing theories of rapid cervical 
cancer progression in HIV-1-positive women and aim to further inform on individualized 





Research ethics  
Ethics approval was obtained from the Human Research Ethics Committee of the University 
of Cape Town (HREC903/2015) and the National Health Laboratory Service (NHLS). Study 
approval was also obtained from the Western Cape Provincial Department of Health.  
 
Sample size, study population and selection criteria  
A total of 256 indigenous South African women were recruited in a hospital-based genetic 
susceptibility case-control study conducted at Groote Schuur Hospital, Cape Town, in the 
Western Cape province of South Africa. The recruitment processes were conducted from 
June 2016 to March 2017. The ethnicity and geographic ancestry of cases and the controls 
were the same in order to reduce the bias due to the diversity of HLA II genes within South 
Africa [301]. The study categorized the cases and controls as ‘Black African’ in terms of 
South Africa’s five official population categories, similar to a previous study [302]. Consent 
was obtained from women who attended the outpatient gynaecological cancer assessment 
clinic, the colposcopy clinic or who were admitted to the gynaecology emergency room, to 
participate in the study. The control group consisted of age-matched healthy women from the 
same study population. The control group was compiled from historical data derived from 
200 archived records in the Laboratory for Tissue Immunology (LTI) at the National Health 
Laboratory Service (NHLS), at Groote Schuur Hospital. The study compiled data from 
unrelated age-matched female donors of related bone marrow, renal and other organ 
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transplants, which represented the background population for the HLA II genes. These HLA 
typing results from the control group were counter checked by a second experienced person 
in the laboratory in order to confirm the allele genotypes, sex, age and ethnicity as 
“Indigenous African” women. 
 
Specimen collection 
Written and signed consent forms were used in the language of the subject’s choice in the 
presence of a witness, and after detailed discussion with patients regarding the aims and 
nature of the study. A trained registered nurse who was fluent in the local languages 
explained the details of the study and answered questions from the patients before their 
consent was requested. Peripheral blood (8ml) was collected using two EDTA tubes (BD 
Vacutainer®, Johannesburg, South Africa) for genomic DNA isolation and HLA typing. 
After visual inspection of the cervix, Gynaecologists collected punch biopsies of abnormal 
cervical lesions. A small section of the tissue biopsy was preserved in Digene® specimen 
transport medium (Qiagen, Johannesburg, South Africa) and then stored at -800C until 
processed in order to preserve the genomic DNA for HPV genotyping. Another fraction of 
the same biopsy was stored in formalin and sent to the Anatomical Pathology Laboratory at 
the NHLS for histopathology analyses as described in a previous study [303]. All patients 
were recruited before the initiation of radiotherapy or chemotherapy in order to avoid DNA 
damage during cancer therapy [304].  
 
HIV-1 antibody test 
According to the South African HIV-1 testing algorithm, 20 µl of the collected peripheral 
whole blood was used for rapid HIV-1 antibody testing (Determine, Alere, Inc., 
Johannesburg, South Africa) for all cases [270]. For the control group, a retrospective follow-
up was done on the NHLS Bone Marrow Registry and the organ transplant database for HIV-
1 status. All women in the control group were HIV-1-seronegative. 
 
 100 
HPV DNA genotyping and detection 
Genomic DNA was extracted from cervical tumour tissue specimens using the Qiagen ® 
QIAamp DNA Mini purification kit (Qiagen, Johannesburg, South Africa) according to the 
manufacturer’s protocol. The concentration of the extracted DNA was quantified with a 
Nanodrop® spectrophotometer (Thermo Fisher, Johannesburg, South Africa). Due to 
generally high genomic DNA concentration from the tissue biopsies, the DNA was diluted 
using nuclease- free water (Thermo Fisher, Johannesburg, South Africa) to reach a 
recommended final concentration of 0.2ng/µl. The HPV genotyping and detection tests were 
performed by using the Linear array® PCR-based HPV genotyping kit (Roche, 
Johannesburg, South Africa). The HPV status was only genotyped for cases, depending on 
the availability of tissue specimens in this study. 
 
HLA Typing  
Genomic DNA was extracted from blood collected from patients using a modification of the 
salting out DNA extraction method for whole blood [305]. A Nanodrop® spectrophotometer 
(Thermo Fisher Scientific, Johannesburg, South Africa) was used to measure the 
concentration and purity of the extracted DNA; using the A260/280 ratio was to be in a range 
of 1.8 to 1.9. The DNA was further diluted using nuclease free water (Thermo Fisher 
Scientific, Johannesburg, South Africa) to reach a recommended final concentration of 
0.3ng/µl. Intermediate resolution by commercial kits using the Luminex platform for reverse 
sequence-specific oligonucleotide primers (SSOP) HLA typing technology were used 
(Immucor, Sussex, England) [306]. The PCRs were performed in thermal cyclers using both 
PCR-SSOP and PCR-sequence-specific primers (SSP) supplied by the manufacturer in the 
HLA II typing kit. Amplification reactions were carried out according to the manufacturer’s 
protocol. The HLA II alleles were analyzed using the HLA II data analysis software, Match 
It ® [307]. Further confirmation of the HLA II genotypes that resulted in significant 
associations were undertaken with Olerup® SSP (Immucor Inc. Johannesburg, South Africa) 




A total of 624 *DRB1 *DQB1 HLA II alleles were analyzed. This study characterized 160 
alleles from cancer patients, 64 alleles from pre-cancer patients and 400 alleles from 
unrelated age-matched women in the healthy control group. Allele frequencies for HLA-
DRB1and HLA-DQB1 were calculated by direct counting, as described in a previous study 
[37]. The observed genotype frequencies in the controls were tested for Hardy-Weinberg 
equilibrium. The HLA allele frequencies for DRB1 and DQB1 alleles were compared 
between the cases and controls using the Fisher’s exact test with 2 × 2 tables or by the χ2 test 
with Mantel-Haenszel correction, where appropriate. Multiple testing correction was not 
required due to the nature of the study [308]. The odds ratios (ORs), 95% confidence intervals 





The results for HLA-DRB1 and -DQB1 allele frequencies in women, regardless of HIV-1 co-
infection are summarized in Table 4.1, which shows that, without consideration of HIV-1 co-
infection status, in terms of cervical cancer susceptibility, HLA-DQB1*03:01 (p=0.002, OR 
4.66, 95% CI 1.85-11.72) and HLA-DQB1*06:02 (p=0.002, OR 2.68, 95% CI 1.45-4.96) 
were significantly associated with cervical cancer disease in cases compared to the healthy 
control group. Furthermore, HLA-DRB1*13:01 (p=0.012, OR 0.18, 95% CI 0.02-0.75) and 
HLA-DQB1*03:19 (p=0.011, OR 0.11, 95% CI 0.003-0.74) were found to be significantly 




Table 4. 1 Relative risk for cervical cancer development with specific HLA-DRB1and -
DQB1 allele exposure without consideration of HIV-1 co-infection status. 




#The significant p-value was disregarded because the confidence interval crosses ‘1’ 
      Relative Risk for pre-cancer Relative Risk for cancer 
HLA 
DRB1   
Cancer 
Allele 





 (2n= 33) 
Healthy controls 




(95%CI)  P-value  
Odds ratio 
(95%CI) P-value 
         
*01:01 0.024 (2) 0.03   (1) 0.024 (5)  1.26(0.03-11.79) 0.59  1(0.19-5.26) >0.999 
*01:02 0.1     (8) 0.121 (4) 0.05   (11)  2.45(0.5-9.0) 0.135  1.91(0.6-5.4) 0.193 
*03:01 0.072 (6) 0.09   (3) 0.073 (15)  1.28(0.22-4.92) 0.721  1(0.31-2.86) >0.999 
*03:02 0.072 (6) 0.15   (5) 0.093 (19)  1.8(0.47-5.43) 0.345  0.77(0.24-2.12) 0.817 
*04:01 0.036 (3) 0 0.024 (5)  N/A N/A  1.52(0.23-8.01) 0.693 
*04:04 0 0.09   (3) 0.02   (4)  5.07(0.7-31.3) 0.057  N/A N/A 
*04:05 0 0.03   (1) 0.005 (1)  6.42(0.08-506) 0.257  N/A N/A 
*07:01 0.084 (7) 0.06   (2) 0.07   (14)  0.86(0.09-4.17) >0.999  1.27(0.42-3.54) 0.62 
*08:01 0.012 (1) 0.03   (1) 0.005 (1)  6.4(0.1-506) 0.257  2.5(0.03-198.7) 0.491 
*08:04 0.012 (1) 0.06   (2) 0.04   (8)  1.6(0.3-7.9) 0.632  0.3(0.01-2.34) 0.454 
*09:01 0.036 (3) 0.03   (1) 0.01   (2)  3.2(0.1-62.6) 0.361  3.86(0.43-46.75) 0.143 
*10:01 0.06   (5) 0 0.024 (5)  N/A N/A  2.6(0.58-11.6) 0.155 
*11:01 0.1     (8) 0.09   (3) 0.112 (23)  0.8(0.14-2.9) >0.999  0.86(0.32-2.1) 0.835 
*11:02 0.084 (7) 0.03   (1) 0.08   (16)  0.37(0.01-2.6) 0.48  1.1(0.37-2.98) 0.813 
*11:04 0.024 (2) 0 0.005 (1)  N/A N/A  5.1(0.26-302.5) 0.197 
*12:01 0.036 (3) 0.06   (2) 0.024 (5)  2.6(0.24-16.69) 0.249  1.52(0.23-8.01) 0.693 
*13:01 0.024 (2) 0 0.122 (25)  N/A N/A  0.18(0.02-0.75) 0.012 
*13:02 0.036 (3) 0.09   (3) 0.07   (14)  1.4(0.2-5.3) 0.713  0.5(0.1-1.9) 0.411 
*13:03 0.072 (6) 0 0.03 (7)  N/A N/A  2.2(0.6-7.9) 0.208 
*14:01 0.024 (2) 0 0.01 (2)  N/A N/A  2.5(0.18-35.45) 0.323 
*15:01 0.05   (4) 0.03   (1) 0.024 (5)  1.26(0.03-11.79) 0.594  2.05(0.4-9.79) 0.281 













      
          
*02:01 0.078 (6) 0.065 (2) 0.09 (18)  0.67(0.07-3.06) >0.999  0.82(0.26-2.27) 0.815 
*02:02 0.13 (10) 0.032 (1) 0.15 (30)  0.18(0.03-1.19) 0.09  0.81(0.33-1.82) 0.706 
*03:01 0.169 (13) 0.063 (2) 0.04 (8)  1.6(0.16-8.54) 0.632  4.66(1.85-11.72) 0.002 
*03:02 0.04   (3) 0.063 (2) 0.055 (11)  1.1(0.12-5.42) 0.696  0.67(0.12-2.6) 0.763 
*03:19 0.013 (1) 0 0.1 (20)  N/A N/A  0.11(0.003-0.74) 0.011 
*04:02 0.1     (8) 0.129 (4) 0.065 (13)  2.1(0.45-7.3) 0.265  1.6(0.55-4.36) 0.322 
*04:04 0 0 0.005(1)  N/A N/A  N/A   N/A 
*05:01 0.065 (5) 0.194 (6) 0.11 (22)  1.87(0.56-5.34)       0.24  0.54(0.15-1.54) 0.268 
*05:03 0.026 (2) 0 0.05 (10)  N/A N/A  0.49(0.05-2.27) 0.519 
*06:02 0.324 (25) 0.29   (9) 0.145 (29)  2.3(0.85-5.81) 0.07  2.68(1.38-5.17) 0.002 
*06:03 0.013 (1) 0.032 (1) 0.07 (14)  0.43(0.01-3.02) 0.7  0.17(0.004-1.15) 0.075 
*06:04 0.013 (1) 0 0.075 (15)  N/A N/A  0.16(0.004-1.05) #0.046 
*06:06 0 0.097 (3) 0  N/A N/A  N/A   N/A 
*06:09 0.026 (2) 0.032 (1) 0.02 (4)  1.58(0.03-16.6)       0.527  1.26(0.11-8.96) >0.999 
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Table 4.2 shows consideration of HIV-1 co-infection status, whereby in HIV-1/HPV co-
infected women who had cervical cancer, HLA-DQB1*03:01 (p=0.001, OR 5.6, 95% CI 1.9-
16.9) and -DQB1*06:02 (p<0.0001, OR 4.5, 95% CI 2.2-9.0) were significantly associated 
with the risk of disease. However, HLA-DRB1*13:01, HLA-DQB1*03:19 showed likely 
protection against cervical cancer due to completely absence or rare in both HIV-1/HPV co-












Table 4. 2 Relative risk for developing cervical cancer in HIV-1/HPV co-infected women 
with specific HLA-DRB1 and -DQB1 allele exposure.  
The cancers may be HIV-1-seronegative but they are not HPV-negative.  (Table from 
Chambuso et al., (2019) [185] with reprint permission from the Journal of Cancer)
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#The significant p-value was disregarded because the confidence interval crosses ‘1’. 
  HLA        
  DRB1 
 







  Healthy    
 Controls  
 
  Allele   
frequency 
 (2n=205) 
Relative Risk for HIV-1 Negative 
cancer 
Relative Risk for HIV-1/HPV 
Co-infected cancer 
 Allele  
frequency 
(2n=60) 
   Allele   
 frequency     
   (2n=23) 
ODDS 
ratio(95%CI) P-value  
ODDS 
ratio(95%CI) P-value 
          
  *01:01 0.017 (1) 0.043 (1) 0.024 (5) 1.9(0.04-17.7) 0.469  0.7(0.01-6.3) >0.99 
*01:02 0.1     (6) 0.087 (2) 0.05   (11) 1.7(0.2-8.7) 0.623  1.9(0.57-6.17) 0.227 
*03:01 0.05   (3)  0.13   (3) 0.073 (15) 1.95(0.33-7.8) 0.399  0.7(0.12-2.5) 0.771 
*03:02 0.05   (3) 0.13   (3) 0.093 (19) 1.5(0.26-5.8) 0.464  0.5(0.1-1.9) 0.425 
*04:01 0.05   (3) 0 0.024 (5) N/A N/A  2.1(0.32-11.3) 0.384 
*04:04 0 0 0.02   (4) N/A N/A  N/A N/A 
*04:05 0 0 0.005 (1) N/A N/A  N/A N/A 
*07:01 0.083 (5) 0.087 (2) 0.068 (14) 1.33(0.14-6.5) 0.663  1.3(0.34-3.9) 0.775 
*08:01 0.017 (1) 0 0.005 (1) N/A N/A  3.5(0.04-275.3) 0.399 
*08:04 0.017 (1) 0 0.04   (8) N/A N/A  0.4(0.01-3.3) 0.689 
*09:01 0.05   (3) 0 0.01   (2) N/A N/A  5.4(0.6-65.6) 0.077 
*10:01 0.083 (5) 0 0.024 (5) N/A N/A  3.7(0.81-16.5) #0.049 
*11:01 0.083 (5) 0.13  (3) 0.112 (23) 1.22(0.21-4.6) 0.728  0.7(0.21-2.1) 0.638 
*11:02 0.067 (4) 0.13  (3) 0.08   (16) 1.8(0.31-7.2) N/A  0.9(0.2-2.8) >0.99 
*11:04 0.033 (2) 0 0.005 (1) N/A N/A  7.1(0.36-421.3) 0.128 
*12:01 0.017 (1) 0.087(2) 0.024 (5) 3.9(0.35-25.54) 0.145  0.7(0.01-6.3) >0.999 
*13:01 0 0.087(2) 0.122 (25) 0.7(0.1-3.2) >0.99  N/A N/A 
*13:02 0.033 (2) 0.043(1) 0.068 (14) 0.6(0.01-4.5) >0.99  0.5(0.1-2.15) 0.537 
*13:03 0.01   (6) 0 0.034 (7) N/A N/A  3.1(0.83-11.4) 0.081 
*14:01 0.017 (1) 0.043 (1)  0.01   (2) 4.7(0.08-93) 0.27  1.74(0.03-33.8) 0.536 
*15:01 0.067 (4) 0 0.024 (5) N/A N/A  2.9(0.55-13.9) 0.118 
*15:03 0.067 (4)  0 0.083 (17) N/A N/A  0.8(0.19-2.6) >0.99 









(2n=195)      
          
 *02:01 0.036 (2) 0.19   (4) 0.092 (18) 2.2(0.5-7.9) 0.247  0.36(0.08-1.6) 0.263 
 *02:02 0.125 (7) 0.143 (3) 0.154 (30) 0.9(0.16-3.3) >0.99  0.78(0.27-1.9) 0.674 
 *03:01 0.196 (11) 0.1     (2) 0.041 (8) 2.4(0.23-13.2) 0.259  5.6(1.9-16.9) 0.001 
 *03:02 0.036 (2) 0.048 (1) 0.056 (11) 0.8(0.02-6.2) >0.99  0.61(0.06-2.9) 0.739 
 *03:19 0 0.048 (1) 0.103 (20) 0.4(0.01-2.9) 0.702  N/A N/A 
 *04:02 0.054 (3) 0.238 (5) 0.067 (13) 4.2(1.3-13.3) 0.022  0.8(0.14-3) >0.99 
 *04:04 0 0 0.005 (1) N/A N/A  N/A N/A 
 *05:01 0.054 (3) 0.1     (2) 0.113 (22) 0.8(0.1-3.7) #0.017  0.44(0.1-1.6) 0.218 
 *05:03 0.018 (1) 0.048 (1) 0.05   (10) 0.9(0.02-6.9) >0.99  0.33(0.01-2.4) 0.465 
 *06:02 0.446 (25) 0 0.149 (29) N/A N/A  4.5(2.2-9.0) <0.0001 
 *06:03 0 0.048 (1) 0.072 (14) 0.63(0.01-4.6) >0.999  N/A N/A 
 *06:04 0.018 (1) 0 0.077 (15) N/A N/A  0.22(0.01-1.47) 0.131 
 *06:09 0.018 (1) 0.048 (1) 0.02   (4) 2.3(0.05-24.9) 0.41  0.86(0.02-8.9) >0.99 
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In addition, the majority of women who were co-infected with HIV-1/HPV had advanced 
cervical disease compared to women who were HIV-1-seronegative. Moreover, alleles 
DQB1*03:01 and DQB1*06:02 were significantly associated with the HIV-1/HPV-co-



























Figure 4. 1 Association of tumour status, specific HLA II alleles and HIV-1/HPV co-
infection.  
(A) HIV-1/HPV co-infection, tumour status and the number of patients. (B) and (C) show 
associations of HLA-DQB1 *03:01 and HLA-DQB1 *06:02 alleles, respectively, in HIV-
1/HPV co-infected cervical cancer patients. (Figure from Chambuso et al., (2019) [185] with 
reprint permission from the Journal of Cancer) 
Where; FIGO = International Federation of Obstetrics and Gynaecology. 
             1a-2b = FIGO cervical cancer stage 1a up to stage 2b. 
      Above 2b = FIGO cervical cancer stage above stage 2b. 
               CIN = Cervical intraepithelial neoplasia, 1= Mild, 2= Moderate 
                CIS = Carcinoma In situ 
    Neg. Pcanc.= Negative precancer 
    Pos. Pcanc. = Positive precancer 
    Neg. Canc. = Negative cancer 
     Pos. Canc. = Positive cancer  
 
 107 
The comparison between intermediate, SSP and Olerup high-resolution HLA II typing only 
for significant alleles is shown in Table 4.3. The study confirmed that the susceptible alleles 




Table 4. 3 Association of HLA II alleles with cervical cancer susceptibility, likely protection and HIV-1/HPV co-infection after 
confirmation with high-resolution gel typing. 
# Total number of alleles (N) from cancer patients and healthy controls do not add up because we are showing only significant alleles in HIV-1/HPV co-infected women. Where; SSP 
= sequence specific primers.   Table from Chambuso et al., (2019) [185] with reprint permission from the Journal of Cancer)
                                            
                                          Cervical cancer and HLA II alleles 
   
Significant    




    SSP high   
   resolution  
   HLA typing 
   Olerup high  
  resolution HLA 







Odds ratio    
(95%CI) p-value 
        
Susceptibility DQB1*03:01 DQB1*03:01 DQB1*03:01:01:01 0.157 (13) 0.039 (8) 4.66(1.85-11.72) 0.002 
 
 
DQB1*06:02  DQB1*06:02 DQB1*06:02:01:01 0.301(25) 0.141(29) 2.68(1.38-5.17) 0.002 
 
Likely protection DRB1*13:01 DRB1*13:01 DRB1*13:01:01:01      0.024 (2) 0.122(25) 0.18(0.02-0.75) 0.012 
 
 
DQB1*03:19 DQB1*03:19  DQB1*03:19:01 0.012(1) 0.098(20) 0.11(0.003-0.74) 0.011 
                                    
                                     
                                 Cervical cancer, HIV-1/HPV co-infection and HLA II alleles  








    Olerup high   
    resolution HLA   







    Odds ratio 
       (95% CI) p-value 
 
Susceptibility DQB1*03:01 DQB1*03:01 DQB1*03:01:01:01 0.108 (9) 0.039(8) 4.4(1.4-13.78) 0.001 
 
 DQB1*06:02  DQB1*06:02  DQB1*06:02:01:01  0.301(25) 0.141(29)      4.5(2.2-9.0) <0.0001 




This is the first study to comprehensively investigate the association of HLA II -DRB1 and -
DQB1 alleles, at the molecular level, with cervical cancer disease in HIV-1/HPV co-infected 
women. Other studies have reported cervical cancer associations with HLA II alleles -
DQB1*03:01 [309], and -DQB1*06:02 [310], but this was in populations with unknown HIV-
1 status. 
 
In the present study, in a different population, we report a unique finding of an association of 
the same HLA II alleles -DQB1*03:01 and -DQB1*06:02 with HIV-1/HPV co-infection in 
women with cervical cancer. As HLA-II -DRB1*13:01 and -DQB1*03:19 were significantly 
absent or rare from women with cervical cancer, the study may infer that these are likely 
protective alleles for cervical cancer development in the study population. This may suggest 
that individuals with HLA-DRB1*13:01 and -DQB1*03:19 alleles, may effectively present the 
oncogenic HPV antigens to the immune system to provide a level of protective immunity. 
These findings are novel and have not previously been reported in cervical cancer disease 
studies in any population.  
 
Studies done amongst different ethnic groups of patients with unknown HIV-1 status have 
shown the possible correlation of HLA II molecules with cervical cancer development [171] 
[129]. For example, studies done in Bolivia [311], Brazil [312], China [37] , Costa Rica [197], 
Mexico [308], Senegal [313], Tunisia [298] and Venezuela [314], have reported cervical cancer 
disease associations between different HLA II alleles and HPV infection but none of them have 
reported on HIV-1 infected patients in their study populations. In another study, however, Hu 
et al. [315] reported that HLA II-DQB1*06:02 was protective against cervical cancer 
progression in Chinese patients with unknown HIV-1 status. The inconsistency in the results 
of other studies to date amongst different populations, including the present study, suggests 




The persistence of oncogenic HPV infection frequently leads to cervical cancer development 
[133, 197, 298]. These results, however, add new evidence that the presence of HIV-1/HPV 
co-infection in addition to specific class II-DRB1 and -DQB1 alleles may aggravate or protect 
against cervical cancer disease development in some women. HIV-1 as a co-infection may not 
be a direct risk factor for cervical cancer disease, although HIV-1-positive status has been 
shown to influence the relative risk for cervical disease development. This means that HPV 
infection alone may influence cervical cancer development to a significant extent. When it is 
combined with a specific HLA II gene of risk for cervical cancer development and in the 
presence of HIV-1 as a co-infection, the combination may increase the relative risk for cervical 
cancer disease development.  
 
The persistence of oncogenic HPV in some women with specific HLA II alleles nearly always 
leads to cervical cancer. This effect can be further exacerbated by the pro-oncogenic effects of 
HIV-1 co-infection, regardless of ART initiation, although the exact mechanism is not yet clear 
[27]. However, de Jong et al. [140], suggested that absence of functional HPV-16-specific CD4 
T-cell immune response found in women with cervical cancer, may explain the further 
development of the disease despite immune reconstitution following ART initiation or in a 
competent CD4 count. The study acknowledges that studies on the association of HLA II alleles 
and cervical cancer progression or susceptibility show inconsistent results worldwide [248, 
309, 316, 317]. However, these findings show that HLA II DRB1*13:01, DQB1*03:01, 
DQB1*03:19 and DQB1*06:02 alleles can modulate the cervical carcinogenesis in HIV-
1/HPV co-infected women. 
 
Due to small sample size, this study was underpowered to assess specific HPV types with 
cervical cancer risk according to HLA II alleles and HIV-1 status. Hospital-based studies are 
likely to have some selection bias because we studied only women who were referred with 
cervical disease, so they do not really represent HIV-1/HPV co-infected women in the general 
population who would have been diagnosed but not referred to the hospital in that time. 
Furthermore, this investigation did not study detailed information on immunocompromised 
status (CD4 count and CD4% of lymphocytes), HIV-1 and HPV viral loads, initiation, regime 
and duration of ART, and the time of acquisition of HIV-1 or HPV co-infection. Moreover, 
this study may have missed the effects of a window period in some of the cases because of the 
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use of HIV-1 antibody test, which takes at least three months for the antibodies to be detected 
in the blood since infection. Retrospective HLA data for the control group could add another 




For the first time, this study provides evidence of the association of HLA II-DRB1, -DQB1 
alleles with cervical cancer development amongst HIV-1/HPV co-infected indigenous South 
African women. This is a novel association from a new study population on the possible 
influence of variations of HLA II alleles and HIV-1/HPV co-infection on cervical cancer 
development. These findings suggest that, it is highly likely that specific HLA II-DQB1*03:01 
and -DQB1*06:02 alleles in the presence of HIV-1/HPV co-infection influence cervical cancer 
disease development in the studied cohort of indigenous South African women. Furthermore, 
HLA II-DRB1*13:01 and -DQB1*03:19 were rare or absent in women with cervical disease 
when compared with the control population. Therefore, identifying mechanisms that give rise 
to this likely protective association of HLA II alleles will provide insight into the development 
of immune-based prevention measures. Additional whole genomic research for allele 
association studies may reveal new potential targets for individualized immune-based cervical 
cancer molecular prevention in HIV-1/HPV co-infected women. Furthermore, analyses of 
other immune-related genes and chromosomes out of the HLA II region may also enlighten the 










CHAPTER 5: Investigation of Cervical Tumour Biopsies for Chromosomal Loss of 
Heterozygosity (LOH) and Microsatellite Instability (MSI) at the HLA II Locus in HIV-
1/HPV Co-Infected Women. 
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A subgroup of women who are co-infected with HIV-1 and HPV progress rapidly to cervical 
disease regardless of the number of absolute CD4 count. LOH and MSI are early, frequent 
genetic alterations occurring in solid tumours. Loss of an allele or part of a chromosome can 
have multiple functional effects on immune response genes, oncogenes, DNA damage-repair 
genes and tumour-suppressor genes. To characterise the genetic alterations that may influence 
rapid tumour progression in some HIV-1-positive women, the extent of LOH and MSI at the 
HLA II locus on chromosome 6p in cervical tumour biopsy DNA samples with regard to HIV-






A total of 164 women with cervical disease were recruited for this study, of which 74 were 
HIV-1-positive and 90 were HIV-1-seronegative. DNA from cervical tumours and matched 
buccal swabs were used for analyses. Six fluorescently-labelled oligonucleotide primer pairs 
in a multiplex PCR amplification were used to study LOH and MSI. Pearson chi-squared test 
for homogeneity of proportions using an exact p-value, a two-proportion z-score test, ROC 
curves and a logistic regression model were used for statistical analyses. All p-values were 
corrected for false discovery rate (FDR) using the Benjamini-Hochberg test and the adjusted 
p-values (q-values) were reported. All tests were significant when both p and q<0.05. 
Results 
Tumour DNA from HIV-1/HPV co-infected women demonstrated a higher frequency of 
LOH/MSI at the HLA II locus on chromosome 6p21.21 than tumour DNA from HIV-1-
seronegative women (D6S2447, 74.2% versus 42.6%; p=0.001, q=0.003), D6S2881 at 6p21.31 
(78.3% versus 42.9%; p=0.002, q=0.004), D6S1666 at 6p21.32 (79% versus 57.1%; p=0.035, 
q=0.052), and D6S2746, at 6p21.33 (64.3% versus 29.4%; p<0.001, q<0.001), respectively. 
Conclusions 
HPV infection alone can induce LOH/MSI at the HLA II locus in cervical tumour DNA, 
whereas HIV-1 co-infection exacerbates it, suggesting that this may accelerate cervical disease 
progression in a subgroup of HIV-1-positive women. 
 
Keywords; Cervical cancer, loss of heterozygosity, microsatellite instability, HLA II locus, 




Women who are co-infected with HIV-1 and HPV are at high risk of developing cervical 
precancerous lesions [26]. These precancerous lesions in HIV-1/HPV co-infected women are 
more aggressive, but only a small subgroup progress rapidly to invasive cervical cancer. This 
progression is unrelated to CD4 count or antiretroviral (ARV) therapy [318, 319]. What is not 
clear, however, is how and why this rapid cervical carcinogenesis is only observed in some 
HIV-1/HPV co-infected women [27].  
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Both HIV-1 and HPV are classified as carcinogenic viruses [320]. On the one hand, 
extrachromosomal HPV viral genomes often integrate into the host genome. This integration 
into the host genome drives the oncogenic process due to the overexpression of HPV viral 
oncoproreins E6 and E7 [130], which in turn, lead to inactivation of critical host DNA-damage-
repair checkpoints during the cell cycle [321]. Inactivation of the cell cycle checkpoints results 
in the accumulation of uncorrected mutations during normal DNA replication. These mutations 
increase host genomic instability and lead to further genetic alterations [2, 265]. On the other 
hand, intracellular HIV-1 Tat proteins can interact directly with the Rb and P53 tumour-
suppressor genes in the host [144, 145]. This interaction induces increased cell proliferation, 
which promotes the effects of HPV oncoproteins E6 and E7 in cervical carcinogenesis [143].  
 
 
In two previous studies, host molecular genetic variations at the HLA II locus on chromosome 
6p and accumulation of repeated genetic alterations were reported to influence the rate of 
cervical disease progression in HIV-1/HPV co-infected women [27, 185]. Furthermore, 
Harima et al. [322], reported that chromosome 6p was one of the chromosomal regions most 
frequently involved in the genetic alterations detected in cervical cancer. The availability of 
tumour biopsies in women with cervical disease can be used to interrogate the host genome for 
individualized tumour-specific early molecular oncogenic drivers [323]. LOH and MSI are 
among the most common earliest genetic alterations, and molecular oncogenic drivers, to occur 
in solid tumours including cervical cancer [322, 324]. Both LOH and MSI may lead to the loss 
of microsatellite alleles, chromosomal loci, or single nucleotide polymorphisms [325].  
 
MSI is a locus-specific change in the length of a short tandem repeat of nucleotide sequence in 
tumour genomic DNA when compared to the length in the normal genomic DNA (e.g. derived 
from white blood cells) from the same patient [326]. MSI is caused by mutational inactivation 
of genes involved in DNA damage-repair [327]. LOH at chromosomal level is the loss of one 
copy of an allele or a chromosomal locus in a certain region of a chromosome. If both copies 
of a gene are inactivated, LOH can result in inactivation of functional tumour suppressor genes, 
oncogenes, immune-response genes and DNA damage-repair genes that occur in the region of 
the chromosomal loss [89, 97]. Inactivation of these important genes leads to physiologically 
uncontrolled cell growth and cell division in tissues where the LOH/MSI has occurred [1].  
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This thesis previously hypothesized that HIV-1/HPV co-infection provokes additional genetic 
alterations at the HLA II locus to influence the rate of cervical disease progression in a subgroup 
of HIV-1-positive women [27]. Furthermore, accumulation of repeated genetic alterations, can 
influence the rate of cervical disease progression in HIV-1/HPV co-infected women [27]. In 
the early stages of the carcinogenesis process, genetic alterations (LOH/MSI) can be identified 
in tumour genomic DNA by using specific DNA markers [325]. LOH/MSI can be studied in 
an individual’s tumour genomic DNA and compared to its status in a matched control i.e. 
buccal mucosa cells or peripheral blood leukocyte DNA from the same patient [325]. 
 
The present study investigated the hypothesis by using host genomic DNA fragments, analyzed 
in a multiplex PCR using a capillary array electrophoresis platform. Six fluorescently-labelled 
oligonucleotide primer pairs were used; BAT 26, D6S266, D6S2447, D6S1666, D6S2746, and 
D6S2881 to study chromosomal LOH/MSI in cervical tumour genomic DNA. These were 
compared to matched control DNA derived from buccal mucosa from the same patient, with 
regard to HIV-1/HPV co-infection in a cohort of women histologically diagnosed with cervical 




Research ethics  
All procedures were performed in accordance with the guidelines of The Declaration of 
Helsinki. Ethical approval for the study was granted by the Human Research Ethics Committee 
of; the University of Cape Town (Number; HREC903/2015), all respective hospitals’ 
gynaecology departments, the Department of Health of the Western Cape Government, and the 
South African National Health Laboratory Service. Consent forms were available in the 
language of the subject’s choice and were signed in front of a witness. This was after detailed 
discussion with patients regarding the aims and nature of the study. A trained registered nurse 
who was fluent in the local languages explained the details of the study and answered all 
questions from the patients before their consent was requested. 
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Study design, subjects and samples  
As part of a large ongoing hospital-based project, a total of 200 patients were recruited from 
three hospitals in the Western Cape, namely; the Groote Schuur Hospital, Somerset Hospital 
and Victoria Wynberg Hospital between June 2016 to March 2017. All patients were referred 
from peripheral health centers to these three hospitals after receiving abnormal Pap smear 
results after the routine cervical screening. Patients were recruited from; the outpatient 
gynaecological cancer assessment clinics, colposcopy clinics and the gynaecological 
emergency rooms. The only criterion for recruitment was that the patient be newly diagnosed 
with cervical disease. The age distribution, ranged from 24 to 91 years, with the majority of 
women in the age group between 30 and 40 years. Of the 200 recruited women, 164 were fully 
investigated in this study.  
 
Prior to the collection of buccal swabs, patients rinsed their mouths with sterile water, and 
mechanically chewed both inner buccal mucosal walls for at least 30 seconds. Both sides of 
buccal mucosa were scraped with a ‘DNA collector dry cotton swab stick’ (Thermo Fisher 
Scientific, Johannesburg, South Africa) at least 20 times per side, as described according to the 
manufacturer’s protocol. The buccal swabs were used to extract normal epithelial control DNA 
which were compared with abnormal tumour DNA from the same patients. 
 
According to the South African HIV-1 testing algorithm, peripheral whole blood (4ml) was 
collected in EDTA tubes (BD Vacutainer, Johannesburg, South Africa). Approximately 20µl 
of the collected peripheral whole blood was used for rapid HIV-1 antibody testing (Determine, 
Alere, Inc., Johannesburg, South Africa) [270].  
 
Gynaecologists used colposcopy inspection to collect punch biopsies of abnormal cervical 
lesions for histopathology analyses and HPV genotyping. All patients were recruited in this 
study before the initiation of the radiotherapy or chemotherapy treatment in order to avoid the 
consequences of DNA damage during cancer therapy [304].   
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Tumour DNA extraction and PCR amplification 
Genomic DNA was extracted using Qiagen ® QIAamp DNA Mini purification kit (Qiagen, 
Johannesburg, South Africa) according to the manufacturer’s protocol. The concentration of 
the extracted DNA was quantified by a Nanodrop® Spectrophotometer (Thermo Fisher 
Scientific, Johannesburg, South Africa). The DNA was diluted using nuclease free water 
(Thermo Fisher Scientific, Johannesburg, South Africa) to a recommended final concentration 
of 0.2ng/µl.  The integrity of genomic DNA was tested by resolving DNA fragments on a 1% 
agarose gel by electrophoresis (Bio-Rad, Johannesburg, South Africa), migrated for 1 hour at 
100 V using 0.2μl of total DNA and 2μL of orange loading dye (Thermo Fisher Scientific, 
Johannesburg, South Africa), followed by staining with ethidium bromide (Sigma-Aldrich, 
Johannesburg, South Africa) and visualization on a Ultra Violet-trans illuminator and the image 
was captured using a gel documentation system (Bio-Rad, Johannesburg, South Africa) [328]. 
Each DNA sample was graded, according to the electrophoretic migration of sample DNA 
compared with 100bp weight ladder (Thermo Fisher Scientific, Johannesburg, South Africa).  
 
The extracted DNA was amplified by PCR-based assays using six fluorescently-labelled 
forward primers with the pair names, dyes and sequence as described in Table 5.1. The dream-
Taq® PCR master-mix 12.5µl (1.5mmol MgCl2, 200 mmol dNTPs, 1 unit Taq DNA 
polymerase) (Thermo Fisher Scientific, Johannesburg, South Africa) was used for 
amplification according to the manufacturer’s protocol. The PCR was carried out in 25μl total 
reaction volumes, each containing 2µl of template DNA, 1µl of each primer (Forward and 
reverse) and 8.5μl of nuclease free water (Thermo Fisher Scientific, Johannesburg, South 
Africa). The reaction mixture was heated to 95°C for 7 minutes, followed by 35 cycles, each 
consisting of 30 seconds denaturation at 94°C, 30 seconds annealing at 53°C, 30 seconds 
extension at 72°C, and a final 7-minutes extension at 72°C. The PCR amplification products 
(5μl) were subjected to electrophoresis (Bio-Rad, Johannesburg, South Africa) on 1% agarose 
gel in 1× Tris-acetate-EDTA buffer at 100 V for 1 hour and stained with ethidium bromide 
(Sigma-Aldrich, Johannesburg, South Africa). The images were obtained in a gel 
documentation system (Bio-Rad, Johannesburg, South Africa) with the expected amplicon 
sizes for each marker as described in Table 5.1.  
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Table 5. 1 Marker names, nucleotide sequences of primers, chromosomal positions and the 
fluorescent dyes used for investigation of LOH and MSI at the respective loci 
 







BAT26 F- TGACTACTTTTGACTTCAGCC 2p21 126 A(26) FAM 
 R- ACCCATTCAACATTTTTAACCC     
      
D6S2746 F-AGATTGTGCCACTGCACTCC 6p21.33 97-197 AAAAC FAM 
 R-ATAGTGCTGAGGTTGAGAGC     
      
D6S2881 F-GCTCGGGATTGAGAGGATTC 6p21.31 239-339 CA PET 
 R-AGCGGCGAGGTGAGCATGTC     
      
D6S266 F-GTTCCTCGGAATCATTTCCTCC 6p21.23 267-298 CTTT FAM 
 
R-
GGCAACAGAGTGAGGCTATCTTTG     
      
D6S1666 F-CTGAGTTGGGCAGCATTTG 6p21.32 131-151 GT NED 
 R-ACCCAGCATTTTGGAGTTG     
      
D6S2447 F-TTGAGAGGTGTGCATGTTAC 6p21.21 178-200 AC VIC 
 R-GCATTTCTCTTCCTTATCACTTC     
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HPV DNA detection and genotyping  
Tumour genomic DNA was diluted using nuclease free water (Thermo Fisher Scientific, 
Johannesburg, South Africa) to reach a recommended final concentration of 0.2ng/µl. PCR-
based Roche Linear Array® HPV genotyping test (Roche Molecular Systems, Pleasanton, CA, 
USA) which identifies 37 different HPV genotypes (HPV-6, -11, -16, -18, -26, -31, -33, -35, -
39, -40, -42, -45, -51, -52, -53, -54, -55, -56, -58, -59, -61, -62, -64, -66, -67, -68, -69, -70, -71, 
-72, -73, -81, -82, -83, -84, -89 (HPV-CP6108) and –IS39) was used for typing HPV according 
to the manufacturer’s instructions. All 37 different HPV genotypes were detected accordingly. 
 
Buccal swab DNA extraction and PCR amplification 
In order to preserve the DNA, all buccal swabs were air dried for at least 20 minutes after 
collection and then stored frozen at -20oC until processed. The genomic DNA was extracted 
using Qiagen QIAamp® DNA extraction kit (Qiagen, Johannesburg, South Africa) according 
to manufacturer’s protocol [329]. Briefly, each swab was placed in a 2ml micro centrifuge tube 
and mixed with 20µl proteinase K and 600 µl Buffer ATL, supplied in the kit. The mixture was 
placed in a thermomixer and incubated at 56°C with shaking at 900rpm for at least one hour; 
where after, further extraction procedures followed as per the manufacturer’s protocol. All 
samples were eluted according to the manufacturer’s instructions. The integrity of genomic 
DNA was tested as described in the previous section.  
 
The extracted DNA was amplified by PCR using human beta-globin gene primers –Bg1 F(5´-
CAACTTCATCCACGTTCACC-3´) and Bg2 R(5´-GAAGAGCCAAGGACAGGTAC-3´), 
and 12.5µl Dream-Taq PCR master-mix (1.5mmol MgCl2, 200mmol dNTPs, 1 unit Taq DNA 
polymerase) (Thermo Fisher Scientific, Johannesburg, South Africa) according to the 
manufacturer’s protocol. The PCR was carried out in 25μl total reaction volumes, each 
containing 2µl of template DNA, 0.5µl of each primer and 10.5μl of nuclease free water 
(Thermo Fisher Scientific, Johannesburg, South Africa). The reaction mixture was heated to 
95°C for 7 minutes, followed by 35 cycles, each consisting of 30 seconds denaturation at 94°C, 
30 seconds annealing at 53°C, 30 seconds extension at 72°C, and a final 7-minutes extension 
at 72°C. The PCR amplification products (5μl) were subjected to electrophoresis (Bio-Rad, 
Johannesburg, South Africa) on 1% agarose gel in 1× Tris-acetate-EDTA buffer at 100V for 1 
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hour and stained with ethidium bromide (Sigma-Aldrich, Johannesburg, South Africa)). The 
images were captured in a gel documentation system (Bio-Rad, Johannesburg, South Africa) 
with expected amplicon size of 268bp.  
 
LOH/MSI analysis 
LOH/MSI analysis was carried out in a ‘blinded’ fashion, i.e. without knowledge of HIV-1 or 
HPV infection status. LOH/MSI was assessed at six highly polymorphic repeat markers; 
BAT26, D6S2447, D6S266, D6S2666, D6S2746 and D6S2881. The markers were chosen on 
the basis of their high heterozygosity informative content value of 0.7 in the HLA II region on 
chromosome 6p as described in the NCBI database (https://www.ncbi.nlm.nih.gov/) with 
supplementary mapping information, where necessary, provided in the Genome Reference 
Consortium (https://www.ncbi.nlm.nih.gov/grc) and the Human Genome Database 
(http://morissardjerome.free.fr/infobiogen/www.gdb.org/gdb/). The forward primers were 
labelled with fluorescent dyes: FAM, NED, PET, or VIC [78, 330].    
 
Five of the markers studied are located in the HLA II locus (Chromosome 6p21), and one 
marker, BAT26, was located in the vicinity of the MSH2 mismatch repair gene on chromosome 
2p21. The BAT 26 marker was used in order to compare it with other markers in the analyses 
due to its high percentage of LOH and its reported accuracy in predicting LOH/MSI as 
previously studied in colorectal tumours [331].  
 
Multiplex PCR reactions were performed and the amplified PCR products were analysed by 
capillary array electrophoresis and GeneMapper® software (Applied Biosystems Inc. CA, 
USA).  After PCR, 0.5µl of amplification product was mixed with 0.25µl GS500-LIZ Size 
Standard and Hi-Di™ Formamide (Applied Biosystems, CA, USA) to a final volume of 
10µl. The resulting mixture was denatured for 5 minutes at 95oC and then cooled on ice for 
at least 3 minutes. All the PCR products were genotyped on 3130x1 Genetic Analyser 
(Applied Biosystems Inc., Hitachi, CA, USA), according to manufacturer’s instructions.  
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MSI was defined as the presence of novel fragment sizes in DNA from tumour which was 
absent in the matched normal DNA from the same patient.  Furthermore, for each 
informative tumour DNA/normal DNA pair, the allelic-imbalance ratio (AIR) was 
calculated. This is the ratio of the heights of both microsatellite alleles in the normal DNA 
divided by the ratio of heights in the tumour DNA from the same patient [325] (see figure 
5.1). An AIR value ≤ 0.67 or ≥ 1.35 was regarded as LOH [89]. The LOH/MSI frequency 
was calculated as a percentage of LOH/MSI alterations present in relation to all informative 
loci (Heterozygous DNA) for each marker. At least two independent experiments were 















Figure 5. 1  Electropherograms A, B, C, D, E and F illustrating the allelic status of tumour 
DNA compared to normal DNA in LOH/MSI analyses by using four fluorescently-labelled 
microsatellites markers.  
Paired tumour and normal heterozygous allele ratios were analysed by allelic-imbalance factor 
by calculating the quotient of the peak ratios for each informative microsatellite alleles in the 
normal DNA divided by the corresponding ratio found in tumour DNA from the same patient 
as follows; Alleles in Normal 1:Normal 2/Tumour 1:Tumour 2. 
 
Statistical analysis 
Data analyses were based on the previously published studies [134, 275, 276]. The number of 
cases with LOH/MSI was divided by the total number of informative cases in that region to get 
the fractional locus loss. If one or more markers showed LOH/MSI, the locus was regarded as 
demonstrating LOH/MSI. Pearson chi-squared test for homogeneity of proportions using an 
exact p-value and multivariate logistic regression model were used for statistical analyses. 
LOH/MSI was used as a dependent variable for testing the significance of LOH/MSI variations 
between different predictor variables of interest within each marker. Normal distribution two-
proportion z-score test was used to test for a statistically significant difference between two 
proportions within the same categorical groups. We used sensitivity, specificity and the area 
under the receiver operating characteristic (ROC) curves to assess if age was a predictor of 
invasive cervical cancer outcome in women with LOH/MSI. The p-values were corrected for 
false discovery rate (FDR) by the Benjamini-Hochberg test and the adjusted p-values (q-
values) were reported. All odds ratios (ORs), 95% confidence intervals (95% CIs), the p-values 










Characteristics of the study cohort 
In this study, matched paired tumour (cervical lesions) and buccal swab DNA samples were 
available from 164 patients of the original 200 recruited patients. The paired samples were 
collected from 24 patients with cervical intraepithelial neoplasm I (CIN 1), 42 patients with 
cervical intraepithelial neoplasm II (CIN 2), 44 patients with cervical intraepithelial neoplasm 
III (CIN 3/Carcinoma in situ) and 54 patients with ICC. Seventy-four patients were HIV-1-
positive and ninety patients were HIV-1-seronegative. A total of 980 PCR reactions were 
performed, 490 each from matched tumour and buccal swab samples. The clinical and 
demographic features of the patients in the study cohort are summarised in Table 5.2. Six 
primer sets were used to analyse DNA microsatellites by a multiplex PCR; the number of paired 















Table 5. 2 Demographic features and the range of variables including clinical predictors 
measured in the subjects of the study cohort. 
 
 
* 14 Invalid HPV results were omitted in the analyses 
 
Variable 
 BAT26  
(N= 59) 
   D6S2881 
(N= 81) 
    D6S2746    
    (N= 107) 
     D6S266    
    (N=37) 
     
D6S2666    
   (N= 97) 
  D6S2447   
   (N=109) 
       
Median age, y (Range) 40 (26-77) 40 (26-77) 42 (28-77) 37 (24-61) 39 (24-66) 39 (24-91) 
Standard Deviation 9.7 9.7 9.6 8.4 8.7 10.6 
       
Age group (years) n (%) n (%) n (%) n (%) n (%) n (%) 
< 30  1 (1.7) 4 (4.9) 5 (4.7) 2 ( 5.4) 6 (6.2) 7 (6.4) 
30-40 30 (50.8) 39 (48.1) 46 (43) 21 (56.8) 54 (55.7) 60 (54.5) 
> 40 28 (47.5) 38 (46.9)   56 (52.3) 14 ( 37.8) 37 (38.1) 42 (38.2) 
       
HIV-1 status       
HIV-1-positive 36 (61) 46 (56.8) 56 (52.3) 19 (51.4) 62 (63.9) 62 (56.9) 
HIV-1-seronegative 23 (39) 35 (43.2) 51 (47.7) 18 (48.6) 35 (36.1) 47 (43.1) 
       
*HPV infection       
Single HPV infection 19 (32.2) 24 (29.6) 36 (33.6) 13 (35.1) 33 (34) 36 (33) 
Multiple HPV infection 33 (55.9) 39 (48.1) 50 (46.7) 18 (48.6) 48 (49.5) 54 (49.5) 
       
High risk HPV 46 (78) 59 (72.8) 81 (75.7) 27 (73) 77 (79.4) 86 (78.9) 
Low risk HPV  6 (10.2) 4 (4.9) 5 (4.7) 4 (10.8) 4 (4.1) 4 (3.7) 
       
Tumour stage       
CIN 1 & 2 20 (33.9) 31 (38.3) 38 (35.5) 17 (45.9) 44 (45.4) 49 (45) 
CIN 3 16 (27.1) 17 (21) 25 (23.4) 9 (24.3) 25 (25.8) 29 (26.6) 
Invasive    23 (39)  33 (40.7) 44 (41.1) 11 (29.7) 28 (28.9) 31 (28.4) 
       
Histopathology       
Mild dysplasia 9 (15.3) 16 (19.8) 19 (17.8) 2 (5.4) 16 (16.5) 18 (16.5) 
Moderate dysplasia 11(18.6)  15 (18.5) 19 (17.8) 15 (40.5) 28 (28.9) 31 (28.4) 
Carcinoma In situ 16 (27.1) 17 (21) 25 (23.4) 9 (24.3) 26 (26.8) 29 (26.6) 
Squamous cell 
carcinoma 20 (33.9) 26 (32.1) 35 (32.7) 8 (21.6) 23 (23.7) 24 (22) 
Adenocarcinoma 3 (5.1) 7 (8.6) 9 (8.4) 3 (8.1) 4 (4.1) 7 (6.4) 
 126 
Table 5. 3 Number of paired samples for which each microsatellite marker was successfully 
resolved. 
 
                Marker      Samples 
  
i) BAT26 59 paired samples 
    
ii) D6S2881 81 paired samples 
    
iii) D6S2746 107 paired samples 
    
iv) D6S266 37 paired samples 
    
v) D6S2666 97 paired samples 
    
vi) D6S2447 109 paired samples 
 
 
Comparisons of LOH/MSI frequency: 
(i) between tumour DNA from precancerous lesions and ICC 
To investigate whether LOH/MSI was different between patients with precancerous lesions 
and ICC, the frequency of LOH/MSI in tumour DNA from precancerous lesions and ICC for 
each marker was compared separately. ICC tumour DNA showed more LOH/MSI only at 
6p21.31 (D6S2881) than precancerous lesions tumour DNA, i.e. 78.8% versus 52.1 % 
respectively, p=0.019. However, the false discovery rate (FDR) q-value was not statistically 









(II) between tumour DNA from HIV-1-positive and HIV-1-seronegative women  
To investigate if LOH/MSI was different between tumour biopsies, depending on HIV-1 
infection status, the frequency of LOH/MSI for all tumour biopsy DNA by examining each 
marker was compared separately in HIV-1-positive and HIV-1-seronegative women. The 
results show that tumour DNA from HIV-1-positive women demonstrated a higher frequency 
of LOH/MSI than tumour DNA from HIV-1-seronegative women at 6p21.21 (D6S2447, 74.2% 
versus 42.6%; p=0.001, q=0.003), 6p21.31 (D6S2881, 78.3% versus 42.9%; p=0.002, 
q=0.004), 6p21.32 (D6S2666, 79% versus 57.1%; p=0.035, q=0.052), and 6p21.33 (D6S2746, 




Table 5. 4 Frequency of LOH/MSI according to cervical disease and HIV-1 status 
(A) Frequency of LOH/MSI between precancerous lesions and ICC. (B) Frequency of 
LOH/MSI between HIV-1-seronegative and HIV-1-positive women. (Pearson chi-square test 







A      B     
   PRECANCEROUS  
                           




LOH/MSI    
     (%) 
Cases 
studied 
LOH/MSI     
      (%) 
                    FDR  
p-value      q-value 
 Cases      
studied 
     LOH/MSI 
           (%) 
Cases 
studied 
 LOH/MSI                            FDR 
     (%)              p-value      q-value 
           
BAT 26 36/59 6/36 (16.7) 23/59 6/23 (26.1) 0.51              1.02 23/59       3/23 (13) 36/59  9/36 (25)    0.334            0.401 
           
D6S266 26/37 12/26 (46.2) 11/37 4/11 (36.4) 0.723            1.085 18/37        9/18 (50) 19/37 7/19 (36.8)    0.515            0.515 
           
D6S2666 69/97 49/69 (71) 28/97 20/28 (71.4) >0.99            0.99 35/97        20/35 (57.1) 62/97  49/62 (79)    0.035            0.052 
           
D6S2881 48/81 25/48 (52.1) 33/81 26/33 (78.8) 0.019            0.114 35/81        15/35 (42.9) 46/81 
36/46 
(78.3)    0.002             0.004 
           
D6S2746 63/107 33/63 (52.4) 44/107  18/44 (40.9) 0.325            0.975 51/107         15/51 (29.4) 56/107 
36/56 
(64.3)   <0.001           <0.001 
           
D6S2447 78/109 48/78 (61.5) 31/109 18/31 (58.1) 0.829             0.99 47/109         20/47(42.6) 62/109 
46/62 
(74.2)     0.001             0.003 
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The present study also compared the odds of having LOH/MSI (LOH/MSI-positive versus 
LOH/MSI-negative cases) according to HIV-1 status for each marker. The results show that 
tumour biopsy DNA from HIV-1-positive women had a higher relative risk of having 
LOH/MSI than tumour biopsy DNA from HIV-1-seronegative women for markers; D6S2881 
(OR 4.8, CI 1.8-12.7, p= 0.002, q=0.004), D6S2746 (OR 4.3, CI 1.9-9.7, p< 0.001, q= 
<0.001), D6S2666 (OR 2.8, CI 1.1-7.7, p= 0.035, q= 0.052) and D6S2447 (OR 3.88, CI 






















                                                                             
                                                                                         Outcome 
                                                                                       BAT 26 (n= 59) 
Exposure        No LOH/MSI (n= 47) LOH/MSI (n= 12) OR     CI P-value     FDR q-value 
  HIV-1-seronegative 
(n=23) 20 (42.6%) 3 (25%) Ref.   
  HIV-1-positive (n= 36) 27 (57.4%) 9 (75%) 2.2 0.5-14   0.334                0.401 
      
                                                                                      D6S2881 (n= 81 ) 
 No LOH/MSI (n= 30 ) LOH/MSI (n= 51)    
  HIV-1-seronegative 
(n= 35)  20 (66.7%) 15 (29.4%) Ref.   
  HIV-1-positive (n= 46)  10 (33.3%) 36 (70.6%) 4.8 1.8-12.7   0.002                 0.004 
      
                                                                                     D6S2746 (n= 107 ) 
 No LOH/MSI (n= 56 ) LOH/MSI (n= 51)    
  HIV-1-seronegative 
(n= 51) 36 (64.3%) 15 (29.4%) Ref.   
  HIV-1-positive (n= 56) 20 (35.7%) 36 (70.6%) 4.3   1.9-9.7  <0.001              <0.001 
      
                                                                                     D6S266 (n= 37 ) 
  No LOH/MSI (n=  21) LOH/MSI (n= 16)    
  HIV-1-seronegative 
(n= 18) 9 (42.9%) 9 (56.2%) Ref.   
  HIV-1-positive (n= 19)                  12(57.1%) 7 (43.8%) 0.58   0.1-2.6    0.515                0.515 
      
                                                                                     D6S2666 (n= 97 ) 
  No LOH/MSI (n= 28 ) LOH/MSI (n= 69)    
  HIV-1-seronegative 
(n= 35) 15 (53.6%) 20 (29%) Ref.   
  HIV-1-positive (n= 62) 13 (46.4%)           49(71%) 2.8   1.1-7.7     0.035                0.052 
      
                                         D6S2447 (n= 109)   
 No LOH/MSI (n= 43 ) LOH/MSI (n= 66)    
  HIV-1-seronegative 
(n= 47) 27 (62.8%) 20 (30.3%) Ref.   
  HIV-1-positive (n= 62) 16 (37.2%) 46 (69.7%) 3.88   1.6-9.5      0.001              0.003 
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Comparison between LOH/MSI status and clinical variables 
In order to control for the effects of other variables that may influence the outcome, a 
multivariate logistic regression model was used to study the association of each variable by 
considering LOH/MSI as a dependent variable for four markers that showed significantly 
different frequency among the studied groups. In this analysis, only HIV-1 status was 
significantly associated with LOH/MSI in DNA marker; D6S2746 (p < 0.0001, q<0.001), 
D6S2881 (p = 0.025, q=0.15), D6S2447 (p = 0.002, q=0.012) and D6S2666 (p= 0.021, 
q=0.063) while tumour stage and histopathology were significantly associated with 
LOH/MSI in DNA marker D6S2666 for tumour stage (p=0.027, q=0.054) and for 
histopathology (p=0.015, q=0.09) (Table 5.6). Furthermore, aging and cancer are highly 
interconnected, older age being a significant risk factor for cancer development [280].  
 
However, in cervical cancer, it has already been reported that HIV-1-positive women develop 
invasive cervical cancer earlier and at a younger age compared to HIV-1-seronegative 
women [99, 100, 281]. Since there is limited data on the impact of age on LOH/MSI in 
cervical cancer development amongst HIV-1-positive women, this investigation sought to 
study whether age could predict invasive cervical cancer outcome in HIV-1-positive women 
with LOH/MSI in the study cohort by plotting specificity against sensitivity for each marker 
by using receiver operating characteristic (ROC) curves to calculate the area under the curves 
(AUC), with p values. This study found that age could predict invasive cervical cancer 
outcome in HIV-1-positive women with LOH/MSI for two DNA markers, D6S2447 








Table 5. 6  Multivariate analysis in logistic regression for each marker by using LOH/MSI 





p    
value 
FDR q      D6S2881  
value        (N= 81) 
                      
 p              FDR q        D6S2447  
 value       value         (N=109) 
 p 
value 
                  
FDR q   D6S2666                 
value     (N= 97) 
 
p       FDR q                                   
value      value 
Variables         
Age n (%) 0.256  0.384            n (%) 
                             
 0.687       1.031 n (%) 0.16 0.48           n (%) 
                   
   0.7         0.84 
< 30 5 (4.7)                     4 (4.9)  7 (6.4)                6 (6.2)  
30-40 46 (43)                  39 (48.1)  60 (55)            54 (55.7)  
>40 
   56 
(52.3)                 38 (46.9)  42 (38.5)            35 (36.1)  
         
HIV-1 status  <0.0001 <0.001  0.025        0.15  0.002 0.012 
               
0.021        0.063 
HIV-1-
seronegative 51 (47.7)                  35 (43.2)  62 (56.9)              35 (36.1)  
HIV-1-positive 56 (52.3)                  46 (56.8)  47 (43.1)              62 (63.9)  
         
HPV risk  0.174 0.522  0.837       1.004  
 
0.997 0.997 
               
0.919        0.919 
Low risk HPV 5 (4.7)                   4 (4.9)  4 (3.7)               4 (4.1)  
High risk HPV 81 (75.7)                   59 (72.8)  86 (78.9)            77 (79.4)  
         
HPV single  
or multiple  0.215 0.43  0.935          0.935  0.353 0.706 0.142       0.213 
Single HPV  36 (33.6)                  24 (29.6)  36 (33)               33 (34)  
Multiple HPV 50 (46.7)                   39 (48.1)  54 (49.5)             48 (49.5)  
         
Tumour stage  1.171 1.171  0.632          1.264  0.818 0.981 0.027       0.054 
CIN 1 & 2 38 (35.5)                    31 (38.3)  49 (45)             44 (45.4)  
CIN 3 25 (23.4)                 17 (21)  29 (26.6)             25 (25.8)  
Invasive 44 (41.1)                   33 (40.7)  31 (28.4)             28 (28.9)  
         
Histopathology  0.646 0.775  0.267         0.801  0.536 0.804 
               
0.015        0.09 
Mild dysplasia 19 (17.8)                  16 (19.8)  18 (16.5)               16 (16.5)  
Moderate  
dysplasia 19 (17.8)                  15 (18.5)  31 (28.4)               28 (28.9)  
Carcinoma  
In Situ 25 (23.4)                 17 (21)  29 (26.6)               26 (26.8)  
SCC 35 (32.7)                    26 (32.1)  24 (22)               23 (23.7)  
ADC  9 (2.8)                    7 (8.6)  7 (6.4)                   4 (4.1)  
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Supplementary figure 5.1. Receiver operating characteristic curves by using age of patients 
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to predict ICC between HIV-1-positive and HIV-1-seronegative women with LOH/MSI for 
four significant DNA markers.(A) ROC curves for DNA marker D6S2746, showing 
prediction for ICC with LOH/MSI in both HIV-1-positive and HIV-1-seronegative women 
by using age. (B) ROC curves for DNA marker D6S2447, showing prediction for ICC with 
LOH/MSI in both HIV-1-positive and HIV-1-seronegative women by using age. (C) ROC 
curves for DNA marker D6S2666, showing prediction for ICC with LOH/MSI in both HIV-
1-positive and HIV-1-seronegative women by using age. (D) ROC curves for DNA marker 
D6S2881, showing prediction for ICC with LOH/MSI in both HIV-1-positive and HIV-1-
seronegative women by using age. 
 
 
Comparison of LOH/MSI status between tumour DNA from precancerous lesions and 
ICC according to HIV-1 infection 
In order to further examine the effects of HIV-1 infection on the status of LOH/MSI, a 
comparison was made of LOH/MSI between tumour DNA from precancerous lesions and 
ICC according to HIV-1 infection for four markers; In marker D6S2746, tumour DNA from 
HIV-1-positive women showed significantly more LOH/MSI than tumour DNA from HIV-
1-seronegative women with precancer (p=0.011, q=0.011). For marker D6S2447, tumour 
DNA from HIV-1-positive women showed more LOH/MSI than tumour DNA from HIV-1-
seronegative women in invasive cancer, although the p-value was not applicable (N/A) due 
to a very low number of HIV-1-seronegative women with LOH/MSI. For marker D6S2666, 
tumour DNA from HIV-1-positive women showed significantly more LOH/MSI than tumour 
DNA from HIV-1-seronegative women with precancer (p=0.001, q=0.002), the p-value was 
not applicable for invasive cancer due to a very low number of HIV-1-seronegative women 
with LOH/MSI. Finally, for marker D6S2881, tumour DNA from HIV-1-positive women 
showed more LOH/MSI than tumour DNA from HIV-1-seronegative women with ICC, 
although the p-value was not applicable due to very low number of HIV-1-seronegative 
women with LOH/MSI (p=0.011, q=0.022) (Figure 5.2). 
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Figure 5. 2 Relationships between LOH/MSI status and HIV-1 status between precancerous 
lesions and ICC tumour biopsies for four DNA markers in A, B, C &D. 
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Comparison of LOH/MSI status between HIV-1-positive and HIV-1-seronegative 
women with Hr-HPV infection. 
Because Hr-HPV infection is a known risk factor for cervical disease development, and HIV-
1 infection increases prevalence, persistence and reduces clearance of HPV-infection [26], 
this study examined whether LOH/MSI between tumour (cervical lesion) biopsy DNA from 
HIV-1-positive women and HIV-1-seronegative women differ according to Hr-HPV 
infection in four markers which showed significant results. Tumour biopsy DNA from HIV-
1-positive women with Hr-HPV infection showed more LOH/MSI than tumour biopsy DNA 
from HIV-1-seronegative women with Hr-HPV infection in marker D6S2746 (p= 0.003, 
q=0.006) (Figure 5.3A), D6S2447 (p= 0.001, q=0.004) (Figure 5.3B) and D6S2881 (p= 
0.005, q=0.007) (Figure 5.3D). However, with marker D6S2666, the difference was not 
statistically significant p=0.172, q=0.172 (Figure 5.3C). 
 
Figure 5. 3 The relationships in LOH/MSI status between HIV-1-positive and HIV-1-
seronegative women with Hr-HPV infection in four markers in A, B, C&D. 
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5.4 Discussion  
 
The present study represents the first in-depth analysis of cancerous changes, viral infection, 
and host LOH/MSI. The study performed comprehensive allelo-typing of isolated genomic 
DNA from buccal swab samples (control DNA), and from cervical precancerous lesions and 
ICC samples. All these samples were from HIV-1-positive and HIV-1-seronegative South 
African women, none of them were HPV vaccinated previously. More importantly, this study 
is the first to offer an opportunity to examine the effects of HIV-1/HPV co-infection in 
cervical cancer by using a host molecular genetics approach. The findings revealed a 
significantly higher frequency of chromosomal LOH/MSI in tumour biopsy DNA from HIV-
1-positive women than from HIV-1-seronegative women at the HLA II locus on chromosome 
6p, as summarised in Supplementary Table 5.1. The investigation also contributes some 
important information to the existing theories of host molecular genetic alterations and 













Supplementary Table 5. 1 Summary of the results 
 
  LOH/MSI, n/N (%)  LOH/MSI, n/N (%) p-value q-value 
                    Cervical disease stage    
DNA marker Pre-invasive lesions Invasive cancer   
BAT 26 6/36 (16.7) 6/23 (26.1) 0.51 1.02 
D6S266 12/26 (46.2) 4/11 (36.4) 0.723 1.085 
D6S2666 49/69 (71) 20/28 (71.4) >0.99      0.99 
D6S2881 25/48 (52.1) 26/33 (78.8) 0.019 0.114 
D6S2746 33/63 (52.4) 18/44 (40.9) 0.325 0.975 
D6S2447 48/78 (61.5) 18/31 (58.1) 0.829 0.99 
     
                        HIV-1 status    
DNA marker HIV-1-seronegative HIV-1-positive   
BAT 26  3/23 (13)  9/36 (25) 0.334 0.401 
D6S266  9/18 (50)  7/19 (36.8) 0.515 0.515 
D6S2666   20/35 (57.1)  49/62 (79) 0.035 0.052 
D6S2881   15/35 (42.9)  36/46 (78.3) 0.002 0.004 
D6S2746   15/51 (29.4)  36/56 (64.3) <0.001 <0.001 
D6S2447   20/47(42.6)  46/62 (74.2) 0.001 0.003 
     
                       High risk HPV    
DNA marker HIV-1-seronegative HIV-1-positive   
D6S2666   18/77 (23.4) 40/77 (51.9) 0.172 0.172 
D6S2881   10/59 (16.9) 30/59 (50.8) 0.005 0.007 
D6S2746   10/81 (12.3) 30/81 (37) 0.003 0.006 
D6S2447  11/86 (12.8) 40/86 (46.5) 0.001 0.004 
     
Multivariate logistic regression analyses    
                                                                                       HIV-1 status    
DNA marker HIV-1-seronegative  HIV-1-positive    
D6S2666  35/97 (36.1) 62/97 (63.9) 0.021 0.063 
D6S2881  35/81 (43.2) 46/81 (56.8) 0.025 0.15 
D6S2746  51/107 (47.7) 56/107 (52.3) <0.0001 <0.001 
D6S2447 62/109 (56.9) 47/109 (43.1) 0.002 0.012 
     
Tumour stage (D6S2666)     
CIN 1 & 2  44/ 97(45.4) 
 0.027 0.054 
CIN 3  25/97 (25.8) 
   
Invasive  28/97 (28.9) 
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Where; AUC=Area under the curve. 
 
Although the duration of oncogenic Hr-HPV infection is recognised as an etiologic factor for 
the development of cervical disease, other host factors, and an understanding of the 
mechanisms involved in the cervical carcinogenesis pathway in the host, remain unknown 
[231]. In view of the association of certain HLA II genes on chromosome 6p with cervical 
cancer, this study has considered the molecular genetic basis of this association in the host.  
 
The present study reports LOH/MSI from tumour DNA in precancerous lesions and 
cancerous lesions even from HIV-1-seronegative women. These results suggesting that, in 
HPV infected women with cervical disease, LOH/MSI is an early genetic event in the 
development of cervical cancer, including the pre-invasive lesions. HIV-1 infection is an 
additional factor that appears to change the genetic makeup of the host cell, which in turn 
causes the overall genomic instability of cervical tumour DNA during the carcinogenic 
process. Although HPV infection alone can induce LOH/MSI at the HLA II locus in cervical 
tumour DNA, HIV-1 co-infection exacerbates it, potentially accelerating cervical disease 
progression in a subgroup of HIV-1-positive women.  
Histopathology (D6S2666) 
    
Mild dysplasia   16/97 (16.5) 
 0.015 0.09 
Moderate dysplasia   28/97 (28.9) 
   
Carcinoma In situ   26/97 (26.8) 
   
Squamous cell carcinoma   23/97 (23.7) 
   
Adeno-squamous cell carcinoma       4/97 (4.1) 
   
     
  ROC curves analyses for age 
 
    
 
 
                                       
                                                LOH/MSI   
DNA marker HIV-1-seronegative                        HIV-1-positive    
D6S2666 AUC=0.8281     p=0.005, q=0.005  AUC=0.7348         p=0.01, q=0.02   
D6S2881 AUC=0.9615     p=0.042, q=0.083 AUC=0.6545         p=0.1354, q=0.1354  
D6S2746 AUC=0.5577     p=0.7989, q=0.7989 AUC=0.6328         p=0.1760, q=0.352   
D6S2447 AUC=0.8611     p=0.1015, q=0.1015 AUC=0.7063         p=0.0224, q=0.044   
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Since LOH/MSI play an important role in cervical carcinogenesis [89], five locus-specific 
DNA markers were used to study LOH/MSI at the HLA II locus on chromosome 6p. This 
region contains the HLA II, specifically, -DRB1 and -DQB1 which are responsible for viral 
infection recognition and antigen presentation to the immune system [32]. Loss of an allele, 
or loss of a part of a chromosome at the HLA II locus, may lead to haplo-insufficiency, and 
can have multiple functional effects on viral immune response genes. Furthermore, if one 
allele of a tumour-suppressor gene is inactivated earlier at a specific locus by somatic 
mutations, then deletion of a second allele, as detected by LOH, may result in loss of function 
of a tumour-suppressor gene or an immune-response gene [332]. These results strongly 
support the argument that the HLA II locus on chromosome 6p is critical in the pathogenesis 
of cervical cancer. The present study has demonstrated that several genetic alterations 
associated with different cervical disease stages regardless of HIV-1 infection status. 
Findings similar to these have been reported by Harima et al. in Japan [322], by Mazurenko 
et al. in Russia [333, 334] and by Pulido et al. in the USA [134]. However, the specific 
tumour-suppressor gene(s) at this locus remain unknown in different study populations. 
 
A previous study [185], described an association, or likely protection from cervical cancer in 
HIV-1/HPV co-infected South African women, with certain HLA II genotypes. Furthermore, 
a study carried out by Meys et al. in 2016 [38] reported that specific HLA immunogenotypes 
can determine the persistence of HPV infection in HIV-1 infected patients even during 
antiretroviral treatment. The presence of HIV-1/HPV co-infection in combination with 
specific HLA II genotypes or a haplotype may increase or decrease the risk of cervical disease 
development. Therefore according to the present study, in the case of likely protective HLA 
II (HLA II alleles associated with decreased cancer risk), presence of LOH/MSI at the HLA 
II locus may further affect the protective function of these genes on HPV infection clearance 
[36]. Additionally, genomic changes and genetic alterations in the cervical pre-cancerous 
lesions and ICC may be induced differently by different types of HPV, and particular HPV-
specific HLA II acting in combination [219, 335, 336]. Since cervical cancer is a complex 
genetic disease, this thesis acknowledges that the influence of epigenetics and other genomic 
changes on cervical cancer progression [128, 337], may also play a part in this process. 
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The presence of MSI is phenotypic evidence that DNA mismatch repair is not functioning 
normally [338]. Therefore, structural genomic changes within the HLA II locus, may 
determine cervical lesions that are likely to progress to invasive cancer due to inactivation of 
immune-response genes and the persistence of oncogenic Hr-HPV infection. HIV-1 Tat 
proteins can also interact directly with functional tumour-suppressor genes in the host (Rb 
and p53) [144, 145], which induces increased cell proliferation and increases the effect of 
Hr-HPV oncoproteins E6 and E7 in cervical carcinogenesis [27, 143].  
 
Genomic instability is an early event in carcinogenesis and arises as a consequence of the 
disruption of critical cell-cycle checkpoints and failure of the DNA damage-repair system as 
observed in premalignant tumour DNA (Table 5.4 and Figure 5.2). These findings are 
similar to those of Migdalska-Sek et al. [89] who reported LOH/MSI as early events in 
precancerous lesions according to HPV infection status, however, the HIV-1 status of their 
patients was unknown. Presence of LOH/MSI in premalignant tumours allows cells to 
acquire the additional mutations, required for malignant transformation [339]. This study 
further suggests that genetic instabilities are early trigger genetic events which may facilitate 
the subsequent establishment of all other hallmarks of cancer.  
 
Other studies performed on LOH/MSI in head and neck cancers, colon cancer, ovarian cancer 
and in cervical cancer in different populations with unknown HIV-1 status, reported frequent 
LOH/MSI in many chromosomes, with LOH/MSI frequencies that varied from 17% to 90% 
[89, 134, 265, 325, 326, 340]. However, in this study, the LOH/MSI frequencies vary from 
13% to 79% (Table 5.5). The discrepancy between the present study and other published 
works could be due to;  
(a) The quality and concentration of genomic DNA. 
 
(b) Differences in the specific DNA markers used. 
 
 142 
(c) Intrinsic genetic differences in genomic DNA composition among different      
populations. 
 
(d) The specific cancer disease of interest, whether it is MSI-High, MSI-Low,  
microsatellite stable or unstable [341]. 
 
(e) The particular chromosomes examined. 
 
(f) The specific PCR optimization conditions used [342].  
 
The presence of dual-oncogenic HPV and HIV-1 infections has remarkable effects on 
genomic instability in our study population. This was demonstrated by the observation that 
Hr-HPV infection influenced the frequency of LOH/MSI at the HLA II locus more in cervical 
tumour DNA from HIV-1-positive women than cervical tumour DNA from HIV-1-
seronegative women, except in DNA marker D6S2666 (p=0.172) (Figure 5.3C). However, 
when this study examined the odds of having LOH/MSI with other predictor variables in a 
multivariate logistic regression analysis, LOH/MSI was significantly associated only with 
HIV-1 status, in all four markers (Table 5.6). This may be due to the effects of including 
many predictor variables at once, which can dilute the true association, scientific plausibility, 
and clinical meaningfulness of any individual result [276].  
 
 
However, the present study obtained interesting results by using the receiver operating 
characteristic (ROC) curves (Supplementary figure 5.1) that age was a significant predictor 
of invasive cervical cancer outcome in HIV-1-positive women with LOH/MSI in DNA 
markers D6S2447 and D6S2666. In combination with Table 5.5 and Table 5.6, these results 
suggest that, age above 30 years is a strong poor prognostic factor for ICC in HIV-1-positive 
women with LOH/MSI by using these two markers. Further studies are warranted on the 
differential effects of specific HPV genotypes and HIV-1 infection on the overall genomic 
instability of cervical tumour DNA during carcinogenesis. 
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The unique strengths of this study include the comparative molecular investigation of the 
frequency of LOH/MSI between tumours from HIV-1-positive and HIV-1-seronegative 
women. The examination of abnormal cervical tumour epithelial DNA and matched normal 
buccal mucosa epithelial DNA, as control DNA. Previously published studies have focused 
almost exclusively on control DNA from whole blood, which may not provide a reasonable 
comparison with a matched abnormal epithelial tumour DNA. Previously published studies 
examining tumour biopsies, have not reported on cervical tumours from HIV-1-positive 
women. The present analysis has focused on chromosome 6p21 only, with five different 
locus-specific DNA markers to amplify fractions of the HLA II locus. Mononucleotide 
repeats were disregarded due to difficult markers analyses and difficulty in distinguishing 
heterozygotes from homozygotes if the allele sizes were very similar, because of ‘stutters’. 
The capillary electrophoresis analyses were repeated by using ethanol precipitation to clean 
the PCR products, wash out excess salts and unincorporated primer leftover after PCR for 
samples which showed poor amplification. PCR-based LOH assays include the ability to 
detect small deletions and the ability to enrich for tumour cells through microdissection [77]. 
This investigation has been able to answer the research question by demonstrating that HIV-
1/HPV co-infection does provoke additional LOH/MSI in cervical tumour DNA during 




The study limitations include the possibility of contaminated tumour samples since histologic 
sections of tumours usually contain a mixture of tumour cells, inflammatory cells, stromal 
cells, and other cellular contaminants. Limited molecular data from the study population on 
the presence of polymorphisms at the primer binding sites, therefore null alleles could not be 
excluded. Relative fluorescent units (RFUs) were very high for some swab samples and very 
low or absent for others which reflects unequal amplification between swab samples. In case 
of inadequate DNA concentration or low DNA concentration, one allele may be 
preferentially amplified over the other, and where one allele has insufficient amplification, 
termed allelic dropout. Off-scale peaks could not be sized accurately and it was not possible 
 144 
to determine the peak heights when the camera was saturated above 8000 RFUs. Finally, we 
did not make any patient follow up in our study.  
 
 
Future research opportunities may include in vivo studies to demonstrate the mechanisms of 
HIV-1/HPV co-infection carcinogenesis with specific HLA II alleles or haplotypes 
combinations, and genome-wide assays including massively parallel DNA sequencing and 
single-nucleotide polymorphism arrays to investigate further in-depth mechanisms and the 





This study has demonstrated a unique relationship between LOH/MSI in cervical tumour 
DNA and HIV-1/HPV co-infection in a cohort of South African women. Tumour DNA from 
HIV-1/HPV co-infected women demonstrated a higher frequency of LOH/MSI than tumour 
DNA from HIV-1-seronegative women at chromosome 6p. Loss of an allele or part of a 
chromosome can have multiple functional effects on immune-response genes, DNA damage-
repair genes and tumour-suppressor genes. The results suggest that HPV infection alone can 
induce LOH/MSI at the HLA II locus in cervical tumour DNA, whereas HIV-1 co-infection 
exacerbates it, possibly accelerating cervical disease progression in a subgroup of HIV-1-
positive women. This work adds to the existing theories of host molecular genetic alterations 







CHAPTER 6: General Discussion, Conclusions with the Strengths and Weaknesses of 
This Study, and the Future Perspectives. 
 
6.1 Summary of the main findings 
The main aim of this research was to study the influence of host molecular genetic variations 
and alterations at the HLA II locus, and HIV-1/HPV co-infection on progression of cervical 
cancer in a cohort of South African women. The molecular analysis performed as part of this 
research was limited to HLA II (DRB1 and DQB1) on chromosome 6p mainly because the 
genetic polymorphisms and alterations at these loci have been reported most likely to 
influence cervical carcinogenesis by allowing HPV persistence. HLA II alleles are involved 
in directing CD4 T-cell responses. It is well established that T-cell recognition of virally-
infected cells works through restricted epitope recognition [166]. Down-regulation of the 
viral peptide-HLA II complex on the infected cells may lead to protection from cytotoxic T-
cells [343]. Therefore, HPV infection may inhibit CD4 helper T-cell recognition through 
down-regulation of HLA II molecules and thereby evade host immunity [344]. Our results 
strongly support the assumption that the HLA II locus on chromosome 6p is critical in the 
pathogenesis of cervical cancer.  
 
The first specific objective was to review the published literature in order to identify genes, 
host molecular genetic variations and genetic alterations in cervical cancer progression that 
may play a role in disease progression in HIV-1/HPV co-infected women. The second 
specific objective was to characterize HPV genotypes within cervical tumour biopsies and 
assess the relationships with cervical disease stage, age, HIV-1 status, absolute CD4 count, 
and CD4 percentage, and to identify the predictive power of these variables for cervical 
disease stage in the cohort of South African women. The third specific objective was to 
determine whether host HLA-DRB1 and -DQB1 backgrounds in HIV-1/HPV co-infected 
women were involved in cervical cancer disease progression. The fourth specific objective 
was to investigate whether HIV-1/HPV co-infection provokes additional LOH/MSI at the 
HLA II locus to influence the rate of cervical disease progression as observed in a subgroup 
of HIV-1-positive women. 
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Carcinogenesis in HIV-1-positive cervical cancer has three major steps: (i) HPV integration 
into the host genome; (ii) dual pro-oncogenic effects of HPV oncoproteins E6/E7, and HIV-
1 oncoproteins Tat within the host genome, and (iii) the accumulation of repeated, unrepaired 
genetic alterations in the host chromosomal DNA. Compared to HIV-1-seronegative cervical 
cancer, HIV-1-positive cervical carcinogenesis has additional oncogenic effects from HIV-1 
Tat oncoproteins. Both HIV-1 and HPV are classified as carcinogenic viruses. Intracellular 
HIV-1 Tat proteins interact directly with the host Rb and p53 tumour-suppressor genes in the 
host. This interaction induces increased cell proliferation, which promotes the effects of HPV 
oncoproteins E6/E7 in cervical carcinogenesis. These additional oncogenic effects may 
influence rapid cervical carcinogenesis observed in some HIV-1-positive women.  
 
 
Rapid cervical carcinogenesis could manifest as a younger age of disease onset, or by a rapid 
progression from non-invasive cervical disease to invasive cervical cancer. HPV infection 
alone can induce LOH/MSI in cervical tumour DNA, whereas HIV-1 co-infection 
exacerbates it, this may influence the rate of cervical disease progression in a subgroup of 
HIV-1-positive women. However, the question remains as to why only few HIV-1-positive 
women develop rapid cervical carcinogenesis? This may be the result of one or more of the 
other inter-population or multi-population genetic differences and a wide range of 
confounding viral and host factors, which include: 
 
(i) The type of antiretroviral drugs administered  
 
(ii) HIV-1 and HPV viral loads 
 
(iii) Duration of HIV-1 infection  
 
(iv) Specific oncogenic HPV genotype infection 
 
(v) HLA genotype variations 
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(vi) Severity of genetic alterations or genetic instabilities 
 
(vii) Environmental effects such as host behaviour and demographics that can influence the  
         rate of cervical disease development in HIV-1/HPV co-infected women.  
 
(viii) The action of many other different host genes that have been found to be positively, or 
negatively associated, with cervical cancer development in different study populations. 
 
This study has identified likely protective HLA associations with HLA II alleles,-
DRB1*13:01 and -DQB1*03:19 which were rare or absent in women with cervical disease 
when compared to the age-matched control population. Conversely, HLA II-DQB1*03:01 
and -DQB1*06:02 appear to be associated with high risk of cervical cancer development. 
These findings will provide insight into individualization in treatment and may direct the 
development of immune-based prevention measures. The presence of LOH/MSI at the HLA 
II locus may affect the likely protective function of specific HLA II alleles on HPV infection 
clearance. HIV-1 as a co-infection may not be a direct risk factor for cervical cancer disease, 
although HIV-1-positive status has been shown to influence the relative risk for cervical 
disease development. Furthermore, although cervical disease was more prevalent in women 
with low CD4 percentage, the crude measurement of CD4 percentage or absolute CD4 count 
in HIV-1/HPV co-infected women is not directly reflective of cervical disease risk, except 
for those above 40 years of age. However, even in those above the age 40 years, this seems 
to depend on the host HLA II background, the extent of LOH/MSI in the HLA II locus, and 
the HPV genotype infection.  
 
This means that HPV infection alone may influence cervical disease development to a 
significant extent when it is combined with the apparently high-risk host HLA II alleles, -
DQB1*03:01 and -DQB1*06:02. In the presence of HIV-1 as a co-infection, the overall 
combination increases the relative risk of cervical cancer development and the rate of cervical 
disease progression. Since there was no level of the absolute CD4 count that puts HIV-1-
positive women at lower risk for oncogenic Hr-HPV infection and cervical disease 
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development, these women may be ideal for individualized HPV vaccination of adult HIV-
1-positive women, at any absolute CD4 count level. 
 
6.2 Strengths and Weaknesses of This Study, and the Future Perspectives 
The work reported here has a number of features that could be improved. These include the 
quality, selection bias of the study cohort and reliability of the analyses performed. The 
strengths of this research include:  
 
 
At the technical level: The high stringency of the DNA purification included gel visualization 
of DNA in order to establish DNA quality and standardized dilution of all DNA samples to 
0.2ng/µl or 0.3ng/µl, if necessary. All DNA markers used were optimized to amplify in two 
multiplexes in order to standardize the results of amplification. Only microsatellite markers 
with the best PCR amplification profiles were selected. The analysis was narrowed to focus 
only on chromosome 6p21, with five different locus-specific DNA markers to amplify 
regions within the HLA II locus. Markers were selected with both high and low 
polymorphism information content (PIC), to accommodate the unknown genetic diversity of 
the study population.  
 
 
At the clinical molecular level: In order to improve the reliability of the comparative 
molecular investigations of the frequencies of LOH/MSI in tumour DNA between HIV-1-
positive and HIV-1-seronegative women, the patient-matched DNA samples were taken from 
the same tissue types, abnormal epithelial DNA and matched normal epithelial DNA. In 






In the statistical analysis and research methods: Effort was made to calculate the adequate 
sample size required and multiple statistical tests were used with different analyses. The 
correction for false discovery rate (FDR) and the use of different study designs for different 
research objectives add more strength to the study findings.  
 
 
Most importantly, the research question has been answered that HIV-1/HPV co-infection 
provokes additional LOH/MSI in cervical tumour DNA which may influence the rate of 
cervical disease progression in a subgroup of HIV-1-positive women. 
 
 
Future research suggested by this study: 
 
To address some of the shortcomings of this work, it would have been better to have more 
information and larger sample numbers in order to study the effects of LOH and MSI 
separately for each marker at the HLA II locus. This was not possible because of the limited 
study duration and budgetary constraints. Increasing the cohort size would make it possible 
to resolve the effects of each oncogenic HPV genotype separately. It would be useful to have 
patient follow up via a longitudinal study to assess cervical disease progression, prognosis 
and survival analysis in relation to the severity of LOH/MSI in HIV-1-positive women 
(amongst other parameters). Further analysis could involve additional information regarding: 
the duration of HIV-1 or HPV infection, detailed information on immunocompromised status 
with nadir CD4 count, HIV-1 and HPV viral loads, HIV-1 sub-types, and ARV drug type, 
and duration of ARV.  
 
 
From a laboratory, and technical viewpoint, it would be ideal to do a confirmatory test for 
HIV-1 RNA in the tumour biopsies used for the analysis and to emphasize the considerations 
for genital HPV contamination during the cervical tumour biopsy processing in order to 
improve technical sampling issues. One of the drawbacks of using tumour biopsy samples is 
the lack of the potential to address tumour genetic heterogeneity. It would be useful to extend 
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this research to include some consideration of tumour heterogeneity, particularly by using 
liquid biopsy or peripheral blood to study circulating tumour DNA.  
 
 
A future study should be carried out to assess specific HPV genotypes with cervical cancer 
risk according to age, HLA II alleles, LOH/MSI, CD4 count, CD4 percentage and HIV-1 
infection, by using more sensitive methods such as high diversity single nucleotide 
polymorphism (SNP) arrays in a blinded randomized manner. This could investigate in-depth 
mechanisms and the presence of cause-effect relationships of our findings. In vivo studies to 
demonstrate the mechanisms of HIV-1/HPV co-infection carcinogenesis with specific HLA 
II alleles or haplotype combinations are a logical extension of this work and are warranted.  
 
 
The advances in Next Generation Sequencing (NGS) and the potential outcomes of NGS 
analysis make it possible to include genome-wide assays, including massively parallel DNA 
sequencing and SNP arrays, to make an SNP-based comparison between HIV-1-positive 
women with persistent and clearing Hr-HPV infection and their HLA immunotypes. Whole 
genome or exome sequencing can yield information on additional rare mutations and novel 
tumour-suppressor genes (TSG) in HIV-1/HPV co-infected women according to specific 
HPV genotypes. It could also enable variant analysis of HPV-16 diversity amongst HIV-1-
positive women with cervical disease in South Africa. 
 
This thesis provides novel insights, new information, and adds new knowledge to the existing 
theories in the field of cervical cancer molecular genetics. It shows the influence of HIV-
1/HPV co-infection on cervical disease progression with regard to: age, absolute CD4 count, 
CD4 percentage, host molecular genetic variations, and genetic alterations at the HLA II locus 
on chromosome 6p. This is the first published research in cervical cancer to analyze the 
relationships between specific host HLA II alleles, CD4 immune status, and the LOH/MSI 
on chromosome 6p in HIV-1/HPV co-infected women worldwide.  
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This work recognizes the urgent need to move away from the “one size fits all” generalization 
and focus on individualization in precision genomic medicine for prevention and treatment 
of cervical cancer in HIV-1/HPV co-infected women. It is, however, acknowledged that there 
may be other host molecular genetic factors that have not been considered in this thesis or 
are as yet unknown, which may influence the rate of cervical disease progression in HIV-
1/HPV co-infected women.  
 
However, identification of early molecular genetic changes and genetic risk factors for 
cervical disease development is very crucial. The benefit of implementing a molecular 
genetic profiling in cervical cancer-screening programs in all women infected with HIV-1 
should be envisaged. Although this project proposed to interrogate only the HLA II locus on 
chromosome 6p, it should be obvious that other regions of the HLA system, other immune 
response genes or whole genomes that may be subject to mutations/rearrangements during 















1. OpenStaxCollage, Cancer and the cell cycle, in Biology, RiceUniversity, Editor. 2013, 
OpenStax Collage: Houston, Texas. p. 291-292. 
2. Lengauer, C., K.W. Kinzler, and B. Vogelstein, Genetic instabilities in human cancers. 
Nature, 1998. 396(6712): p. 643-9. 
3. Damjanov, I., Neoplasia, in Pathology Secrets. 2009, Elsevier Health Sciences. p. 76-97. 
4. Wright, T.C., et al., Precancerous Lesions of the Cervix, in Blaustein’s Pathology of the 
Female Genital Tract, R.J. Kurman, L.H. Ellenson, and B.M. Ronnett, Editors. 2011, Springer 
US: Boston, MA. p. 193-252. 
5. Ahmad, A., Introduction to Cancer Metastasis. 2016, University of South Alabama, USA: 
Academic Press. 390. 
6. Khieu, M. and S. Butler, Cancer, Squamous Cell, High Grade Squamous Intraepithelial 
Lesion (HGSIL). 2017, ncbi: StatPearls publishing 2018. 
7. van der Horst, J., et al., Increasing incidence of invasive and in situ cervical 
adenocarcinoma in the Netherlands during 2004-2013. Cancer Med, 2017. 6(2): p. 416-
423. 
8. Mareel, M. and A. Leroy, Clinical, cellular, and molecular aspects of cancer invasion. 
Physiol Rev, 2003. 83(2): p. 337-76. 
9. Vogelstein, B. and K.W. Kinzler, The multistep nature of cancer. Trends Genet, 1993. 9(4): 
p. 138-41. 
10. Hanahan, D. and R.A. Weinberg, Hallmarks of cancer: the next generation. Cell, 2011. 
144(5): p. 646-74. 
11. zur Hausen, H., Papillomaviruses in the causation of human cancers - a brief historical 
account. Virology, 2009. 384(2): p. 260-5. 
12. Williamson, A.L., et al., The Cape Town declaration on human papillomavirus related 
disease. Papillomavirus Res, 2018. 5: p. 59-60. 
13. Zur Hausen, H., F. Barré-Sinoussi, and L. Montagnier, The Nobel Prize in Physiology or 
Medicine 2008. OF MEDICAL SCIENCES, 1992. 15: p. 25. 
14. Hopman, A.H.N. and F.C.S. Ramaekers, Development of the Uterine Cervix and Its 
Implications for the Pathogenesis of Cervical Cancer, in Pathology of the Cervix, C.S. 
Herrington, Editor. 2017, Springer International Publishing: Cham. p. 1-20. 
15. Meijer, C. and R.D.M. Steenbergen, Gynaecological cancer: Novel molecular subtypes of 
cervical cancer - potential clinical consequences. Nat Rev Clin Oncol, 2017. 14(7): p. 397-
398. 
16. Global Burden of Disease Cancer, C., et al., Global, Regional, and National Cancer 
Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted 
Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden 
of Disease Study. JAMA Oncol, 2017. 3(4): p. 524-548. 
17. WHO, Global strategy towards eliminating cervical cancer as a public health problem 2019: 
https://www.who.int/docs/default-source/cervical-cancer/cerv-cancer-elimn-strategy-
16dec-12pm.pdf. p. 8. 
18. Ferlay, J., et al., Cancer incidence and mortality worldwide: sources, methods and major 
patterns in GLOBOCAN 2012. Int J Cancer, 2015. 136(5): p. E359-86. 
19. Jemal, A. and L.A. Torre, The Global Burden of Cancer. The American Cancer Society's 
Principles of Oncology: Prevention to Survivorship, 2018: p. 33-44. 
 153 
20. Steyn, K., J. Fourie, and N. Temple, Chronic diseases of lifestyle in South Africa: 1995–2005. 
Cape Town: South African Medical Research Council, 2006: p. 33-47. 
21. Olorunfemi, G., et al., Temporal trends in the epidemiology of cervical cancer in South 
Africa (1994-2012). Int J Cancer, 2018. 143(9): p. 2238-2249. 
22. Registry, S.A.N.C., Cancer in South Africa, N.I.f.C. Diseases, Editor. 2014, National Institute 
for Communicable Diseases: Johannesburg. 
23. Registry, S.A.N.C., Cancer in South Africa. 2011: Johannesburg. 
24. Munoz, N., et al., Epidemiologic classification of human papillomavirus types associated 
with cervical cancer. N Engl J Med, 2003. 348(6): p. 518-27. 
25. Schiffman, M., et al., Human papillomavirus and cervical cancer. Lancet, 2007. 370(9590): 
p. 890-907. 
26. Williamson, A.L., The Interaction between Human Immunodeficiency Virus and Human 
Papillomaviruses in Heterosexuals in Africa. Journal of Clinical Medicine, 2015. 4(4): p. 579-
592. 
27. Chambuso, R., et al., Impact of Host Molecular Genetic Variations and HIV/HPV Co-
infection on Cervical Cancer Progression: A Systematic review. Oncomedicine, 2018. 3: p. 
82-93. 
28. Rajkumar, R., Introductory Chapter: Cervical Cancer - Screening, Treatment and Prevention, 
in Cervical Cancer - Screening, Treatment and Prevention - Universal Protocols for Ultimate 
Control, R. Rajkumar, Editor. 2018. p. 10. 
29. Dusingize, J.C., et al., Cigarette Smoking and the Risks of Basal Cell Carcinoma and 
Squamous Cell Carcinoma. J Invest Dermatol, 2017. 137(8): p. 1700-1708. 
30. Elemam, Y., et al., Herpes Simplex Virus type 2, Epstein Barr Virus and Human Papilloma 
Virus Co-infection in Cervical Squamous Cell Carcinoma among Sudanese Females. 2018. 
31. Zoodsma, M., et al., Familial cervical cancer: case reports, review and clinical implications. 
Hered Cancer Clin Pract, 2004. 2(2): p. 99-105. 
32. Chen, D., et al., Genome-wide association study of susceptibility loci for cervical cancer. J 
Natl Cancer Inst, 2013. 105(9): p. 624-33. 
33. Lynch, H.T., et al., Hereditary Factors in Gynecologic Cancer. Oncologist, 1998. 3(5): p. 319-
338. 
34. Hemminki, K., C. Dong, and P. Vaittinen, Familial risks in cervical cancer: Is there a 
hereditary component? International Journal of Cancer, 1999. 82(6): p. 775-781. 
35. Magnusson, P.K., P. Lichtenstein, and U.B. Gyllensten, Heritability of cervical tumours. Int J 
Cancer, 2000. 88(5): p. 698-701. 
36. Magnusson, P.K. and U.B. Gyllensten, Cervical cancer risk: is there a genetic component? 
Molecular medicine today, 2000. 6(4): p. 145-148. 
37. Hu, Y., et al., Association of HLA-DRB1, HLA-DQB1 Polymorphisms with HPV 16 E6 Variants 
among Young Cervical Cancer Patients in China. J Cancer, 2017. 8(12): p. 2401-2409. 
38. Meys, R., et al., HLA Immunogenotype Determines Persistent Human Papillomavirus Virus 
Infection in HIV-Infected Patients Receiving Antiretroviral Treatment. J Infect Dis, 2016. 
213(11): p. 1717-24. 
39. Zhang, X., et al., The HLA-DQB1 gene polymorphisms associated with cervical cancer risk: A 
meta-analysis. Biomed Pharmacother, 2015. 73: p. 58-64. 
40. Safaeian, M., et al., Human Leukocyte Antigen Class I and II Alleles and Cervical 
Adenocarcinoma. Front Oncol, 2014. 4: p. 119. 
41. Yuan, H., et al., HPV positive neuroendocrine cervical cancer cells are dependent on Myc 
but not E6/E7 viral oncogenes. Sci Rep, 2017. 7: p. 45617. 
 154 
42. Li, W., et al., Down-regulation of HLA class I antigen in human papillomavirus type 16 E7 
expressing HaCaT cells: correlate with TAP-1 expression. Int J Gynecol Cancer, 2010. 20(2): 
p. 227-32. 
43. Mine, K.L., et al., Gene network reconstruction reveals cell cycle and antiviral genes as 
major drivers of cervical cancer. Nat Commun, 2013. 4: p. 1806. 
44. Nilyanimit, P., et al., Comparison of Four Human Papillomavirus Genotyping Methods: 
Next-generation Sequencing, INNO-LiPA, Electrochemical DNA Chip, and Nested-PCR. Ann 
Lab Med, 2018. 38(2): p. 139-146. 
45. Dixit, R., C. Bhavsar, and Y.S. Marfatia, Laboratory diagnosis of human papillomavirus virus 
infection in female genital tract. Indian J Sex Transm Dis AIDS, 2011. 32(1): p. 50-2. 
46. Shetty, K., A. Chattopadhyay, and J. Leigh, Detection and typing of human papilloma virus 
in the oral mucosa of patients infected with human immunodeficiency virus. Oral Oncology 
Extra, 2005. 41(10): p. 311-315. 
47. Mbulawa, Z.Z.A., et al., High human papillomavirus (HPV) prevalence in South African 
adolescents and young women encourages expanded HPV vaccination campaigns. PLoS 
One, 2018. 13(1): p. e0190166. 
48. Singh, M., et al., Distinct clinico-immunological profile of patients infected with human 
papilloma virus genotypes 6 and 11. Virusdisease, 2017. 28(2): p. 200-204. 
49. Kardani, K. and A. Bolhassani, Types of Benign or Malignant Diseases Associated with HPV 
Infections. HPV Infections: Diagnosis, Prevention, and Treatment, 2018: p. 30. 
50. Cogliano, V., et al., Carcinogenicity of human papillomaviruses. Lancet Oncol, 2005. 6(4): p. 
204. 
51. Mudini, W., et al., Human Papillomavirus Genotypes in Invasive Cervical Carcinoma in HIV-
Seropositive and HIV-Seronegative Women in Zimbabwe. J Acquir Immune Defic Syndr, 
2018. 79(1): p. e1-e6. 
52. Kaliff, M., et al., Findings of multiple HPV genotypes in cervical carcinoma are associated 
with poor cancer-specific survival in a Swedish cohort of cervical cancer primarily treated 
with radiotherapy. Oncotarget, 2018. 9(27): p. 18786-18796. 
53. Gage, J.C., et al., Comparison of the cobas Human Papillomavirus (HPV) test with the 
hybrid capture 2 and linear array HPV DNA tests. J Clin Microbiol, 2012. 50(1): p. 61-5. 
54. Kardani, K. and A. Bolhassani, HPV Proteins and Their Functions. HPV Infections: Diagnosis, 
Prevention, and Treatment, 2018: p. 8. 
55. Rodriguez-Carunchio, L., et al., HPV-negative carcinoma of the uterine cervix: a distinct 
type of cervical cancer with poor prognosis. BJOG, 2015. 122(1): p. 119-27. 
56. Rad, A., et al., HPV types in cervical cancer tissue in South Africa: A head-to-head 
comparison by mRNA and DNA tests. Medicine (Baltimore), 2017. 96(47): p. e8752. 
57. Wang, X., et al., LncRNA PVT1 promotes the growth of HPV positive and negative cervical 
squamous cell carcinoma by inhibiting TGF-beta1. Cancer Cell Int, 2018. 18: p. 70. 
58. Agoston, E.S., et al., Polymerase chain reaction detection of HPV in squamous carcinoma of 
the oropharynx. Am J Clin Pathol, 2010. 134(1): p. 36-41. 
59. Reis Machado, J., et al., Mucosal immunity in the female genital tract, HIV/AIDS. Biomed 
Res Int, 2014. 2014: p. 350195. 
60. Andrea Rubbert, G.B.a.M.O., structure of HIV-1, in HIV BOOK, J.K.R. Christian Hoffmann, 
Editor. 2011, Medizin Fokus Verlag, Hamburg: Hamburg, Germany. 
61. Tshokey, T., et al., Normal CD4 Count in Healthy Voluntary Blood Donors in the Jigme Dorji 
Wangchuck National Referral Hospital, Thimphu, Bhutan. International Blood Research & 
Reviews, 2018: p. 1-8. 
 155 
62. Lawrie, D., et al., Local reference ranges for full blood count and CD4 lymphocyte count 
testing. South African Medical Journal, 2009. 99(4). 
63. Firnhaber, C., et al., Diverse and high prevalence of human papillomavirus associated with 
a significant high rate of cervical dysplasia in human immunodeficiency virus–infected 
women in Johannesburg, South Africa. Acta cytologica, 2009. 53(1): p. 10-17. 
64. Enebe, J.T., et al., Effect of Low CD4 Cell Count on Cervical Squamous Intraepithelial Lesions 
among HIV-Positive Women in Enugu, Southeastern Nigeria. J Clin Diagn Res, 2015. 9(11): 
p. QC07-10. 
65. Goicoechea, M. and R. Haubrich, CD4 lymphocyte percentage versus absolute CD4 
lymphocyte count in predicting HIV disease progression: an old debate revisited. J Infect 
Dis, 2005. 192(6): p. 945-7. 
66. Sabbah, A., et al., A retrospective analysis of dental implant survival in HIV patients. J Clin 
Periodontol, 2019. 46(3): p. 363-372. 
67. Achhra, A.C., et al., Difference in absolute CD4+ count according to CD4 percentage 
between Asian and Caucasian HIV-infected patients. Journal of AIDS & clinical research, 
2010. 1(1): p. 1-4. 
68. Hoffmann, C., J. Rockstroh, and B. Kamps, HIV medicine. 2003: Flying Publisher Paris, 
Cagliari, Wuppertal, Sevilla. 
69. Shen, R., H.E. Richter, and P.D. Smith, Early HIV-1 target cells in human vaginal and 
ectocervical mucosa. Am J Reprod Immunol, 2011. 65(3): p. 261-7. 
70. German Advisory Committee Blood (Arbeitskreis Blut), S.A.o.P. and T.b. Blood’, Human 
Immunodeficiency Virus (HIV), in Transfusion Medicine and Hemotherapy. 2016. p. 203-
222. 
71. Ganser, B.K., et al., Assembly and analysis of conical models for the HIV-1 core. Science, 
1999. 283(5398): p. 80-3. 
72. De Falco, G., et al., Interaction between HIV-1 Tat and pRb2/p130: a possible mechanism in 
the pathogenesis of AIDS-related neoplasms. Oncogene, 2003. 22(40): p. 6214. 
73. Aloni-Grinstein, R., et al., p53 and the Viral Connection: Back into the Future (double 
dagger). Cancers (Basel), 2018. 10(6): p. 178. 
74. Tempfer, C.B. and M.-A. Reymond, Sporadic Cancers, in The Molecular Basis of Human 
Cancer, W.B. Coleman and G.J. Tsongalis, Editors. 2017, Springer New York: New York, NY. 
p. 323-334. 
75. Pelengaris, S. and M. Khan, The molecular biology of cancer: A bridge from bench to 
bedside. 2013: John Wiley & Sons. 
76. Lee, E.Y. and W.J. Muller, Oncogenes and tumor suppressor genes. Cold Spring Harb 
Perspect Biol, 2010. 2(10): p. a003236. 
77. Hunt, J.L., Loss of Heterozygosity, in Cell and Tissue Based Molecular Pathology, M.H. 
Stoler, Editor. 2009, Churchill Livingstone: Philadelphia. p. 50-55. 
78. Ramos, T.D.P. and L.M.F. Amorim, Molecular biology techniques for loss of heterozygosity 
detection: the glioma example. Jornal Brasileiro de Patologia e Medicina Laboratorial, 
2015. 51: p. 189-196. 
79. Zheng, H.T., et al., Loss of heterozygosity analyzed by single nucleotide polymorphism 
array in cancer. World J Gastroenterol, 2005. 11(43): p. 6740-4. 
80. Harima, Y., et al., Loss of heterozygosity on chromosome 6p21.2 as a potential marker for 
recurrence after radiotherapy of human cervical cancer. Clin Cancer Res, 2000. 6(3): p. 
1079-85. 
81. Lo, K.C., et al., Comprehensive analysis of loss of heterozygosity events in glioblastoma 
using the 100K SNP mapping arrays and comparison with copy number abnormalities 
 156 
defined by BAC array comparative genomic hybridization. Genes Chromosomes Cancer, 
2008. 47(3): p. 221-37. 
82. Thiagalingam, S., et al., Loss of heterozygosity as a predictor to map tumor suppressor 
genes in cancer: molecular basis of its occurrence. Curr Opin Oncol, 2002. 14(1): p. 65-72. 
83. Ivansson, E., Contribution of Immunogenetic factors  in susceptibility to cervical cancer, in 
Department of Genetics and Pathology, Faculty of Medicine. 2009, Uppsala University: 
Uppsala University. p. 56. 
84. Borges, A.H., R. Dubrow, and M.J. Silverberg, Factors contributing to risk for cancer among 
HIV-infected individuals, and evidence that earlier combination antiretroviral therapy will 
alter this risk. Curr Opin HIV AIDS, 2014. 9(1): p. 34-40. 
85. Sudenga, S.L., et al., Dense genotyping of immune-related loci identifies variants 
associated with clearance of HPV among HIV-positive women in the HIV epidemiology 
research study (HERS). PLoS One, 2014. 9(6): p. e99109. 
86. Mehta, A.M., et al., Cervical Carcinogenesis and Immune Response Gene Polymorphisms: A 
Review. J Immunol Res, 2017. 2017: p. 8913860. 
87. Ryland, G.L., et al., Loss of heterozygosity: what is it good for? BMC Med Genomics, 2015. 
8: p. 45. 
88. Gorringe, K.L., Loss of Heterozygosity. Encyclopedia of Life Sciences, 2016. 
89. Migdalska-Sek, M., et al., Assessment of the frequency of genetic alterations (LOH/MSI) in 
patients with intraepithelial cervical lesions with HPV infection: a pilot study. Med Oncol, 
2016. 33(5): p. 51. 
90. Juko-Recirep, I., Analysis of genetic susceptibility to cervical cancer using candidate gene 
and GWAS approaches, in Faculty of Meidcine. 2015, Uppsala University: Sweden. p. 52. 
91. Mann, C.J., Observational research methods. Research design II: cohort, cross sectional, 
and case-control studies. Emerg Med J, 2003. 20(1): p. 54-60. 
92. Chang, C.Q., et al., A systematic review of cancer GWAS and candidate gene meta-analyses 
reveals limited overlap but similar effect sizes. Eur J Hum Genet, 2014. 22(3): p. 402-8. 
93. Ramjee, G., et al., Individual and Population Level Impact of Key HIV Risk Factors on HIV 
Incidence Rates in Durban, South Africa. PLoS One, 2016. 11(4): p. e0153969. 
94. Ravenscroft, G., et al., Actin nemaline myopathy mouse reproduces disease, suggests other 
actin disease phenotypes and provides cautionary note on muscle transgene expression. 
PLoS One, 2011. 6(12): p. e28699. 
95. WHO, Epidemiological Fact Sheet on HIV and AIDS Core data on epidemiology and 
response (South Africa). 2008. 
96. Balandya, B.S., A.B. Pembe, and H.A. Mwakyoma, Cervical pre-malignant lesions in HIV 
infected women attending Care and Treatment Centre in a tertiary hospital, Dar es Salaam, 
Tanzania. East Afr J Public Health, 2011. 8(3): p. 185-9. 
97. Migdalska-Sek, M., D. Pastuszak-Lewandoska, and E. Brzezianska, MSI and LOH in the 
development and prognosis of follicular cell-derived thyroid tumours. Endokrynol Pol, 
2012. 63(2): p. 126-36. 
98. Ononogbu, U., et al., Cervical cancer risk factors among HIV-infected Nigerian women. 
BMC Public Health, 2013. 13(1): p. 582. 
99. Chambuso, R.S., E. Kaambo, and S. Stephan, Observed Age Difference and Clinical 
Characteristics of Invasive Cervical Cancer Patients in Tanzania; A Comparison between 
HIV-Positive and HIV-Negative Women. Journal of Neoplasm, 2017. 2(3). 
100. Chambuso, R.S., et al., Influence of HIV/AIDS on Cervical Cancer: A Retrospective Study 
From Tanzania. J Glob Oncol, 2017. 3(1): p. 72-78. 
 157 
101. Adler, D.H., et al., Cumulative Impact of HIV and Multiple Concurrent Human 
Papillomavirus Infections on the Risk of Cervical Dysplasia. Adv Virol, 2016. 2016: p. 
7310894. 
102. Kriek, J.M., et al., Female genital tract inflammation, HIV co-infection and persistent 
mucosal Human Papillomavirus (HPV) infections. Virology, 2016. 493: p. 247-54. 
103. Moodley, J.R., et al., Human papillomavirus prevalence, viral load and pre-cancerous 
lesions of the cervix in women initiating highly active antiretroviral therapy in South Africa: 
a cross-sectional study. BMC Cancer, 2009. 9: p. 275. 
104. Alves, B.M., et al., The effect of human leukocyte antigen G alleles on human 
papillomavirus infection and persistence in a cohort of HIV-positive pregnant women from 
Brazil. Infect Genet Evol, 2015. 34: p. 339-43. 
105. Nyagol, J., et al., The effects of HIV-1 Tat protein on cell cycle during cervical 
carcinogenesis. Cancer Biol Ther, 2006. 5(6): p. 684-90. 
106. Ghebre, R.G., et al., Cervical cancer control in HIV-infected women: Past, present and 
future. Gynecol Oncol Rep, 2017. 21: p. 101-108. 
107. Kelly, H.A., et al., Associations of Human Papillomavirus (HPV) genotypes with high-grade 
cervical neoplasia (CIN2+) in a cohort of women living with HIV in Burkina Faso and South 
Africa. PLoS One, 2017. 12(3): p. e0174117. 
108. van Bogaert, L.J., The impact of human immunodeficiency virus infection on cervical 
preinvasive and invasive neoplasia in South Africa. Ecancermedicalscience, 2013. 7: p. 334. 
109. Agorastos, T., et al., Primary screening for cervical cancer based on high-risk human 
papillomavirus (HPV) detection and HPV 16 and HPV 18 genotyping, in comparison to 
cytology. PLoS One, 2015. 10(3): p. e0119755. 
110. Sundstrom, K., et al., Interactions Between High- and Low-Risk HPV Types Reduce the Risk 
of Squamous Cervical Cancer. J Natl Cancer Inst, 2015. 107(10). 
111. Zhang, X., et al., Genetic variants and risk of cervical cancer: epidemiological evidence, 
meta-analysis and research review. BJOG, 2014. 121(6): p. 664-74. 
112. Gokhale, P., et al., Variations in immunogenetics, human papillomavirus (HPV) infection & 
predisposition to cervical cancer in Indian women. Indian J Med Res, 2014. 140 Suppl: p. 
S36-43. 
113. Passmore, J.A.S. and A.L. Williamson, Host Immune Responses Associated with Clearance 
or Persistence of Human Papillomavirus Infections. Current Obstetrics and Gynecology 
Reports, 2016. 5(3): p. 177-188. 
114. Pantanowitz, L. and P. Michelow, Review of human immunodeficiency virus (HIV) and 
squamous lesions of the uterine cervix. Diagn Cytopathol, 2011. 39(1): p. 65-72. 
115. Denny, L.A., et al., Human papillomavirus, human immunodeficiency virus and 
immunosuppression. Vaccine, 2012. 30 Suppl 5: p. F168-74. 
116. Papasavvas, E., et al., High-risk oncogenic HPV genotype infection associates with 
increased immune activation and T cell exhaustion in ART-suppressed HIV-1-infected 
women. Oncoimmunology, 2016. 5(5): p. e1128612. 
117. Wani, K. and C.K. Nair, Genetic alterations in cervical cancer. Indian J Exp Biol, 2003. 41(8): 
p. 789-96. 
118. Kang, S., et al., Interleukin-1 beta-511 polymorphism and risk of cervical cancer. J Korean 
Med Sci, 2007. 22(1): p. 110-3. 
119. Lutkowska, A., et al., Analysis of rs8067378 Polymorphism in the Risk of Uterine Cervical 
Cancer from a Polish Population and its Impact on Gasdermin B Expression. Mol Diagn 
Ther, 2017. 21(2): p. 199-207. 
 158 
120. Guzman, V.B., et al., New approach reveals CD28 and IFNG gene interaction in the 
susceptibility to cervical cancer. Hum Mol Genet, 2008. 17(12): p. 1838-44. 
121. Ivansson, E.L., I. Juko-Pecirep, and U.B. Gyllensten, Interaction of immunological genes on 
chromosome 2q33 and IFNG in susceptibility to cervical cancer. Gynecol Oncol, 2010. 
116(3): p. 544-8. 
122. Wei, L.Z., et al., Meta-analysis on the relationship between HLA-DRBl gene polymorphism 
and cervical cancer in Chinese population. PLoS One, 2014. 9(2): p. e88439. 
123. Ou, C.Y., et al., Analysis of microsatellite instability in cervical cancer. Int J Gynecol Cancer, 
1999. 9(1): p. 67-71. 
124. Mazurenko, N.N., et al., Loss of heterozygosity at chromosome 6 as a marker of early 
genetic alterations in cervical intraepithelial neoplasias and microinvasive carcinomas. 
Molecular Biology, 2006. 40(3): p. 385-395. 
125. Abdus-Salam, A., O. Ogunnorin, and R. Abdus-Salam, HIV Seroprevalence in Patients with 
Carcinoma of the Cervix in Ibadan, Nigeria. Ghana Med J, 2008. 42(4): p. 141-3. 
126. Boccalon, M., et al., Intra-epithelial and invasive cervical neoplasia during HIV infection. 
Eur J Cancer, 1996. 32A(13): p. 2212-7. 
127. Whitham, H.K., et al., A Comparison of the Natural History of HPV Infection and Cervical 
Abnormalities among HIV-Positive and HIV-Negative Women in Senegal, Africa. Cancer 
Epidemiol Biomarkers Prev, 2017. 26(6): p. 886-894. 
128. Ojesina, A.I., et al., Landscape of genomic alterations in cervical carcinomas. Nature, 2014. 
506(7488): p. 371-5. 
129. Chattopadhyay, K., A comprehensive review on host genetic susceptibility to human 
papillomavirus infection and progression to cervical cancer. Indian J Hum Genet, 2011. 
17(3): p. 132-44. 
130. McBride, A.A. and A. Warburton, The role of integration in oncogenic progression of HPV-
associated cancers. PLoS Pathog, 2017. 13(4): p. e1006211. 
131. PA, L., The molecular genetics of cervical carcinoma. British Journal of Cancer, 1999. 
80(12): p. 2008-2018. 
132. de Freitas, A.C., et al., Susceptibility to cervical cancer: an overview. Gynecol Oncol, 2012. 
126(2): p. 304-11. 
133. Al-Daraji, W.I. and J.H. Smith, Infection and cervical neoplasia: facts and fiction. Int J Clin 
Exp Pathol, 2009. 2(1): p. 48-64. 
134. Arias-Pulido, H., N. Joste, and C.M. Wheeler, Loss of heterozygosity on chromosome 6 in 
HPV-16 positive cervical carcinomas carrying the DRB1*1501-DQB1*0602 haplotype. 
Genes Chromosomes Cancer, 2004. 40(4): p. 277-84. 
135. Adefolaju, G.A., K.E. Theron, and M.J. Hosie, Effects of HIV protease, nucleoside/non-
nucleoside reverse transcriptase inhibitors on Bax, Bcl-2 and apoptosis in two cervical cell 
lines. Biomed Pharmacother, 2014. 68(2): p. 241-51. 
136. Louie, K.S., S. de Sanjose, and P. Mayaud, Epidemiology and prevention of human 
papillomavirus and cervical cancer in sub-Saharan Africa: a comprehensive review. Trop 
Med Int Health, 2009. 14(10): p. 1287-302. 
137. McDonald, A.C., et al., Distribution of Human Papillomavirus Genotypes among HIV-
Positive and HIV-Negative Women in Cape Town, South Africa. Front Oncol, 2014. 4: p. 48. 
138. Investigators, S.T., et al., Short-course antiretroviral therapy in primary HIV infection. N 
Engl J Med, 2013. 368(3): p. 207-17. 
139. Guidry, J.T. and R.S. Scott, The interaction between human papillomavirus and other 
viruses. Virus Res, 2017. 231: p. 139-147. 
 159 
140. de Jong, A., et al., Human papillomavirus type 16-positive cervical cancer is associated with 
impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res, 2004. 64(15): 
p. 5449-55. 
141. Moodley, M. and S. Mould, Invasive cervical cancer and human immunodeficiency virus 
(HIV) infection in KwaZulu-Natal, South Africa. J Obstet Gynaecol, 2005. 25(7): p. 706-10. 
142. Cubie, H.A., Diseases associated with human papillomavirus infection. Virology, 2013. 
445(1-2): p. 21-34. 
143. Nicol, A.F., et al., Cell-cycle and suppressor proteins expression in uterine cervix in HIV/HPV 
co-infection: comparative study by tissue micro-array (TMA). BMC Cancer, 2008. 8: p. 289. 
144. Barillari, G., et al., Entrance of the Tat protein of HIV-1 into human uterine cervical 
carcinoma cells causes upregulation of HPV-E6 expression and a decrease in p53 protein 
levels. Oncol Lett, 2016. 12(4): p. 2389-2394. 
145. Vernon, S.D., et al., The HIV-1 tat protein enhances E2-dependent human papillomavirus 
16 transcription. Virus Res, 1993. 27(2): p. 133-45. 
146. Webster, K., et al., The human papillomavirus (HPV) 16 E2 protein induces apoptosis in the 
absence of other HPV proteins and via a p53-dependent pathway. J Biol Chem, 2000. 
275(1): p. 87-94. 
147. Hirbod, T., et al., Stable CD4 expression and local immune activation in the ectocervical 
mucosa of HIV-infected women. J Immunol, 2013. 191(7): p. 3948-54. 
148. Nkwanyana, N.N., et al., Impact of human immunodeficiency virus 1 infection and 
inflammation on the composition and yield of cervical mononuclear cells in the female 
genital tract. Immunology, 2009. 128(1 Suppl): p. e746-57. 
149. Bebell, L.M., et al., Relationship between levels of inflammatory cytokines in the genital 
tract and CD4+ cell counts in women with acute HIV-1 infection. J Infect Dis, 2008. 198(5): 
p. 710-4. 
150. Iuliano, M., et al., Human Papillomavirus E6 and E7 oncoproteins affect the cell 
microenvironment by classical secretion and extracellular vesicles delivery of inflammatory 
mediators. Cytokine, 2018. 106: p. 182-189. 
151. Mantovani, A., et al., Cancer-related inflammation. Nature, 2008. 454(7203): p. 436-44. 
152. Allavena, P., et al., Pathways connecting inflammation and cancer. Curr Opin Genet Dev, 
2008. 18(1): p. 3-10. 
153. Akram Husain, R. and V. Ramakrishnan, A review of risk factors in the development of 
cervical malignancy. Cancer Sci Res Open Access, 2016. 3(1): p. 1-4. 
154. Nicol, A.F., et al., Immune factors involved in the cervical immune response in the HIV/HPV 
co-infection. J Clin Pathol, 2008. 61(1): p. 84-8. 
155. Tan, S.C. and R. Ankathil, Genetic susceptibility to cervical cancer: role of common 
polymorphisms in apoptosis-related genes. Tumour Biol, 2015. 36(9): p. 6633-44. 
156. Williams, V.M., et al., HPV-DNA integration and carcinogenesis: putative roles for 
inflammation and oxidative stress. Future Virol, 2011. 6(1): p. 45-57. 
157. Wong, N.S., et al., A multilevel approach to assessing temporal change of CD4 recovery 
following HAART initiation in a cohort of Chinese HIV positive patients. J Infect, 2015. 
70(6): p. 676-8. 
158. Allen, M., et al., HLA DQ-DR haplotype and susceptibility to cervical carcinoma: indications 
of increased risk for development of cervical carcinoma in individuals infected with HPV 18. 
Tissue Antigens, 1996. 48(1): p. 32-7. 
159. Zoodsma, M., et al., Analysis of the entire HLA region in susceptibility for cervical cancer: a 
comprehensive study. J Med Genet, 2005. 42(8): p. e49. 
 160 
160. Koko, M., et al., In-silico analysis of MHC genes in hereditary colorectal cancer shows 
identical by state SNP sharing affecting HLA-DQB1 binding groove. bioRxiv, 2016: p. 
040436. 
161. Hardikar, S., et al., A population-based case-control study of genetic variation in cytokine 
genes associated with risk of cervical and vulvar cancers. Gynecol Oncol, 2015. 139(1): p. 
90-6. 
162. Beskow, A.H. and U.B. Gyllensten, Host genetic control of HPV 16 titer in carcinoma in situ 
of the cervix uteri. Int J Cancer, 2002. 101(6): p. 526-31. 
163. Stauss, H.J., et al., Induction of cytotoxic T lymphocytes with peptides in vitro: identification 
of candidate T-cell epitopes in human papilloma virus. Proc Natl Acad Sci U S A, 1992. 
89(17): p. 7871-5. 
164. Chen, D., et al., A variant upstream of HLA-DRB1 and multiple variants in MICA influence 
susceptibility to cervical cancer in a Swedish population. Cancer Med, 2014. 3(1): p. 190-8. 
165. Zhao, X., et al., Loss of heterozygosity at 6p21 and HLA class I expression in esophageal 
squamous cell carcinomas in China. Asian Pac J Cancer Prev, 2011. 12(10): p. 2741-5. 
166. Das Ghosh, D., et al., Impact of genetic variations and transcriptional alterations of HLA 
class I genes on cervical cancer pathogenesis. Int J Cancer, 2017. 140(11): p. 2498-2508. 
167. Lazarczyk, M., et al., The EVER Proteins as a Natural Barrier against Papillomaviruses: a 
New Insight into the Pathogenesis of Human Papillomavirus Infections. Microbiology and 
Molecular Biology Reviews, 2009. 73(2): p. 348-+. 
168. Chen, D. and U. Gyllensten, Systematic investigation of contribution of genetic variation in 
the HLA-DP region to cervical cancer susceptibility. Carcinogenesis, 2014. 35(8): p. 1765-9. 
169. Ivansson, E.L., et al., MHC loci affecting cervical cancer risk: distinguishing the effects of 
HLA-DQB1 and non-HLA genes TNF, LTA, TAP1 and TAP2. Genes Immun, 2008. 9(7): p. 613-
23. 
170. Engelmark, M., et al., Affected sib-pair analysis of the contribution of HLA class I and class 
II loci to development of cervical cancer. Hum Mol Genet, 2004. 13(17): p. 1951-8. 
171. Leo, P.J., et al., Defining the genetic susceptibility to cervical neoplasia-A genome-wide 
association study. PLoS Genet, 2017. 13(8): p. e1006866. 
172. Chen, D. and U. Gyllensten, A cis-eQTL of HLA-DRB1 and a frameshift mutation of MICA 
contribute to the pattern of association of HLA alleles with cervical cancer. Cancer Med, 
2014. 3(2): p. 445-52. 
173. Badano, I., et al., Analysis of TNFalpha promoter SNPs and the risk of cervical cancer in 
urban populations of Posadas (Misiones, Argentina). J Clin Virol, 2012. 53(1): p. 54-9. 
174. Deshpande, A., et al., TNF-alpha promoter polymorphisms and susceptibility to human 
papillomavirus 16-associated cervical cancer. J Infect Dis, 2005. 191(6): p. 969-76. 
175. Maciag, P.C. and L.L. Villa, Genetic susceptibility to HPV infection and cervical cancer. Braz J 
Med Biol Res, 1999. 32(7): p. 915-22. 
176. Chen, X., et al., Genetic susceptibility of cervical cancer. Journal of Biomedical Research, 
2011. 25(3): p. 155-164. 
177. Diaz-Padilla, I., et al., Genetic polymorphisms as predictive and prognostic biomarkers in 
gynecological cancers: a systematic review. Gynecol Oncol, 2012. 124(2): p. 354-65. 
178. Shi, Y., et al., A genome-wide association study identifies two new cervical cancer 
susceptibility loci at 4q12 and 17q12. Nat Genet, 2013. 45(8): p. 918-22. 
179. Garner, D., Clinical application of DNA ploidy to cervical cancer screening: A review. World 
J Clin Oncol, 2014. 5(5): p. 931-65. 
180. Passerini, V., et al., The presence of extra chromosomes leads to genomic instability. Nat 
Commun, 2016. 7: p. 10754. 
 161 
181. Danielsen, H.E., M. Pradhan, and M. Novelli, Revisiting tumour aneuploidy - the place of 
ploidy assessment in the molecular era. Nat Rev Clin Oncol, 2016. 13(5): p. 291-304. 
182. Barh, D. and M. Gunduz, Noninvasive Molecular Markers in Gynecologic Cancers. 2015: 
CRC Press. 
183. Scotto, L., et al., Integrative genomics analysis of chromosome 5p gain in cervical cancer 
reveals target over-expressed genes, including Drosha. Mol Cancer, 2008. 7: p. 58. 
184. Jafari-Ghahfarokhi, H., et al., Small supernumerary marker chromosomes and their 
correlation with specific syndromes. Adv Biomed Res, 2015. 4: p. 140. 
185. Chambuso, R., et al., Human Leukocyte Antigen (HLA) Class II -DRB1 and -DQB1 Alleles and 
the Association with Cervical Cancer in HIV/HPV Co-Infected Women in South Africa. J 
Cancer, 2019. 10(10): p. 2145-2152. 
186. Su, T.H., et al., CTLA-4 gene and susceptibility to human papillomavirus-16-associated 
cervical squamous cell carcinoma in Taiwanese women. Carcinogenesis, 2007. 28(6): p. 
1237-40. 
187. Sunthamala, N., et al., E2 proteins of high risk human papillomaviruses down-modulate 
STING and IFN-kappa transcription in keratinocytes. PLoS One, 2014. 9(3): p. e91473. 
188. Westrich, J.A., C.J. Warren, and D. Pyeon, Evasion of host immune defenses by human 
papillomavirus. Virus Res, 2017. 231: p. 21-33. 
189. Wang, S.S., et al., Common genetic variants and risk for HPV persistence and progression 
to cervical cancer. PLoS One, 2010. 5(1): p. e8667. 
190. Craveiro, R., et al., The role of p73 G4C14-to-A4T14 polymorphism in the susceptibility to 
cervical cancer. DNA Cell Biol, 2012. 31(2): p. 224-9. 
191. Scott, M.E., et al., Cervical cytokines and clearance of incident human papillomavirus 
infection: Hawaii HPV cohort study. Int J Cancer, 2013. 133(5): p. 1187-96. 
192. Hu, J.X., Q. Gao, and L. Li, Peroxiredoxin 3 is a novel marker for cell proliferation in cervical 
cancer. Biomed Rep, 2013. 1(2): p. 228-230. 
193. Safaeian, M., et al., Single nucleotide polymorphisms in the PRDX3 and RPS19 and risk of 
HPV persistence and cervical precancer/cancer. PLoS One, 2012. 7(4): p. e33619. 
194. Hu, X., et al., TP53, MDM2, NQO1, and susceptibility to cervical cancer. Cancer Epidemiol 
Biomarkers Prev, 2010. 19(3): p. 755-61. 
195. Pontillo, A., et al., Role of inflammasome genetics in susceptibility to HPV infection and 
cervical cancer development. J Med Virol, 2016. 88(9): p. 1646-51. 
196. Famooto, A., et al., RPS19 and TYMS SNPs and Prevalent High Risk Human Papilloma Virus 
Infection in Nigerian Women. PLoS One, 2013. 8(6): p. e66930. 
197. Wang, S.S., et al., Common variants in immune and DNA repair genes and risk for human 
papillomavirus persistence and progression to cervical cancer. J Infect Dis, 2009. 199(1): p. 
20-30. 
198. Bordignon, V., et al., How Human Papillomavirus Replication and Immune Evasion 
Strategies Take Advantage of the Host DNA Damage Repair Machinery. Viruses-Basel, 
2017. 9(12): p. 390. 
199. McKay, J., et al., Immuno-related polymorphisms and cervical cancer risk: The IARC 
multicentric case-control study. PLoS One, 2017. 12(5): p. e0177775. 
200. Lou, H., et al., Genome Analysis of Latin American Cervical Cancer: Frequent Activation of 
the PIK3CA Pathway. Clin Cancer Res, 2015. 21(23): p. 5360-70. 
201. Henderson, S., et al., APOBEC-mediated cytosine deamination links PIK3CA helical domain 
mutations to human papillomavirus-driven tumor development. Cell Rep, 2014. 7(6): p. 
1833-41. 
 162 
202. Kanao, H., et al., Overexpression of LAMP3/TSC403/DC-LAMP promotes metastasis in 
uterine cervical cancer. Cancer Res, 2005. 65(19): p. 8640-5. 
203. Mine, K.L., et al., Gene network reconstruction reveals cell cycle and antiviral genes as 
major drivers of cervical cancer. Nature Communications, 2013. 4: p. 1806. 
204. Tsakogiannis, D., et al., Sites of disruption within E1 and E2 genes of HPV16 and association 
with cervical dysplasia. J Med Virol, 2015. 87(11): p. 1973-80. 
205. Ganguly, N. and S.P. Parihar, Human papillomavirus E6 and E7 oncoproteins as risk factors 
for tumorigenesis. Journal of Biosciences, 2009. 34(1): p. 113-123. 
206. Yue, C., et al., Polymorphism of the pre-miR-146a is associated with risk of cervical cancer 
in a Chinese population. Gynecol Oncol, 2011. 122(1): p. 33-7. 
207. Gomez-Gomez, Y., J. Organista-Nava, and P. Gariglio, Deregulation of the miRNAs 
expression in cervical cancer: human papillomavirus implications. Biomed Res Int, 2013. 
2013: p. 407052. 
208. Filippova, M., et al., The human papillomavirus 16 E6 protein binds to tumor necrosis 
factor (TNF) R1 and protects cells from TNF-induced apoptosis. J Biol Chem, 2002. 277(24): 
p. 21730-9. 
209. Habbous, S., et al., Human papillomavirus and host genetic polymorphisms in 
carcinogenesis: a systematic review and meta-analysis. J Clin Virol, 2014. 61(2): p. 220-9. 
210. Zhang, L., et al., URG4 overexpression is correlated with cervical cancer progression and 
poor prognosis in patients with early-stage cervical cancer. BMC Cancer, 2014. 14: p. 885. 
211. Sano, T., et al., Expression status of p16 protein is associated with human papillomavirus 
oncogenic potential in cervical and genital lesions. American Journal of Pathology, 1998. 
153(6): p. 1741-1748. 
212. Gammoh, N., et al., The Mdm2 ubiquitin ligase enhances transcriptional activity of human 
papillomavirus E2. J Virol, 2009. 83(3): p. 1538-43. 
213. White, E.A., K. Munger, and P.M. Howley, High-Risk Human Papillomavirus E7 Proteins 
Target PTPN14 for Degradation. MBio, 2016. 7(5): p. e01530-16. 
214. Buitrago-Perez, A., et al., Molecular Signature of HPV-Induced Carcinogenesis: pRb, p53 
and Gene Expression Profiling. Curr Genomics, 2009. 10(1): p. 26-34. 
215. Jain, V., et al., Polymorphism of CYP1A1 gene variants rs4646903 and rs1048943 relation 
to the incidence of cervical cancer in Chhattisgarh. Environ Toxicol Pharmacol, 2017. 52: p. 
188-192. 
216. Chlon, T.M., et al., High-risk human papillomavirus E6 protein promotes reprogramming of 
Fanconi anemia patient cells through repression of p53 but does not allow for sustained 
growth of induced pluripotent stem cells. Journal of virology, 2014. 88(19): p. 11315-
11326. 
217. Carneiro, B.A., et al., FGFR3-TACC3: A novel gene fusion in cervical cancer. Gynecol Oncol 
Rep, 2015. 13: p. 53-6. 
218. Liu, Y., et al., Comprehensive mapping of the human papillomavirus (HPV) DNA integration 
sites in cervical carcinomas by HPV capture technology. Oncotarget, 2016. 7(5): p. 5852-64. 
219. Grozdanov, P., et al., Characterization of genomic changes in the cervical pre-cancerous 
lesions and tumors induced by different types of human papillomaviruses. Virusdisease, 
2016. 27(3): p. 271-276. 
220. Kuglik, P., et al., Genome-wide screening of DNA copy number alterations in cervical 
carcinoma patients with CGH+SNP microarrays and HPV-FISH. Int J Clin Exp Pathol, 2014. 
7(8): p. 5071-82. 
221. Klug, S.J., et al., TP53 codon 72 polymorphism and cervical cancer: a pooled analysis of 
individual data from 49 studies. Lancet Oncol, 2009. 10(8): p. 772-84. 
 163 
222. Veena, M.S., et al., Inactivation of the cystatin E/M tumor suppressor gene in cervical 
cancer. Genes Chromosomes Cancer, 2008. 47(9): p. 740-54. 
223. Kloth, J.N., et al., Combined array-comparative genomic hybridization and single-
nucleotide polymorphism-loss of heterozygosity analysis reveals complex genetic 
alterations in cervical cancer. BMC Genomics, 2007. 8: p. 53. 
224. Martinez-Nava, G.A., et al., Cervical Cancer Genetic Susceptibility: A Systematic Review and 
Meta-Analyses of Recent Evidence. PLoS One, 2016. 11(7): p. e0157344. 
225. Litwin, T.R., et al., Somatic Host Cell Alterations in HPV Carcinogenesis. Viruses, 2017. 9(8). 
226. Alexandrov, L.B., et al., Signatures of mutational processes in human cancer. Nature, 2013. 
500(7463): p. 415-21. 
227. Immuno-related polymorphisms and cervical cancer risk: The IARC multicentric case-
control study. 2017, Public Library of Science. p. 1-13. 
228. Bodelon, C., et al., Genetic variation in CD83 and risks of cervical and vulvar cancers: a 
population-based case-control study. Gynecol Oncol, 2012. 124(3): p. 525-8. 
229. Yu, K.J., et al., CD83 polymorphisms and cervical cancer risk. Gynecol Oncol, 2009. 114(2): 
p. 319-22. 
230. Kim, Y.T. and M. Zhao, Aberrant cell cycle regulation in cervical carcinoma. Yonsei Med J, 
2005. 46(5): p. 597-613. 
231. Bahrami, A., et al., Genetic susceptibility in cervical cancer: From bench to bedside. J Cell 
Physiol, 2018. 233(3): p. 1929-1939. 
232. Kordi Tamandani, D.M., et al., No association of TAP1 and TAP2 genes polymorphism with 
risk of cervical cancer in north Indian population. J Assist Reprod Genet, 2009. 26(4): p. 
173-8. 
233. Einstein, M.H., et al., Genetic variants in TAP are associated with high-grade cervical 
neoplasia. Clin Cancer Res, 2009. 15(3): p. 1019-23. 
234. Chen, D., et al., Analysis of the genetic architecture of susceptibility to cervical cancer 
indicates that common SNPs explain a large proportion of the heritability. Carcinogenesis, 
2015. 36(9): p. 992-998. 
235. Mathew, C.G., Fanconi anaemia genes and susceptibility to cancer. Oncogene, 2006. 
25(43): p. 5875-84. 
236. Juko-Pecirep, I., E.L. Ivansson, and U.B. Gyllensten, Evaluation of Fanconi anaemia genes 
FANCA, FANCC and FANCL in cervical cancer susceptibility. Gynecol Oncol, 2011. 122(2): p. 
377-81. 
237. Park, J.W., M.K. Shin, and P.F. Lambert, High incidence of female reproductive tract 
cancers in FA-deficient HPV16-transgenic mice correlates with E7's induction of DNA 
damage response, an activity mediated by E7's inactivation of pocket proteins. Oncogene, 
2014. 33(26): p. 3383-91. 
238. Mehta, A.M., et al., Differences in genetic variation in antigen-processing machinery 
components and association with cervical carcinoma risk in two Indonesian populations. 
Immunogenetics, 2015. 67(5-6): p. 267-75. 
239. Mehta, A.M., et al., Molecular backgrounds of ERAP1 downregulation in cervical 
carcinoma. Anal Cell Pathol (Amst), 2015. 2015: p. 367837. 
240. Zhou, X., et al., Polymorphisms in HPV E6/E7 protein interacted genes and risk of cervical 
cancer in Chinese women: a case-control analysis. Gynecol Oncol, 2009. 114(2): p. 327-31. 
241. Chen, Y., et al., CD192 gene variant and susceptibility to cervical cancer: a meta analysis. 
Int J Clin Exp Med, 2015. 8(6): p. 9341-7. 
 164 
242. Chatterjee, K., et al., CCR2-V64I polymorphism is associated with increased risk of cervical 
cancer but not with HPV infection or pre-cancerous lesions in African women. BMC Cancer, 
2010. 10: p. 278. 
243. Coelho, A., et al., The influence of chemokine receptor CCR2 genotypes in the route to 
cervical carcinogenesis. Gynecol Obstet Invest, 2007. 64(4): p. 208-12. 
244. Xiao, M.S., et al., Genetic polymorphisms of the CASP8 gene promoter may not be 
associated with colorectal cancer in Han Chinese from southwest China. PLoS One, 2013. 
8(7): p. e67577. 
245. Chen, D., et al., Pathway analysis of cervical cancer genome-wide association study 
highlights the MHC region and pathways involved in response to infection. Hum Mol 
Genet, 2014. 23(22): p. 6047-60. 
246. Chen, D., et al., Pooled analysis of genome-wide association studies of cervical 
intraepithelial neoplasia 3 (CIN3) identifies a new susceptibility locus. Oncotarget, 2016. 
7(27): p. 42216-42224. 
247. Isaakidis, P., et al., HPV infection, cervical abnormalities, and cancer in HIV-infected women 
in Mumbai, India: 12-month follow-up. Int J Womens Health, 2013. 5: p. 487-94. 
248. Madeleine, M.M., et al., Human leukocyte antigen class II and cervical cancer risk: a 
population-based study. J Infect Dis, 2002. 186(11): p. 1565-74. 
249. Shi, Y.Y., et al., A genome-wide association study identifies two new cervical cancer 
susceptibility loci at 4q12 and 17q12. Nature Genetics, 2013. 45(8): p. 918-U262. 
250. Qiu, H., et al., Cytotoxic Tlymphocyte-associated antigen4 polymorphisms and 
susceptibility to cervical cancer: a metaanalysis. Mol Med Rep, 2013. 8(6): p. 1785-94. 
251. Bruwer, Z., et al., Predictive genetic testing in children: constitutional mismatch repair 
deficiency cancer predisposing syndrome. J Genet Couns, 2014. 23(2): p. 147-55. 
252. Bruwer, Z., M. Futter, and R. Ramesar, Communicating cancer risk within an African 
context: Experiences, disclosure patterns and uptake rates following genetic testing for 
Lynch syndrome. Patient Education and Counseling, 2013. 92(1): p. 53-60. 
253. Torre, L.A., et al., Global cancer statistics, 2012. CA Cancer J Clin, 2015. 65(2): p. 87-108. 
254. Kelly, H., et al., Association of antiretroviral therapy with high-risk human papillomavirus, 
cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a 
systematic review and meta-analysis. Lancet HIV, 2018. 5(1): p. e45-e58. 
255. Stewart, T.S., J. Moodley, and F.M. Walter, Population risk factors for late-stage 
presentation of cervical cancer in sub-Saharan Africa. Cancer Epidemiol, 2018. 53: p. 81-
92. 
256. Depuydt, C.E., et al., Changes in type-specific human papillomavirus load predict 
progression to cervical cancer. J Cell Mol Med, 2012. 16(12): p. 3096-104. 
257. McDonald, A.C., et al., Distribution of Human Papillomavirus Genotypes among HIV-
Positive and HIV-Negative Women in Cape Town, South Africa. Front Oncol, 2014. 4(48): p. 
48. 
258. Massad, L.S., et al., Association of cervical precancer with human papillomavirus types 
other than 16 among HIV co-infected women. American Journal of Obstetrics and 
Gynecology, 2016. 214(3): p. 354. e1-354. e6. 
259. Cuzick, J., et al., Performance of the Xpert HPV assay in women attending for cervical 
screening. Papillomavirus Research, 2015. 1: p. 32-37. 
260. Dreyer, G., Clinical implications of the interaction between HPV and HIV infections. Best 
Pract Res Clin Obstet Gynaecol, 2018. 47: p. 95-106. 
261. Massad, L.S., Replacing the Pap Test With Screening Based on Human Papillomavirus 
Assays. JAMA, 2018. 320(1): p. 35-37. 
 165 
262. Badial, R.M., et al., Detection and genotyping of human papillomavirus (HPV) in HIV-
infected women and its relationship with HPV/HIV co-infection. Medicine (Baltimore), 
2018. 97(14): p. e9545. 
263. van Aardt, M.C., et al., Oncogenic and incidental HPV types associated with histologically 
confirmed cervical intraepithelial neoplasia in HIV-positive and HIV-negative South African 
women. 2016. Vol. 106. 2016. 
264. Freitas, B.C., et al., HPV Infection and Cervical Abnormalities in HIV Positive Women in 
Different Regions of Brazil, a Middle-Income Country. Asian Pac J Cancer Prev, 2015. 
16(18): p. 8085-91. 
265. Cheung, T.H., et al., Clinicopathologic significance of loss of heterozygosity on chromosome 
1 in cervical cancer. Gynecol Oncol, 2005. 96(2): p. 510-5. 
266. Van Aardt, M.C., et al., Oncogenic and incidental HPV types associated with histologically 
confirmed cervical intraepithelial neoplasia in HIV-positive and HIV-negative South African 
women. S Afr Med J, 2016. 106(6): p. 617-622. 
267. Tartaglia, E., et al., Prevalence of HPV infection among HIV-positive and HIV-negative 
women in Central/Eastern Italy: Strategies of prevention. Oncology Letters, 2017. 14(6): p. 
7629-7635. 
268. Mbatha, J.N., et al., High-risk human papillomavirus types in HIV-infected and HIV-
uninfected young women in KwaZulu-Natal, South Africa: implications for vaccination. 
Infect Dis (Lond), 2017. 49(8): p. 601-608. 
269. Pecorelli, S., L. Zigliani, and F. Odicino, Revised FIGO staging for carcinoma of the cervix. Int 
J Gynaecol Obstet, 2009. 105(2): p. 107-8. 
270. Department of Health, R.o.S.A., NATIONAL HIV COUNSELLING AND TESTING POLICY 
GUIDELINES, D.o. Health, Editor. 2015, Department of Health 
www.health-e.org.za. p. 8-12. 
271. Coetzee, L.M. and D.K. Glencross, Performance verification of the new fully automated 
Aquios flow cytometer PanLeucogate (PLG) platform for CD4-T-lymphocyte enumeration in 
South Africa. PLoS One, 2017. 12(11): p. e0187456. 
272. Gbadamosi-Akindele, R.L.a., CD4 count. 2019, Treasure Island (FL) (Creighton University: 
StartPeals NCBI. 
273. Glencross, D.K., et al., African regional external quality assessment for CD4 T-cell 
enumeration: Development, outcomes, and performance of laboratories. Cytometry Part B: 
Clinical Cytometry, 2008. 74B(S1): p. S69-S79. 
274. Guiguet, M., et al., CD4+ T-cell percentage is an independent predictor of clinical 
progression in AIDS-free antiretroviral-naive patients with CD4+ T-cell counts >200 
cells/mm3. Antivir Ther, 2009. 14(3): p. 451-7. 
275. Hu, Z.D., Z.R. Zhou, and S. Qian, How to analyze tumor stage data in clinical research. J 
Thorac Dis, 2015. 7(4): p. 566-75. 
276. Ranganathan, P., C.S. Pramesh, and R. Aggarwal, Common pitfalls in statistical analysis: 
Logistic regression. Perspect Clin Res, 2017. 8(3): p. 148-151. 
277. Teame, H., et al., Factors associated with cervical precancerous lesions among women 
screened for cervical cancer in Addis Ababa, Ethiopia: A case control study. PLoS One, 
2018. 13(1): p. e0191506. 
278. Ribeiro, A.A., et al., HPV infection and cervical neoplasia: associated risk factors. Infect 
Agent Cancer, 2015. 10(1): p. 16. 
279. Yarchoan, R. and T.S. Uldrick, HIV-associated cancers and related diseases. New England 
Journal of Medicine, 2018. 378(11): p. 1029-1041. 
 166 
280. Cho, W.C., Molecular Connections of Aging and Cancer. Aging Dis, 2017. 8(5): p. 685-687. 
281. Abraham, A.G., et al., Invasive cervical cancer risk among HIV-infected women: a North 
American multicohort collaboration prospective study. J Acquir Immune Defic Syndr, 2013. 
62(4): p. 405-13. 
282. Denny, L., et al., Human papillomavirus prevalence and type distribution in invasive 
cervical cancer in sub-Saharan Africa. Int J Cancer, 2014. 134(6): p. 1389-98. 
283. van Aardt, M.C., et al., Unique human papillomavirus-type distribution in South African 
women with invasive cervical cancer and the effect of human immunodeficiency virus 
infection. Int J Gynecol Cancer, 2015. 25(5): p. 919-25. 
284. Naucler, P., et al., Human papillomavirus type-specific risk of cervical cancer in a 
population with high human immunodeficiency virus prevalence: case-control study. J Gen 
Virol, 2011. 92(Pt 12): p. 2784-91. 
285. Gebo, K.A., et al., Absolute CD4 vs. CD4 percentage for predicting the risk of opportunistic 
illness in HIV infection. J Acquir Immune Defic Syndr, 2004. 36(5): p. 1028-33. 
286. Hulgan, T., et al., CD4 lymphocyte percentage predicts disease progression in HIV-infected 
patients initiating highly active antiretroviral therapy with CD4 lymphocyte counts >350 
lymphocytes/mm3. J Infect Dis, 2005. 192(6): p. 950-7. 
287. Claassen, C.W., et al., Discordance between CD4+ T-lymphocyte counts and percentages in 
HIV-infected persons with liver fibrosis. Clin Infect Dis, 2012. 54(12): p. 1806-13. 
288. Anyimadu, H., et al., The Impact of Absolute CD4 Count and Percentage Discordance on 
Pneumocystis Jirovecii Pneumonia Prophylaxis in HIV-Infected Patients. J Int Assoc Provid 
AIDS Care, 2018. 17: p. 2325958218759199. 
289. Barros, M.R., Jr., et al., Activities of stromal and immune cells in HPV-related cancers. J Exp 
Clin Cancer Res, 2018. 37(1): p. 137. 
290. Bratcher, L.F. and V.V. Sahasrabuddhe, The impact of antiretroviral therapy on HPV and 
cervical intraepithelial neoplasia: current evidence and directions for future research. Infect 
Agent Cancer, 2010. 5: p. 8. 
291. Denny, L., et al., Human papillomavirus infection and cervical disease in human 
immunodeficiency virus-1-infected women. Obstet Gynecol, 2008. 111(6): p. 1380-7. 
292. Dlamini, S.K., et al., Guidelines for the vaccination of HIV-infected adolescents and adults in 
South Africa. Southern African Journal of HIV Medicine, 2018. 19(1): p. 1-8. 
293. Kelly, H.A., et al., Associations of Human Papillomavirus (HPV) genotypes with high-grade 
cervical neoplasia (CIN2+) in a cohort of women living with HIV in Burkina Faso and South 
Africa. PLOS ONE, 2017. 12(3): p. e0174117. 
294. Desruisseau, A.J., D. Schmidt-Grimminger, and E. Welty, Epidemiology of HPV in HIV-
positive and HIV-negative fertile women in Cameroon, West Africa. Infect Dis Obstet 
Gynecol, 2009. 2009: p. 810596. 
295. Choudhury, S.A., et al., Higher Prevalence of Human Papillomavirus-Related Cervical 
Precancerous Abnormalities in HIV-Infected Compared to HIV-Uninfected Women. J Natl 
Med Assoc, 2016. 108(1): p. 19-23. 
296. Ahdieh, L., et al., Prevalence, incidence, and type-specific persistence of human 
papillomavirus in human immunodeficiency virus (HIV)-positive and HIV-negative women. J 
Infect Dis, 2001. 184(6): p. 682-90. 
297. De Vuyst, H., et al., Prevalence of human papillomavirus in women with invasive cervical 
carcinoma by HIV status in Kenya and South Africa. Int J Cancer, 2012. 131(4): p. 949-55. 
298. Ben Othmane, Y., et al., HLA class II susceptibility to cervical cancer among Tunisian 
women. Bull Cancer, 2012. 99(9): p. 81-6. 
 167 
299. Zhang, B., et al., The E5 protein of human papillomavirus type 16 perturbs MHC class II 
antigen maturation in human foreskin keratinocytes treated with interferon-gamma. 
Virology, 2003. 310(1): p. 100-8. 
300. Tshabalala, M., G.D. Morse, and L.S. Zijenah, HLA genetic polymorphisms: role in HIV-1 
susceptibility, disease progression and treatment outcomes. Retrovirology: Research and 
Treatment, 2013. 5: p. 1. 
301. Paximadis, M., et al., Human leukocyte antigen class I (A, B, C) and II (DRB1) diversity in the 
black and Caucasian South African population. Hum Immunol, 2012. 73(1): p. 80-92. 
302. Tshabalala, M., J. Mellet, and M.S. Pepper, Human Leukocyte Antigen Diversity: A Southern 
African Perspective. J Immunol Res, 2015. 2015: p. 746151. 
303. USA, Q., Digene-hc2-dna-collection-device-flyer, in www.theHPVtest.com. 2008: 
www.qiagen.com/hpv  
304. López-González, A., P. Ibeas Millán, and M. Provencio, DNA damage and repair in cancer 
therapy. Journal of Cancer Science and Therapy, 2013. 
305. Nasiri, H., et al., Modified salting-out method: high-yield, high-quality genomic DNA 
extraction from whole blood using laundry detergent. J Clin Lab Anal, 2005. 19(6): p. 229-
32. 
306. Bunce, M., PCR-Sequence-Specific Primer Typing of HLA Class I and Class II Alleles, in MHC 
Protocols, S.H. Powis and R.W. Vaughan, Editors. 2003, Humana Press: Totowa, NJ. p. 143-
171. 
307. Mellet, J., C.M. Gray, and M.S. Pepper, HLA typing: Conventional techniques v. next-
generation sequencing. 2015. Vol. 106. 2015. 
308. Bernal-Silva, S., et al., HLA-DRB1 Class II antigen level alleles are associated with persistent 
HPV infection in Mexican women; a pilot study. Infect Agent Cancer, 2013. 8(1): p. 31. 
309. Madeleine, M.M., et al., Comprehensive analysis of HLA-A, HLA-B, HLA-C, HLA-DRB1, and 
HLA-DQB1 loci and squamous cell cervical cancer risk. Cancer Res, 2008. 68(9): p. 3532-9. 
310. Wu, Y., et al., Polymorphic amino acids at codons 9 and 37 of HLA-DQB1 alleles may confer 
susceptibility to cervical cancer among Chinese women. Int J Cancer, 2006. 118(12): p. 
3006-11. 
311. Cervantes, J., et al., HLA-DRB1*1602 allele is positively associated with HPV cervical 
infection in Bolivian Andean women. Human Immunology, 2003. 64(9): p. 890-895. 
312. de Araujo Souza, P.S., et al., Interaction between polymorphisms of the human leukocyte 
antigen and HPV-16 variants on the risk of invasive cervical cancer. BMC Cancer, 2008. 8: 
p. 246. 
313. Lin, P., et al., HLA Class II DR-DQ and Increased Risk of Cervical Cancer among Senegalese 
Women1. Cancer Epidemiology, Biomarkers & Prevention, 2001. Vol. 10: p. 1037–1045. 
314. Dao, D.D., et al., HLA-DQB1 and cervical cancer in Venezuelan women. Gynecol Oncol, 
2005. 96(2): p. 349-54. 
315. Hu, J.M., et al., Human leukocyte antigen-DRB1*1501 and DQB1*0602 alleles are cervical 
cancer protective factors among Uighur and Han people in Xinjiang, China. International 
Journal of Clinical and Experimental Pathology, 2014. 7(9): p. 6165-6171. 
316. Krul, E.J., et al., HLA and susceptibility to cervical neoplasia. Hum Immunol, 1999. 60(4): p. 
337-42. 
317. Cuzick, J., et al., Association between high-risk HPV types, HLA DRB1*and DQB1*alleles 
and cervical cancer in British women. British Journal of Cancer, 2000. 82(7): p. 1348-1352. 
318. Menon, S., et al., Determining the HPV vaccine schedule for a HIV-infected population in 
sub Saharan Africa, a commentary. Virol J, 2018. 15(1): p. 129. 
 168 
319. Liu, G., et al., HIV-positive women have higher risk of human papilloma virus infection, 
precancerous lesions, and cervical cancer. Aids, 2018. 32(6): p. 795-808. 
320. Clifford, G.M., S. Tully, and S. Franceschi, Carcinogenicity of Human Papillomavirus (HPV) 
Types in HIV-Positive Women: A Meta-Analysis From HPV Infection to Cervical Cancer. Clin 
Infect Dis, 2017. 64(9): p. 1228-1235. 
321. Gariglio, P., J. Organista-Nava, and E. Alvarez-Rios, Role of HR-HPVs E6 and E7 
Oncoproteins in Cervical Carcinogenesis. J Mol Genet Med, 2016. 10(216): p. 1747-
0862.1000216. 
322. Harima, Y., et al., Loss of heterozygosity on chromosome 6p21.2 as a potential marker for 
recurrence after radiotherapy of human cervical cancer. Clinical Cancer Research, 2000. 
6(3): p. 1079-1085. 
323. Hyman, D.M., B.S. Taylor, and J. Baselga, Implementing Genome-Driven Oncology. Cell, 
2017. 168(4): p. 584-599. 
324. Migdalska-Sek, M., et al., Clinicopathological Significance of Overall Frequency of Allelic 
Loss (OFAL) in Lesions Derived from Thyroid Follicular Cell. Mol Diagn Ther, 2019. 23(3): p. 
369-382. 
325. Lin, J.C., et al., Microsatellite alteration in head and neck squamous cell carcinoma patients 
from a betel quid-prevalent region. Sci Rep, 2016. 6: p. 22614. 
326. Kamat, N., et al., Microsatellite instability and loss of heterozygosity detected in middle-
aged patients with sporadic colon cancer: A retrospective study. Oncol Lett, 2013. 6(5): p. 
1413-1420. 
327. Vassileva, V., et al., Genes involved in DNA repair are mutational targets in endometrial 
cancers with microsatellite instability. Cancer Res, 2002. 62(14): p. 4095-9. 
328. Isaiah, I.N. and M.B. Joseph, Comparative Dynamics of DNA Isolated from Buccal Swab for 
Forensic Investigation “Pro and Post Brushing from Some Adult Males in Benin Metropolis, 
Nigeria”. J Forensic Sci Criminol, 2016. 4(5): p. 501. 
329. Qiagen, Q., South Africa Protocol: Isolation of Total DNA from Surface and Buccal Swabs. 
2012: p. 13-16. 
330. Brys, M., et al., Diagnostic value of DNA alteration: loss of heterozygosity or allelic 
imbalance-promising for molecular staging of prostate cancers. Med Oncol, 2013. 30(1): p. 
391. 
331. Gan, C., et al., Applicability of next generation sequencing technology in microsatellite 
instability testing. Genes (Basel), 2015. 6(1): p. 46-59. 
332. Roberts, L.R. and N.F. LaRusso, Potential roles of tumor suppressor genes and 
microsatellite instability in hepatocellular carcinogenesis in southern African blacks. World 
J Gastroenterol, 2000. 6(1): p. 37-41. 
333. Mazurenko, N., et al., High resolution mapping of chromosome 6 deletions in cervical 
cancer. Oncol Rep, 1999. 6(4): p. 859-63. 
334. Mazurenko, N.N., et al., [Loss of heterozygosity at chromosome 6 as a marker of early 
genetic alterations in cervical intraepithelial neoplasias and microinvasive carcinomas]. 
Mol Biol (Mosk), 2006. 40(3): p. 436-47. 
335. Alaez-Verson, C., et al., HPV-16 and HLA-DRB1 alleles are associated with cervical 
carcinoma in Mexican Mestizo women. Arch Med Res, 2011. 42(5): p. 421-5. 
336. Beskow, A.H., M. Moberg, and U.B. Gyllensten, HLA class II allele control of HPV load in 
carcinoma in situ of the cervix uteri. Int J Cancer, 2005. 117(3): p. 510-4. 
337. Duenas-Gonzalez, A., et al., Epigenetics of cervical cancer. An overview and therapeutic 
perspectives. Mol Cancer, 2005. 4: p. 38. 
 169 
338. Larrea, A.A., S.A. Lujan, and T.A. Kunkel, SnapShot: DNA mismatch repair. Cell, 2010. 
141(4): p. 730 e1. 
339. Chen, J.J., Genomic Instability Induced By Human Papillomavirus Oncogenes. N Am J Med 
Sci (Boston), 2010. 3(2): p. 43-47. 
340. Alves, L.N., et al., Analysis of microsatellite instability and loss of heterozygosity in ovarian 
cancer: a study in the population of Espirito Santo, Brazil. Genet Mol Res, 2013. 12(2): p. 
1996-2001. 
341. Popat, S., R. Hubner, and R.S. Houlston, Systematic review of microsatellite instability and 
colorectal cancer prognosis. J Clin Oncol, 2005. 23(3): p. 609-18. 
342. Matevska-Geshkovska, N., et al., Influence of MSI and 18q LOH markers on capecitabine 
adjuvant monotherapy in colon cancer patients. Pharmgenomics Pers Med, 2018. 11: p. 
193-203. 
343. Crux, N.B. and S. Elahi, Human Leukocyte Antigen (HLA) and Immune Regulation: How Do 
Classical and Non-Classical HLA Alleles Modulate Immune Response to Human 
Immunodeficiency Virus and Hepatitis C Virus Infections? Front Immunol, 2017. 8: p. 832. 
344. Kanodia, S., L.M. Fahey, and W.M. Kast, Mechanisms used by human papillomaviruses to 

















CONSENT FORM FOR PARTICIPATION IN THE RESEARCH PROJECT 
 170 
 








Buffers used in this study  
  
10X TBE buffer  
108 g Tris, 55 g boric acid and 9.3 g EDTA.  
Dissolved and make up to 1 liter. Autoclave  
  
0.5X TBE buffer  
45mM Tris-borate (v/v)  
1mM EDTA (w/v)  
pH was adjusted to 8.3  
  
TE buffer  
10 mM Tris-HCl,  
1 mM EDTA (w/v)  
pH 8.0 
 
Lysis buffer  
50 mM Tris: 50 mM EDTA, pH 8.0 + 1% Sarcosyl  
  
Ethidium Bromide (EtBr)  
1x (0.2 ml/ml glycerol and 5 mg/ml bromophenol). To dissolved shake it.  
  
Loading buffer  
0.25% (w/v) bromophenicol blue and 0.25% (w/v) xylene cyanol in 30% (v/v) glycerol 
in sterile distilled water.  
  
10X TE  
100mM Tris-Cl pH 7.5  
 173 
10mM EDTA 
Dissolve 12.11 g Tris and 3.72 g of EDTA in 700 ml distilled water. pH was adjusted to 
7.5 with concentrated HCL. The volume was filled up to 1 L before autoclaving 
